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Abstract 
 
Polycomb group (PcG) proteins are important for establishing the patterns of gene 
expression in different cell types and are critical for the maintenance of pluripotency. 
They participate in multi-component complexes, such as Polycomb repressive 
complex 1 (PRC1), which modify, and bind to, histone tails. A number of auxiliary 
proteins consistently associate with PRC1, including the three subunits of protein 
kinase CK2 (CK2). The work described in this thesis investigates the interaction of 
CK2 with PRC1 components and the implications for PRC1 function.  
 
The data suggest that CK2 can directly bind to members of the CBX family, the 
mammalian orthologues of Polycomb in Drosophila. In the case of CBX7, residues 
within the conserved Pc box, near the C-terminus, were critical for this interaction. 
Interestingly, these residues were also required for the interaction between CBX7 
and RING2, another core component of mammalian PRC1. Whether CBX7 is 
phosphorylated by CK2 remains equivocal and likewise, it has been difficult to 
demonstrate a role for CK2 in the ability of CBX7 to function as a transcriptional 
repressor.  
 
In addition to their role as regulators of gene expression, PcG proteins have been 
recently implicated in the DNA damage response (DDR). Moreover, several 
proteins involved in the DDR are known to be CK2 substrates. To explore the link 
between CK2 and PRC1 in the context of DNA damage, a cell system was 
established in which multiple sequence-specific double-strand breaks (DSBs) could 
be induced in human diploid fibroblasts. Interestingly, detection of PRC1 proteins 
by both immunofluorescence and genome-wide ChIP-seq suggests that they are 
not recruited to DSBs in this system. Furthermore, the data indicate that extensive 
DNA damage does not mobilise PRC1 complexes from known binding sites. 
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Chapter 1. Introduction 
Multicellular organisms are composed of a variety of cell types that have 
specialised functions. Although these cells contain the same genetic information, 
their differences are established by individual patterns of gene expression. DNA is 
packaged into a highly organised structure known as chromatin. This involves the 
wrapping of DNA around histone octamers, which are composed of two copies 
each of histone H2A, H2B, H3 and H4, to form a nucleosome. Nucleosomes are 
further organised to form chromatin. Regions of open chromatin (euchromatin), and 
regions of condensed chromatin (heterochromatin), generally correspond to 
transcriptionally active (or potentially active) and transcriptionally silenced genes 
respectively (Khorasanizadeh, 2004).  
 
Regulation of gene expression can be mediated by changes in the chromatin 
structure, which are typically associated with specific modifications to histone tails. 
Histone tails are unstructured N-terminal regions of the core histones that protrude 
from the nucleosome. These histone tails can be chemically modified, for example, 
by acetylation, methylation, ubiquitination and phosphorylation. Some of these 
modifications can directly affect the state of chromatin. For example, in vitro studies 
of histone acetylation suggest that this modification neutralises the positive charge 
of histone tails and therefore reduces their affinity for negatively charged phosphate 
groups of DNA (Hong et al., 1993). This can result in a more relaxed and open 
chromatin conformation; lending itself more readily to transcription. Other histone 
modifications are specifically recognised by certain proteins that can remodel the 
chromatin or promote/repress transcription directly. The terminology for these 
modifications describes both the type of modification, and the histone and residue 
at which it occurs. For example, tri-methylation of lysine 27 on histone H3 is 
denoted: H3K27me3. Together, these modifications are thought to generate a code 
that defines the chromatin state, the associated proteins, and the transcriptional 
status of a region of DNA; this is the histone code hypothesis (Jenuwein and Allis, 
2001). 
 
Both H3K27me3 and H3K9me3 are markers of transcriptionally silenced chromatin. 
H3K9me3 is associated with constitutive and facultative heterochromatin (Bannister 
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et al., 2001, Lachner et al., 2001, Nakayama et al., 2001, Peters et al., 2002). 
Constitutive heterochromatin is principally found within centromeric, 
pericentromeric (Gilbert and Allan, 2001) and telomeric regions (Schoeftner and 
Blasco, 2009) that contain highly repetitive DNA sequences. Facultative 
heterochromatin forms in the euchromatin environment to stably repress target 
genes. The most extensively studied example of facultative chromatin is at the 
inactive X chromosome in somatic cells of female mammals (Chow and Heard, 
2009).  
 
Gene silencing within euchromatic regions is generally associated with the 
H3K27me3 mark. This mark is both catalysed and recognised by members of the 
Polycomb group (PcG) of proteins. By maintaining patterns of transcriptionally 
silenced genes, PcG proteins preserve the memory of cellular identity. These 
proteins are also clearly relevant to pluripotency and to senescence, largely 
because of effects on the CDKN2A locus.  
 
1.1 Polycomb group (PcG) protein complexes 
Polycomb group (PcG) proteins were originally identified in Drosophila as 
regulators of the Hox genes. Hox gene expression determines body segment 
patterning of the developing Drosophila embryo. In cooperation with Trithorax 
group (TrxG) proteins, which are positive regulators of transcription, PcG proteins 
are responsible for maintaining patterns of Hox gene expression and therefore the 
lineage commitment of specific cells (reviewed in (Kennison, 1995) and (Ringrose 
and Paro, 2004)). Most PcG proteins have been ascribed names based on 
phenotypes that arise from dominant or recessive PcG gene mutations in 
Drosophila. For example, Extra sex combs (Esc) (Slifer, 1942) and Polycomb (Pc) 
mutants (Lewis, 1947) have sex combs on their second and third legs that are 
absent in wild-type Drosophila. There are 18 documented PcG genes in Drosophila 
(Ringrose and Paro, 2004). Drosophila PcG proteins pertinent to this thesis are 
outlined in Table 1.1. 
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1.1.1 Composition of PcG complexes 
The co-localisation of several Drosophila PcG proteins on polytene chromosomes 
suggested that PcG proteins might associate in complexes (Franke et al., 1992, 
Martin and Adler, 1993, Rastelli et al., 1993, Lonie et al., 1994). The first direct 
evidence for a PcG complex was the purification of the Drosophila Polycomb 
repressive complex 1 (PRC1). PRC1 contains four core PcG proteins, Pc, Ph, 
Posterior sex combs (Psc), and Sex combs extra (Sce), and sub-stoichiometric 
amounts of Sex Combs on Midleg (SCM) (Francis et al., 2001, Shao et al., 1999). 
The core components of PRC1 were shown to be sufficient to block the remodelling 
of nucleosomes by SWI/SNF in vitro (Francis et al., 2001). Three further multi-PcG 
protein complexes have been described in Drosophila: Polycomb repressive 
complex 2 (PRC2), pleiohomeotic (Pho) repressive complex (PhoRC) and dRAF 
(dRING-associated factors). PRC2 contains three core PcG proteins, Enhancer of 
zeste (E(z)), Suppressor of zeste 12 (Su(z)12) and Extra sex combs (Esc) 
(Czermin et al., 2002, Muller et al., 2002). PhoRC contains two core PcG proteins, 
Pho and dSfmbt (Klymenko et al., 2006). dRAF is a non-canonical PRC1, 
comprising Sce, Psc and the histone demethylase KDM2 (Lagarou et al., 2008). 
 
Analogous complexes have been described in mammals, with most attention 
focused on PRC1 and PRC2 (Levine et al., 2002, Cao et al., 2002, Kuzmichev et 
al., 2002). Mammalian PRC2 contains a highly conserved homologue of each 
Drosophila PRC2 protein, two in the case of E(z): Enhancer of zeste homologue 1 
(EZH1) and EZH2, Embryonic ectoderm development (EED) and Suppressor of 
zeste 12 (SUZ12). However, there has been a substantial expansion of the PcG 
genes during evolution and mammals encode multiple homologues of each 
Drosophila PRC1 protein. There are five Pc homologues (CBX2, 4, 6, 7 and 8), 
three Ph homologues (HPH1, 2 and 3), six Psc homologues (NSPC1, MEL18, 
RNF3, BMI1, RNF159 and MBLR) and two Sce homologues (RING1 and 2). 
Virtually all of these proteins have alternative names, in different studies and 
species (summarised in Table 1.1), and there is currently no accepted consensus. 
Throughout this thesis, human proteins/genes will be in upper case whereas 
mouse proteins/gene and Drosophila equivalents will be in mixed case.  
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Importantly, just one representative of each PcG protein family appears to be 
present in any one mammalian PRC1 complex (Dietrich et al., 2007, Gao et al., 
2012, Maertens et al., 2009, Sanchez et al., 2007, Vandamme et al., 2011). 
Currently, there is limited evidence of preferential interactions between specific 
components (Gao et al., 2012). Allowing for free assortment, there could be as 
many as 180 different permutations of PRC1. This has led to speculation that 
different PRC1 subtypes may have functional specificity, perhaps operating in 
different cell types or at a subset of PcG repressed genes. Indeed, CBX7 appears 
to be the predominant Pc component in embryonic stem cells (ESCs). During ESC 
differentiation, CBX7 expression is downregulated, resulting in the upregulation of 
CBX2, 4 and 8 (O'Loghlen et al., 2012, Morey et al., 2012). In addition, chromatin 
immunoprecipitation followed by high-throughput sequencing (ChIP-seq) in ESCs 
suggested CBX7 and CBX6 occupy different target genes (Morey et al., 2012). 
However, ChIP-seq analyses in human fibroblasts (Pemberton et al., Submitted) 
have shown that CBX6, 7 and 8 invariably occupy the same loci.  
 
PcG proteins have also been detected in other types of affinity purified complex 
based on proteins such as E2F6, L3MBTL2, BcoR, FBXL10 and RYBP (Trojer et 
al., 2011, Trimarchi et al., 2001, Gearhart et al., 2006, Sanchez et al., 2007). 
Functional characterisation of these complexes has been limited, a notable 
exception being a set of PRC1-like complexes that comprise representatives from 
the Sce and Psc families bound to either RYBP (RING and YY1 binding protein) or 
YAF2 (YY1-associated factor 2) instead of Pc. Interestingly, RYBP and CBX7 form 
nearly identical intermolecular beta sheet structures with the C-terminus of RING2 
(Wang et al., 2010) and biochemical analysis suggest that CBX7 and RYBP bind to 
RING proteins in a mutually exclusive manner (Tavares et al., 2012, Gao et al., 
2012). These complexes will hereafter be referred to as CBX-PRC1 and RYBP-
PRC1. 
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PRC1 
Drosophila Mouse Human 
Polycomb (Pc) Cbx2/M33/pc 
Cbx4/MPc2 
Cbx6 
Cbx7/mCbx7 
Cbx8/Pc3 
CBX2/M33/PC 
CBX4/hPC2 
CBX6 
CBX7 
CBX8/HPC3 
Polyhomeotic (Ph) Mph1/Phc1/Rae28/Edr1 
Mph2/Phc2/Edr2 
Mph3/Phc3/Edr3 
HPH1/PHC1/EDR1/RAE28 
HPH2/PHC2/EDR2/PH2 
HPH3/PHC3/EDR3 
Sex combs extra (Sce) Ring1a/Ring1 
Ring1b/Ring2 
RING1A/RING1/RNF1 
RING1B/RING2/RNF2 
Posterior sex combs 
(Psc) 
Nspc1/Pcgf1 
Mel18/Pcgf2/Rnf110/Zfp144 
Pcgf3/Rnf3/RNF3A 
Bmi1/Pcgf4/Rnf51 
Pcgf5/Rnf159 
Mblr/Pcgf6/Rnf134 
NSPC1/PCGF1/RNF68 
MEL18/PCGF2/RNF110 
PCGF3/RNF3/RNF3A 
BMI1/PCGF4/RNF51 
PCGF5/RNF159 
MBLR/PCGF6/RNF134 
 
 
PRC2 
Drosophila Mouse Human 
Extra sex combs (Esc) Eed/17Rn5 EED/HEED/WAIT1 
Enhancer of zeste (E(z)) Ezh1 
Ezh2/Enx-1/KMT6 
EZH1 
EZH2/ENX-1/KMT6 
Suppressor of zeste (Su(z)) Suz12 SUZ12/CHET9/JJAZ1 
Table 1.1 PcG proteins of Drosophila, mouse and human PRC1 and PRC2.  
Alternative PcG protein names are shown. The PcG protein names used in this 
thesis are in bold. 
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1.2 PcG complex recruitment to target genes 
1.2.1 Sequence-specific recruitment of PcG complexes  
Drosophila PcG complexes associate with cis-regulatory DNA sequences termed 
Polycomb responsive elements (PREs) that are required for PcG-mediated 
repression (Muller and Kassis, 2006). The few PREs that have been characterised 
to date show limited sequence conservation, apart from binding sites for proteins 
such as Pho, Zeste and GAGA factor. Pho is the only PcG protein that has 
sequence-specific DNA binding activity (Brown et al., 1998), and, as it has been 
shown to interact with both PRC1 and PRC2 in vitro, it is implicated in the 
recruitment of these complexes to PREs (Wang et al., 2004b, Mohd-Sarip et al., 
2002). Other PRE-binding proteins, for example Zeste (Saurin et al., 2001), also 
interact with PcG proteins. The role of other PRE-binding proteins is less clear as 
Drosophila with null-mutations in the corresponding genes do not demonstrate PcG 
phenotypes (Goldberg et al., 1989) 
 
Because of the lack of sequence conservation, it has proved difficult to identify 
PREs in mammals, but two candidates have recently been described. The first of 
these, PRE-kr, regulates PcG repression of MafB/Kreisler gene in mouse F9 cells 
(Sing et al., 2009). The second, D11.12, lies between HOXD11 and HOXD12 in 
human ESCs (Woo et al., 2010). Both PRE-kr and D11.12 contain binding sites for 
YY1, the mammalian homologue of Drosophila Pho (Brown et al., 1998). Although 
it is tempting to speculate that YY1 is involved in the recruitment of PcG complexes 
to PREs, perhaps via interactions with RYBP or YAF2, there is currently no 
evidence that this is the case (Tavares et al., 2012). Recently Bmi1 was shown to 
directly bind the Runx1/CBFβ transcription factor complex. Furthermore, this study 
also demonstrated similar patterns of chromatin occupancy between Ring1b and 
Runx1/CBFβ (Yu et al., 2012). Other sequence-specific DNA binding proteins such 
as Oct4, Sox2 and Nanog have been implicated in PcG complex recruitment 
because of their similar chromatin localisation (Boyer et al., 2006, Lee et al., 
2006b). However there is little evidence for an interaction between these 
transcription factors and PcG proteins.  
 
Chapter 1 Introduction 
 23 
1.2.2 PcG complex recruitment by non-coding RNAs  
While a role for sequence-specific DNA binding proteins in PcG recruitment is by 
no means excluded, studies in both Drosophila and mammalian cells have 
suggested an alternative possibility. For example, in Drosophila, non-coding RNAs 
(ncRNAs) of the bithoraxoid complex are critical for PcG-mediated regulation, 
although there is some debate about the mechanism. One school of thought is that 
antisense transcription through PREs prevents PcG binding and repression, while 
other studies suggest that ncRNAs are essential for recruitment of PcG complexes 
and long-range interactions between PREs (Grimaud et al., 2006, Petruk et al., 
2006, Schmitt et al., 2005, Sanchez-Elsner et al., 2006). In mammalian systems, 
the classical example is the silencing of the inactive X chromosome, which relies 
on recruitment of PcG complexes by the Xist ncRNA. The discovery of literally 
thousands of long ncRNAs (lncRNAs), such as HOTAIR, HOTTIP, TUG1, suggests 
this may be a much more widespread phenomenon. HOTAIR is transcribed from 
within the HOXC locus and appears to function in trans to promote PcG repression 
of HOXD genes (Rinn et al., 2007). Given the inherent sequence specificity of 
lncRNAs, these would serve as elegant PcG complex recruiters. However, some 
lncRNAs, such as HOTTIP, appear to have the opposite effect and promote 
transcription by recruiting TrxG complexes (Schuettengruber, 2011). Others, such 
as the ANRIL transcript from the INK4a-ARF-INK4b locus and short RNAs 
expressed from CpG island/promoter regions, are viewed as acting in cis rather 
than trans (Kanhere et al., 2010, Yap et al., 2010, Kotake et al., 2011). Most of 
these studies conclude that the ncRNAs interact directly with PRC2 components, 
such as SUZ12 and EZH2. However, the chromodomains of Pc proteins have also 
been shown to interact with RNA (Akhtar et al., 2000) and the recruitment of Cbx 
proteins to target genes depends, in part, on this interaction (Bernstein et al., 
2006b). 
 
1.2.3 Recruitment of PRC1 to H3K27me3 
Importantly, the Pc chromodomain has been shown to bind trimethylated histone 
tails at lysine 9 and 27 on histone H3 (H3K9me3 and H3K27me3)(Min et al., 2003, 
Fischle et al., 2003, Cao et al., 2002, Bernstein et al., 2006b, Ringrose et al., 2004). 
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As the PRC2 complex is an H3K27me3-specific methyltransferase, catalysed by 
the SET domain in the E(z) protein, an attractive model has been proposed in 
which the trimethylation of H3K27 by PRC2 is responsible for recruitment of PRC1. 
In support of this idea, mutations in the chromodomain of Pc abolish the ability of 
Pc to bind chromatin in vivo (Cao et al., 2002, Czermin et al., 2002, Fischle et al., 
2003, Kuzmichev et al., 2002, Messmer et al., 1992, Min et al., 2003, Muller et al., 
2002). Furthermore, the methyltransferase activity of PRC2 is important for the 
binding of PRC1 at PREs (Cao et al., 2002), but PRC1 binding to regions of 
H3K27me3 does not require the continued presence of PRC2 (Wang et al., 2004b). 
In addition, the H3K27-specific demethylases, UTX and JMJD3, have been shown 
to reduce the binding of PRC1 to target genes (Agger et al., 2007, Lee et al., 2007). 
However, although genome-wide mapping of H3K27me3 in Drosophila has shown 
this mark to be largely coincidental with both binding of PRC1 and PRC2, the 
domain of H3K27me3 is broader than that bound by PRC1, suggesting this mark is 
not sufficient for recruitment (Schwartz et al., 2006). It has also been argued that 
the binding affinity between Pc and H3K27me3 is too low to account for locus-
specific recruitment. Importantly, at some loci, PRC1 binding can occur in the 
absence of a functional PRC2 complex, suggesting that at least in some instances 
the H3K27me3 mark is not necessary for PRC1 recruitment (Pasini et al., 2007, 
Schoeftner et al., 2006, Vincenz and Kerppola, 2008). 
 
1.3 PRC1 repression of target genes 
Chromodomains are also present in the HP1 proteins (α, β, and γ), which bind 
preferentially to H3K9me3 and are necessary for the formation of heterochromatin. 
Interestingly HP1γ is found within euchromatin, whereas HP1α and HP1β  are 
predominantly found at pericentromeric sites (Minc et al., 1999, Vakoc et al., 2005). 
Although heterochromatin and PcG-mediated repression are generally considered 
separate modes of transcriptional silencing (Beisel and Paro, 2011), the 
compaction of chromatin is common to both. Compact chromatin has the potential 
to limit access to the transcriptional machinery and to impede the progression of 
RNA polymerase II (Pol II) through nucleosomes, which requires the loosening of 
histone-DNA interactions (Lorch et al., 1987, Bondarenko et al., 2006).  
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Regulation of gene transcription by Pol II can occur at the initiation, elongation and 
termination stages. Pol II is assembled at promoters with multiple general 
transcription factors (GTFs), forming a large protein complex known as the pre-
initiation complex (PIC). PIC comprises a minimal set of GTFs, including TFIIE and 
TFIID (containing the TATA-binding protein TBP). Recruitment of Pol II is also 
greatly influenced by the Mediator complex, nucleosome remodelling complexes, 
histone modifying enzymes and DNA-binding transcriptional activators. A tightly 
controlled exchange of factors accompanies the transition from transcriptional 
initiation to early elongation. This, in part, is orchestrated by the phosphorylation of 
the C-terminal domain (CTD) of Pol II, which contains multiple heptad repeats with 
the consensus sequence YSPTSPS. Phosphorylation of CTD at serine 5, by the 
CDK7 subunit of TFIIH, is thought to destabilise the interaction of Pol II with 
promoter-bound factors and thereby facilitate promoter escape. The transition from 
early to productive elongation is triggered by recruitment of p-TEFb, which 
phosphorylates the CTD at serine 2. p-TEFb recruitment leads to the release of 
pausing factors and association of factors that promote productive elongation 
(reviewed in (Nechaev and Adelman, 2011)). Recent in vitro work has shown that 
PRC1 inhibits the binding of Mediator and assembly of PIC, although TFIID 
promoter binding is unaffected (Lehmann et al., 2012). However, ChIP studies 
have demonstrated that poised Pol II (phosphorylated at serine 5) can be enriched 
at PcG targets in mouse ESCs. Such targets lack the form of Pol II associated with 
active transcription (phosphorylated at serine 2). Importantly, Ring1b was required 
to maintain this poised state of transcription (Stock et al., 2007).  
 
1.3.1 PcG-mediated chromatin compaction 
The ability of PRC1 to compact chromatin was first demonstrated by Francis and 
colleagues. Using electron microscopy, they visualised PRC1-dependent 
nucleosome compaction in vitro (Francis et al., 2004). In vivo, chromatin 
compaction at the Hoxb and Hoxd loci is dependent on Ring1b and contributes to 
transcriptional repression of the Hox genes (Eskeland et al., 2010).  
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The only catalytic function attributed to the PRC1 complex is E3 ubiquitin ligase 
activity, based on the concerted action of the RING domains of Psc and Sce 
proteins. Importantly, the purified complexes have been shown to catalyse the 
monoubiquitination of histone H2A at lysine 119 (H2AK119Ub) (Buchwald et al., 
2006, de Napoles et al., 2004, Wang et al., 2004a). H2AK119Ub is invariably found 
at PcG target genes (Endoh et al., 2012, Kallin et al., 2009) and is regarded as the 
histone mark that promotes chromatin condensation and/or affects protein-
nucleosome interactions to directly to repress transcription. Indeed, depletion of 
Ring1a and Ring1b from mESCs results in loss of H2AK119Ub and de-repression 
of PcG targets (Stock et al., 2007). Moreover, a recent study in mouse ESCs 
suggested that the catalytic activity of Ring1b is important for repression of PcG 
targets, albeit to varying degrees (Endoh et al., 2012). However, nucleosome 
compaction by PRC1 in vitro is independent of histone-tails (Francis et al., 2004). 
Furthermore, the catalytic activity of Ring1b is dispensable for both chromatin 
compaction and gene repression at the Hox loci (Eskeland et al., 2010).  
 
Recent data from Tavares and colleagues, has questioned whether canonical 
PRC1 complexes are responsible for H2AK119Ub at target genes. In Eed-/- mESCs, 
the enrichment of H2AK119Ub at PcG target genes is equivalent to that in wild-type 
mESCs. Ring1b was also enriched at these PcG target genes, but to a greatly 
reduced extent in Eed-/- mESCs, whereas H3K27me3 and CBX7 could only be 
detected at PcG targets in the wild-type cells. RYBP was enriched at PcG targets 
to a similar extent in both wild-type and Eed-/- mESCs (Tavares et al., 2012). These 
data have suggested that RYBP is recruited independently of PRC2 and that 
RYBP-PRC1 may be responsible for H2AK119Ub at PcG targets, at least in 
mESCs. Indeed, there is evidence that RYBP-PRC1 has stronger enzymatic 
activity towards H2AK119 than CBX2- or CBX8-PRC1, although these complexes 
demonstrate an equivalent potential to compact nucleosomes in vitro (Gao et al., 
2012). Thus, the extent to which H2AK119Ub is mediated by canonical PRC1 
complexes, and its importance for PcG repression, remains controversial (Gutierrez 
et al., 2012).  
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1.3.2 Higher-order regulation of chromatin by PcG proteins 
In addition to chromatin compaction, PcG-mediated repression is likely to involve 
higher-order chromatin configurations. Long-range interactions have been 
observed between Drosophila PREs, which assemble with multimeric PcG 
complexes called Polycomb bodies. These can be observed by 
immunofluorescence as discrete nuclear foci (Buchenau et al., 1998). There is 
evidence that Ph and Pc both have the propensity to self-associate (Kim et al., 
2002, Kyba and Brock, 1998, Min et al., 2003, Reijnen et al., 1995). This 
characteristic may serve to promote the assembly of multimeric PRC1 complexes.  
Importantly, Polycomb bodies co-localise with PcG repressed genes that are 
maintained in a silent transcriptional state and disruption of long-range PRE 
interactions can result in derepression of PcG targets (Bantignies et al., 2011, 
Lanzuolo et al., 2007). In Drosophila therefore, it seems that higher-order 
chromatin structure can be important for PcG repression.  
 
In mammalian cells, PcG proteins have also been observed in nuclear speckles by 
immunofluorescence. Human fibroblasts contain approximately 100 nuclear PcG 
protein speckles, which are evenly distributed throughout the nucleus (Voncken et 
al., 1999, Buchenau et al., 1998, Saurin et al., 1998). However, the composition of 
these assemblies and their importance for PcG repression remains to be 
established. In human tumour cell lines, PRC1 proteins are typically found in a few 
(~5-15 per cell) large nuclear bodies that associate with pericentromeric 
heterochromatin (Alkema et al., 1997, Saurin et al., 1998, Cmarko et al., 2003, 
Hernandez-Munoz et al., 2005). Whether these more prominent PRC1 foci reflect 
changes in PRC1 genome-wide binding patterns or changes in PRC1-PRC1 
complex interactions remains to be established. 
 
1.4 PcG proteins in stem cell maintenance and differentiation 
1.4.1 Regulation of pluripotency and cell fate 
Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of the 
mammalian blastocyst. They are pluripotent, having the potential to differentiate 
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into all derivatives of the three primary germ layers, and have limitless replicative 
potential (Nishikawa et al., 2007). These characteristics of ES cells are ensured by 
a specialised chromatin-state that is maintained by epigenetic regulators such as 
the PcG and TrxG proteins. Bivalent domains, regions of chromatin containing both 
H3K27me3 and H3K4me3, are a primary feature of the ES chromatin landscape. 
Such domains are typically found at the promoters of genes encoding lineage-
specific transcription factors (Bernstein et al., 2006a). As discussed above, 
H3K27me3 is a repressive mark with implications for PcG protein recruitment. 
Conversely, H3K4me3 is an active mark that is responsible for recruiting 
nucleosome remodelling proteins (Santos-Rosa et al., 2003) and histone 
deacetylases (Pray-Grant et al., 2005) to promote transcription. H3K4me3 is 
catalysed by TrxG proteins (Schuettengruber et al., 2011). These opposing 
modifications result in a poised state of transcription at bivalent promoters (Stock et 
al., 2007). Ring1b is required to maintain this poised state of transcription (Stock et 
al., 2007). As cells differentiate, bivalent domains tend to be resolved into 
transcriptionally active or silent states, marked by H3K4me3 or H3K27me3 
respectively (Bernstein et al., 2006a).  
 
Among the most prevalent PcG targets in ES cells are genes that encode proteins 
involved in cell fate determination. During differentiation and cellular commitment to 
a specific lineage there is selective de-repression of PcG targets. For example, 
during neuronal differentiation, PcG targets ZIC1 and MEIS1 (transcription factors 
required for neurogenesis) are expressed and PcG proteins are displaced from 
these genes (Bracken et al., 2006). However, PcG repression is also more dynamic 
than originally appreciated. For example, neuronal progenitors have been shown to 
acquire PcG repression (described by detection of H3K27me3) at genes that are 
not PcG targets in ES cells. Furthermore, PcG repression of these “new” targets is 
subsequently lost during terminal differentiation, repression in the progenitor having 
been a transient, poised state of PcG repression (Mohn et al., 2008).   
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1.4.2 Regulation of the self-renewal capacity of stem cells  
Like ES cells, somatic stem cells (SCCs) have the capacity to self-renew and to 
differentiate into a variety of cell types, depending on the tissue of origin. Somatic 
stem cells have been identified in a number of tissues including the nervous system, 
the haematopoietic system, lung, intestine and skin (reviewed in (Snippert and 
Clevers, 2011)) and are important for maintaining tissue homeostasis. Evidence 
implicating PcG proteins in stem cell self-renewal has mostly come from studies on 
Bmi1 knockout mice. The mice that survive to adulthood have neural and 
haematopoietic defects that reflect a deficiency in stem cell numbers rather than 
their failure to differentiate (Iwama et al., 2004, Jacobs et al., 1999a, Lessard and 
Sauvageau, 2003, Leung et al., 2004, Molofsky et al., 2003, Park et al., 2003). 
Although the analyses of other PcG gene knockouts have been much less 
extensive, a number appear to impair some aspects of stem cell renewal, including 
Mph1, Ring1b, Cbx2 and Ezh2 (Kamminga et al., 2006, Ohta et al., 2002, Cales et 
al., 2008, Core et al., 1997). Remarkably, where tested, the proliferative defects in 
the PcG knockout mice can be largely rescued by concomitant inactivation of 
INK4a-Arf. 
 
1.5 The INK4a-ARF-INK4b locus and cellular senescence 
1.5.1 The INK4a-ARF-INK4b locus  
The INK4a-ARF-INK4b locus is found on human chromosome 9p21, and the 
equivalent region of mouse chromosome 4. INK4a and INK4b are thought to have 
arisen by gene duplication. Between these genes lies an additional exon, exon 1β. 
Transcription from the promoter of exon 1β results in an RNA product that 
incorporates exons 2 and 3 of INK4a. This RNA is translated in an alternative 
reading frame from INK4a and was therefore named ARF (Quelle et al., 1995). 
 
The products of INK4a and INK4b are commonly referred to as p16INK4a and 
p15INK4b. These INK4 proteins are cyclin-dependent kinase inhibitors, which directly 
bind to CDK4 and CDK6 and block the assembly of catalytically active cyclin D-
CDK4/6 complexes (Pavletich, 1999). In addition, by sequestering CDK4 and 
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CDK6, the INK4 proteins increase the availability of the CIP/KIP family of CDK 
inhibitors to bind and inhibit cyclin E-CDK2 and cyclin A-CDK2 (Sherr and Roberts, 
1999). As these cyclin-CDK complexes orchestrate progression through the cell 
cycle, at least in part by phosphorylating and inactivating the retinoblastoma gene 
product (pRb) and its relatives, elevated expression of p16INK4a or p15INK4b results in 
a G1 phase cell cycle arrest (reviewed in (Sherr, 2000, Ortega et al., 2002)). 
 
Importantly, ARF is not a CDK inhibitor and bears no structural similarities to the 
INK4 family, which are composed of ankyrin type repeats (Pavletich, 1999). As well 
as its unusual genomic organisation, ARF has an unusual amino acid composition 
and the primary sequence is poorly conserved. It is also credited with binding to a 
wide variety of cellular proteins but its best-characterised function is its interaction 
with MDM2 (Bothner et al., 2001). MDM2 is an E3 ubiquitin ligase that catalyses 
the polyubiquitination of p53, resulting in its proteasome-mediated degradation. 
Binding of ARF to MDM2 inhibits this activity leading to the accumulation of a 
transcriptionally active pool of p53 (Sherr, 2000, Michael and Oren, 2003). 
Although the situation is complicated by feedback loops, through which, p53 
activates the expression of MDM2 and represses that of ARF, events that cause 
up-regulation of ARF generally induce a p53-dependent cell cycle arrest in G1 and 
G2, presumably mediated by p21 (Lowe and Sherr, 2003).  
 
It is clear, therefore, that all three proteins encoded by the INK4a-ARF-INK4b locus 
are able to cause cell cycle arrest. However, the balance of evidence suggests 
these proteins are not involved in regulating the cell cycle per se. Instead, the 
expression of these proteins seems to be important for establishing a state of 
permanent cell-cycle arrest, termed senescence.  
 
1.5.2 Cellular senescence 
Hayflick and colleagues originally proposed the concept of senescence when they 
observed that human diploid fibroblasts (HDFs) had a limited replicative potential 
when propagated under cell culture conditions. The number of population doublings 
achieved by a particular cell strain was consistent, suggesting a counting 
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mechanism (Hayflick and Moorhead, 1961). One factor governing this limited 
replication potential is the loss of telomeric DNA at each cell division, which occurs 
due to the incomplete replication of the lagging strand by DNA polymerase 
(Olovnikov, 1971, Watson, 1972). Telomeres are repetitive sequences at 
chromosome ends that protect the loss of coding genomic information. In stem 
cells, telomere length is maintained by telomerase which catalyses telomere 
elongation (reviewed in (Hiyama and Hiyama, 2007)). When telomeres reach a 
critical length, their structure is disrupted causing a persistent DNA damage 
response (DDR) that can induce permanent cell-cycle arrest (Fumagalli et al., 
2012). This is known as replicative senescence. Ectopic expression of human 
telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, can 
extend the lifespan of normal somatic cells in culture (Bodnar et al., 1998). 
 
Both the p53 and pRB pathways are key regulators of senescence (reviewed in 
(Campisi and d'Adda di Fagagna, 2007)). Senescent cells show marked changes in 
gene expression patterns, although it is difficult to separate those involved in 
causing senescence and those that result from the senescent cell state. These 
changes include the striking accumulation of p16INK4a, preceded by p21CIP1 (Alcorta 
et al., 1996). Curiously expression of p18INK4c, another member of the INK4 family 
of proteins, is downregulated (Gagrica et al., 2012). Human cells do not 
demonstrate any appreciable differences in ARF RNA levels, but the situation is 
very different in mouse fibroblasts where ARF accumulates. Although the reasons 
behind the species difference are not entirely clear, laboratory mice have 
exceptionally long telomeres. Consequently, the senescence of MEFs in culture is 
a reflection of oxidative stress rather than eroded telomeres, and can be alleviated 
by growing cells in low oxygen conditions (Parrinello et al., 2003). 
 
In addition to telomere erosion and oxidative stress, other forms of cellular stress 
will also induce premature senescence, including the activation of oncogenes. For 
example, in primary cells, expression of oncogenic RAS is a potent inducer of 
senescence (Serrano et al., 1997). Such oncogene-induced senescence (OIS) is 
generally accompanied by upregulation of p53 and increased expression from 
INK4a-ARF-INK4b. Interestingly, the contribution of INK4a-ARF-INK4b to this 
arrest is attributable to p16INK4a in HDFs, whereas ARF plays the predominant role 
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in MEFs (Brookes et al., 2002, Kamijo et al., 1997). OIS is thought to result from a 
DDR triggered by oncogene-induced replication stress (Bartkova et al., 2006, Di 
Micco et al., 2006).  
 
1.5.3 Characteristics of senescent cells 
Senescence is often described as being irreversible, largely distinguishing it from 
quiescence, which can be reversed by addition of the appropriate growth signals. In 
culture, senescent cells remain metabolically active and viable without increasing in 
number. These cells acquire a number of phenotypic characteristics, such as 
enlarged and flattened morphology, and single, prominent nucleoli (Campisi and 
d'Adda di Fagagna, 2007). Senescent cells also have an increased lysosomal 
content that results in high levels of lysosomal β-galactosidase (Lee et al., 2006a). 
This feature, referred to as senescence-associated β-galactosidase (SA-β-Gal) 
activity, is commonly used as a marker for senescence. For this assay, 5-bromo-4-
chloro-3-indolyl-β-D-galactoside (X-gal) is used to detect β-galactosidase activity at 
a suboptimal pH (Dimri et al., 1995).  
 
Dramatic changes in chromatin can also be a feature of senescent cells. 
Senescent-associated heterochromatin foci (SAHF) are DAPI-dense, subnuclear 
structures that are enriched with heterochromatic proteins and histone 
modifications, such as H3K9me3, that are associated with heterochromatin (Narita 
et al., 2003, Zhang et al., 2007). SAHF have been observed in replicative 
senescence but are a more prominent feature of oncogene-induced senescence 
(Di Micco et al., 2011). It has been proposed that the formation of SAHF facilitates 
the transcriptional silencing of E2F target genes (Narita et al., 2003). However, the 
observation that senescence can be established in the absence of SAHF formation, 
questions the extent to which SAHF play a causative role in senescence (Di Micco 
et al., 2011). Another feature of senescent cells is that they have a specialised 
secretory programme, termed the senescence-associated secretory phenotype 
(SASP) (Coppe et al., 2008). This includes the increased expression of 
inflammatory cytokines and cognate receptors that appear to enhance the 
senescence phenotype in culture (Acosta et al., 2008, Kuilman et al., 2008). 
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Furthermore, there are indications that, in vivo, the SASP could act as a 
mechanism for clearance of incipient cancer cells by the innate immune system 
(Kang et al., 2011). 
 
1.5.4 Role of senescence in tumour suppression 
Importantly, OIS is not confined to cultured cells but has been observed in pre-
malignant lesions in both humans and mice. An example of this is human naevi. 
Human naevi are benign tumours of melanocytes that frequently contain oncogenic 
mutations in BRAF or RAS and display classical hallmarks of senescence, 
including SA-β-Gal activity and p16INK4a expression (Michaloglou et al., 2005). This 
lends credence to the idea that senescence is an important tumour suppressive 
mechanism that prevents the expansion of cells that have sustained oncogenic 
mutations. Indeed, bypass, or escape from senescence, has been described as 
one of the “Hallmarks of Cancer” (Hanahan and Weinberg, 2000, Hanahan and 
Weinberg, 2011). 
 
This would explain the importance of INK4a in human cancer. INK4a was identified 
as a melanoma susceptibility gene in 1994 (Nobori et al., 1996, Kamb et al., 1994). 
Recent meta-analyses have indicated that the region around CDKN2A is the most 
frequently altered genomic locus in human cancer (Beroukhim et al., 2010, Bignell 
et al., 2010). The COSMIC database implies that of over 25,000 human tumour 
samples analysed, 14% have somatic mutations in CDKN2A (Forbes et al., 2008). 
Furthermore, CDKN2A is frequently hypermethylated in tumours (Esteller et al., 
2001), causing transcriptional silencing of this locus. The majority of point 
mutations and intragenic alterations in this region, in both sporadic and familial 
human tumours, target INK4a rather than ARF or INK4b (Sharpless, 2005, Ruas 
and Peters, 1998). In mice, ARF seems to play a more important role in tumour 
suppression. Individual knockout of either Ink4a or Arf predisposes mice to 
spontaneous tumour formation and this effect is amplified in double knockout mice 
(Sharpless et al., 2004). Furthermore, studies in MEFs have shown that although 
Arf and p16Ink4a accumulate after passaging, spontaneous escape from 
senescence occurs in ARF-/- MEFs but not Inka-/- MEFs (Krimpenfort et al., 2001). 
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1.6 PcG complexes in cancer 
As discussed in more detail in Chapter 1.8, there is compelling evidence that 
INK4a-ARF-INK4b is regulated by PcG complexes. The seminal observation in this 
regard was that Bmi1-/- MEFs undergo premature senescence as a consequence of 
de-repression of Ink4a/Arf (Jacobs et al., 1999a). Conversely, BMI1 and CBX7 can 
extend replicative lifespan, when ectopically expressed, by down-regulating 
p16INK4a (Gil et al., 2004, Itahana et al., 2003). 
 
The oncogenic potential of Cbx7 was shown when transgenic mice, in which Cbx7 
is expressed from the Eµ promoter, developed follicular lymphoma (Scott et al., 
2007). Bmi1 was originally identified as an oncogene that collaborates with Myc in 
MuLV-induced lymphomas (van Lohuizen et al., 1991, Haupt et al., 1991). Although, 
Bmi1 can also have INK4a-independent effects in cancer, the oncogenic co-
operation of Bmi1 and Myc during lymphomagenesis is dependent on Bmi1 
repression of CDNK2A (Jacobs et al., 1999b). Furthermore, BMI1 is amplified in B 
cell lymphoma and breast cancer (Bea et al., 2001) and EZH2 is over-expressed in 
a number of tumour types (van Kemenade et al., 2001, Varambally et al., 2002, 
Bachmann et al., 2006, Bracken et al., 2003, Kleer et al., 2003).  
 
A frequent epigenetic change observed in tumour cells is the hypermethylation of 
PcG target genes (Ohm et al., 2007, Widschwendter et al., 2007, Schlesinger et al., 
2007). Indeed, PcG target genes are up to 12-times more likely to have cancer-
specific promoter DNA hypermethylation than non-PcG genes (Widschwendter et 
al., 2007). This DNA methylation may be promoted at PcG targets by the 
interaction of EZH2 and CBX7 with DNA methyltransferases (DNMTs) (Vire et al., 
2006, Mohammad et al., 2009). The effect of aberrantly silenced PcG target genes 
is thought to favour stem cell-like properties such as increased proliferative 
potential and a dedifferentiated cell state. Cancer cells that exhibit such properties, 
“cancer stem cells”, have been proposed to drive the formation and growth of 
tumours (Reya et al., 2001).  
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In addition to global upregulation of PcG proteins, alterations in PcG recruitment at 
specific targets could account for aberrant transcriptional programmes in cancer 
(Sparmann and van Lohuizen, 2006). Indeed factors implicated in PcG recruitment, 
including certain transcription factors and ncRNAs, are often dysregulated in 
primary and metastatic tumours. For example, the transcription factor OCT4, which 
occupies a significant proportion of PcG targets in human ES cells (Lee et al., 
2006b), is highly expressed in human germ cell tumours and required for their 
growth (Gidekel et al., 2003, Looijenga et al., 2003). Elevated expression of OCT4 
could therefore impair differentiation of cancer-associated stem cells. The ncRNA 
HOTAIR, which has been shown to recruit PRC2 complexes at specific target loci, 
is also expressed at elevated levels in primary breast tumours and is associated 
with a more metastatic phenotype (Gupta et al., 2010).  
 
1.7 Changes in PcG proteins at senescence 
Remarkably little is known about how various stress signals induce expression from 
CDKN2A to implement senescence. Although many signalling pathways are 
reputed to regulate CDKN2A (reviewed in (Gil and Peters, 2006)), our 
understanding of their integration and how they impact on PcG-associated 
mechanisms is sparse. Some PcG proteins are downregulated during replicative 
senescence (Itahana et al., 2003, Gil et al., 2004) but it is not clear that the 
decreased levels can account for derepression of CDKN2A. Interestingly, 
oncogenic RAS causes up-regulation of the H3K27me3 demethylase JMJD3 and 
down-regulates the EZH2 H3K27 methyltransferase. This results in a global 
reduction of H3K27me3 and activation of INK4a, leading to increased expression of 
p16INK4a (Barradas et al., 2009). However, it is not clear how locus specificity is 
achieved, as the related H3K27me3 demethylase UTX has no effect on INK4a 
expression. 
 
One possibility that has been suggested is that recruitment of either PRC2 or PRC1 
to the CDKN2A locus is specified by the lncRNA ANRIL (Yap et al., 2010, Kotake 
et al., 2011). ANRIL is transcribed in the antisense direction relative to INK4a and 
ARF and initiates at a site that is approximately 300 bp upstream of the 
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transcriptional start site of ARF, suggesting that ARF and ANRIL share a 
bidirectional promoter. As one report suggests that the levels of ANRIL decrease 
during replicative senescence in IMR90 cells, this could potentially release PcG 
repression specifically at CDKN2A (reviewed in (Aguilo et al., 2011)).  
 
1.8 Association of PcG complexes with INK4a-ARF-INK4b  
As alluded to above, several lines of evidence suggested a link between various 
PcG proteins and INK4a-ARF-INK4b. For example, Bmi1-null mice show 
proliferative defects that can be rescued by the concurrent knockout of CDKN2A 
(Jacobs et al., 1999a). Furthermore, overexpression of BMI1, CBX7 or CBX8 in 
human and mouse fibroblasts can delay the onset of senescence by repressing 
CDKN2A (Bracken et al., 2007, Dietrich et al., 2007, Gil et al., 2004, Itahana et al., 
2003). However, the first evidence for a direct connection was ChIP data from 
Bracken and colleagues, showing Bmi1, Cbx8, Ezh2 and H3K27me3 enrichment 
across the locus. In human and mouse fibroblasts, PcG protein binding peaks at 
the promoter and first exon of INK4a. Very little binding of PRC1 proteins is seen at 
the ARF and INK4b promoters. ChIP for H3K27me3 shows a much broader binding 
profile, although the peak still centres on INK4a (Bracken et al., 2007). Subsequent 
genome wide ChIP (both ChiP-on-chip and ChIP-seq) has shown that the INK4b 
and ARF promoter are also occupied by PcG complexes in mouse and human ES 
cells (Ku et al., 2008).  
 
Further ChIP studies in human fibroblasts have demonstrated that CBX4, CBX6, 
CBX7, CBX8, BMI1, MEL18, RING1, RING2, HPH1, HPH2, and HPH3, all bind at 
the INK4a locus (Dietrich et al., 2007, Bracken et al., 2007, Maertens et al., 2009, 
Pemberton et al., Submitted). Remarkably, the binding patterns are very similar if 
not identical, implying that many different types of PRC1 complex are associating 
with a relatively small region of DNA. Moreover, sequential ChIP studies with 
antibodies against different members of the Pc, Ph and Sce families, suggest that 
multiple variants of PRC1 associate simultaneously with the same DNA (Maertens 
et al., 2009, Pemberton et al., Submitted). This is thought to reflect the presence of 
Polycomb bodies in mammalian cells that comprise many different permutations of 
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PRC1 (Pemberton et al., Submitted). Conversely, the equivalent structures in 
Drosophila consist of multimers of the same PRC1. Such a scenario would explain 
why shRNA-mediated knockdown of any one of several mammalian PRC1 proteins 
(e.g. BMI1, MEL18, CBX6, CBX7, CBX8, RING1 and RING2) causes up-regulation 
of p16 and a senescent-like growth arrest (Maertens et al., 2009, Dietrich et al., 
2007, Pemberton et al., Submitted). 
 
1.9 The DNA damage response (DDR) 
1.9.1 An overview of the DDR 
Recent evidence has emerged that in addition to their well-established role as 
transcriptional repressors, PcG proteins are involved in the DNA damage response 
(DDR). The DDR refers to DNA damage signalling and repair networks that are 
crucial for maintaining genome integrity. Thousands of DNA lesions arise in human 
cells each day, typically caused by errors in DNA replication or by oxidative stress 
but also by environmental factors such as ultraviolet light and toxic chemicals. 
Failure to repair these lesions, or prevent their transmission to daughter cells, can 
result in the types of mutations and chromosomal aberrations that contribute to 
developmental defects, cancer and aging (reviewed in (Jackson and Bartek, 2009)) 
 
The nature of the DDR is determined by the type of DNA damage, and the cell 
cycle state in which it occurs. Double strand breaks (DSBs) are repaired by two 
main pathways: homologous recombination (HR) and non-homologous end-joining 
(NHEJ). HR is restricted to the S and G2 phases as it requires a homologous 
template, typically a sister chromatid, that is only available following DNA 
replication. NHEJ (the predominant pathway in higher eukaryotes) does not require 
a template and so can operate throughout the cell cycle (albeit with a higher 
mutagenic frequency) (Hartlerode and Scully, 2009). Single strand breaks (SSBs) 
elicit their own repair pathway (Caldecott, 2008).  
 
Various experimental strategies are used to introduce DNA damage and they have 
different outcomes. Exposing cells to genotoxic drugs, ionising radiation (IR), and 
ultraviolet (UV) radiation can induce global DNA damage consisting of both DSBs 
Chapter 1 Introduction 
 38 
and SSBs. These breaks occur randomly and their positions will differ between 
cells in the population, although less condensed regions of chromatin can be more 
susceptible to DNA damage (Elia and Bradley, 1992, Costes et al., 2007), More 
targeted DNA damage can be induced by laser microirradiation. Importantly, the 
laser wavelength, and energy output will all affect the type and density of DNA 
lesions (Polo and Jackson, 2011). This approach offers control over the physical 
location of the damage within a cell nucleus but not the genomic location of the 
DNA lesions. To generate site-specific breaks, it is necessary to use sequence 
specific endonucleases such as I-SceI, I-PpoI and AsiSI, but these agents also 
have limitations. For example, as there are no I-SceI cut sites in the human 
genome they have to be artificially introduced (Rouet et al., 1994). I-PpoI cuts more 
frequently but typically within repeated sequences in the ribosomal genes 
(Berkovich et al., 2007). The AsiSI restriction enzyme has 1219 target sites 
(consensus GCGATCGC) in the human genome (Hg19 release; personal 
communication from Harshil Patel, LRI Bioinformatics and Biostatistics service). 
However, CpG methylation of the consensus can inhibit AsiSI cleavage (Roberts et 
al., 2010). Nucleases can also be targeted to specific loci by fusing the nuclease 
domain to a sequence-specific zinc finger protein (Miller et al., 2007). However, 
these zinc finger nucleases (ZFN) are generally designed to cut at a single defined 
site.  Finally, it is possible to induce artificial telomere uncapping and a localised 
DDR by depletion of components that protect chromosome ends (d'Adda di 
Fagagna et al., 2003, Takai et al., 2003). 
 
1.9.2 Proteins involved in the DDR 
Proteins involved in the DDR can be categorised as DNA damage sensors, 
transducers, mediators and effectors. In mammalian cells, DSBs are detected by 
the MRN complex (MRE11-RAD50-NBS1), which contributes to the recruitment 
and activation of ATM (Falck et al., 2005, Lavin, 2007, Lee and Paull, 2005, Uziel 
et al., 2003). ATM is a transducer kinase, which, with the aid of mediator proteins 
such as 53BP1, BRCA1 and MDC1, activates the effector kinases CHK1 and 
CHK2 (Harper and Elledge, 2007) (Figure 1.1). The ultimate targets of this 
signalling cascade include DNA repair factors, cell cycle regulators, transcription 
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factors and regulators of apoptosis. This cascade involves many additional proteins. 
Among these, are a number of histone modifying enzymes, chromatin remodelling 
complexes and histone chaperones, highlighting the importance of the chromatin 
context for an effective DDR (Misteli and Soutoglou, 2009, van Attikum and Gasser, 
2009). The phosphorylation of the histone variant H2AX on serine 139 (γH2AX) has 
been the most widely studied histone modification induced by DSBs. γH2AX 
spreads from DSBs into large domains of surrounding chromatin and can be 
visualised as cytologically discernible foci by immunofluorescence (Haaf et al., 
1995, Maser et al., 1997, Scully et al., 1997). These foci are thought to be 
important for the accumulation and retention of DDR proteins. Histone 
ubiquitination is also important for orchestrating the assembly of DDR proteins at 
DNA breaks. The ubiquitination of H2A and H2AX by RNF8 and RNF168 promotes 
the recruitment of various DDR proteins, such as 53BP1 and BRCA1, to DSBs 
(Huen et al., 2007, Kolas et al., 2007, Mailand et al., 2007). Ubiquitination of H2AX 
is thought to cause local changes in chromatin structure revealing methylated 
lysine residues in core histones. Exposure of methylated histones may aid 53BP1 
recruitment by its tudor domain (Stewart, 2009). The SUMO E3 ligases PIAS1 and 
PIAS4 rapidly accumulate at sites of DNA damage. These E3 ligases promote the 
association of BRCA1 and 53BP1 with DSBs, and PIAS4 is important for the 
effective ubiquitination of H2A at these sites (Galanty et al., 2009). 
 
The E3 ubiquitin ligase activity of PRC1 and SUMO E3 ligase activity of CBX4 have 
both been implicated in the DDR. Interestingly, the function of CBX4 in this 
response may be to promote PRC1 recruitment to DSBs by sumoylating BMI1 
(Ismail et al., 2012).   
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Figure 1.1 DNA damage response at double strand breaks 
Schematic illustrating the key proteins recruited to DSBs and the protein 
modifications they facilitate. Upon sensing a DSB the MRN complex recruits 
and actives the ATM kinase. Activated ATM has a number of substrates 
including CHK1, CHK2, p53, BRCA1, MDC1 and histone H2AX. MDC1 
recognises and binds γH2AX. Phosphorylated MDC1 serves to recruit RNF8 to 
DSBs. RNF8 and RNF168 can catalyse the ubiquitination of H2A and H2AX, 
which is important for the recruitment of both 53BP1 and BRCA1 (reviewed in 
(Bohgaki et al., 2010)).  
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1.10  Evidence implicating PcG proteins in the DDR 
1.10.1 Recruitment of PcG proteins to DSBs 
The earliest indications that PcG proteins might be involved in the DDR came from 
studies of PHF1 and EZH2. PHF1, a human homologue of Polycomblike (PCL), 
which associates with PRC2 complexes (Cao et al., 2008), was detected at sites of 
laser microirradiation in HeLa cells (Hong et al., 2008). ChIP experiments revealed 
EZH2 and H3K27me3 enrichment at an I-SceI cut site (O'Hagan et al., 2008). 
Subsequent studies have extended these observations, demonstrating the co-
localisation of various PRC1 components with sites of DNA damage by visualising 
either endogenous proteins (BMI1, MEL18, RING2, CBX4) or GFP-tagged proteins 
(CBX4, CBX6, CBX7, CBX8, RING1, RING2, HPH1 and 2) in different contexts 
(Ismail et al., 2010, Chou et al., 2010, Facchino et al., 2010, Ginjala et al., 2011). 
Together these studies provide strong evidence that PRC1 proteins are recruited to 
sites of DNA damage in response to a variety of damage stimuli including IR, laser 
microirradiation and nucleases. However, it is of note that the majority of these 
studies have been conducted in either MEFs or human cancer cells lines. 
 
A number of DDR proteins interact with PRC1 proteins and these interactions are 
often enhanced following DNA damage. For example, in GBM cells, BMI1 binds 
endogenous phospho-ATM only after irradiation (Facchino et al., 2010). 
Furthermore, the interaction of H2AX with BMI1 and RING2 was enhanced 
following IR treatment (Pan et al., 2011). These interactions are probably not 
important for the initial recruitment of PRC1 proteins but may be required for their 
sustained localisation at sites of DNA damage (Chou et al., 2010, Ismail et al., 
2010, Ismail et al., 2012, Ginjala et al., 2011). The kinetics of PRC1 recruitment to 
sites of microirradiation are comparable to those of early DNA damage response 
proteins, such as RNF8, NBS1 and MRE11, but the details differ in the published 
studies (Ismail et al., 2010, Chou et al., 2010, Ginjala et al., 2011). Likewise, there 
are varied opinions about how long the association of PRC1 proteins is sustained 
in different contexts.  
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1.10.2 Importance of PcG proteins for DNA damage repair 
Studies in Bmi1-/- MEFs have implicated PcG proteins in the recruitment of 53BP1 
and BRCA1 to DNA breaks, particularly at early points after microirradiation (Ismail 
et al., 2010). However, the recruitment of Mre11, Rnf8, Nbs1 and phospho-ATM to 
DSBs is normal in BMI-/- MEFs. In addition, neither MEL18 nor BMI1 are required 
for H2AX phosphorylation at sites of DNA damage (Chou et al., 2010, Ismail et al., 
2010). However, IR-induced ubiquitination of H2AX is significantly reduced in Bmi1-
/- MEFs or in U2OS cells following BMI1 knockdown (Ismail et al., 2010). Rnf8-/- 
MEFs still contain considerable amounts of mono-ubiquitinated H2AX following 
irradiation but these levels are reduced by around 80% following knockdown of 
Bmi1. These data demonstrate a role for BMI1-RING2 in the mono-ubiquitination of 
H2AX that is independent of RNF8 (Ismail et al., 2010).  
 
Depletion of DDR proteins decreases the effectiveness of the DDR and thereby 
sensitises cells to DNA damage. Cell survival following IR treatment can be 
assessed by clonogenic assays. Depletion of BMI1, CBX4 or RING2 in different cell 
backgrounds increases the sensitivity of these cells to IR (Ginjala et al., 2011, Pan 
et al., 2011, Ismail et al., 2010, Facchino et al., 2010, Ismail et al., 2012). Bmi1-/- 
MEFs and Rnf8 -/- MEFs show similar sensitivity to IR. Importantly, the knockdown 
of Bmi1 in Rnf8-/- MEFs or of Rnf8 in Bmi1-/- MEFs increases the sensitivity of these 
cells to IR, suggesting BMI1-RING2 and RNF8 have individual contributions to the 
DDR (Ismail et al., 2010).  
 
1.11 Protein kinase CK2 (CK2) 
1.11.1 Auxiliary proteins that co-purify with PRC1 complexes 
It is over 10 years since the first description of a mammalian PRC1 complex. In the 
ensuing decade there have been several descriptions of affinity purified complexes 
based on different tagged PRC1 proteins (Dietrich et al., 2007, Gao et al., 2012, 
Maertens et al., 2009, Sanchez et al., 2007, Vandamme et al., 2011). PRC1 
proteins have also been found in other types of complex as discussed in Chapter 
1.1.1. Moreover, a number of auxiliary proteins that are not encoded by recognised 
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PcG genes consistently co-purify with PRC1 complexes. Examples include WDR68, 
MOV10, USP7, USP11 and CK2 (formerly known as casein kinase 2) (Maertens et 
al., 2010, Nicholls, 2006). Curiously, CK2 appears to be the only auxiliary protein 
that has a connection to the DDR.  
 
1.11.2 Interaction of CK2 with PRC1 complexes 
CK2 is a heterotetramer with two catalytic subunits, α and/or α’, and two regulatory 
β subunits. Peptides representing all three subunits were detected by mass 
spectrometry analysis of proteins that co-purify with mCbx7 from 293T cells 
(Nicholls, 2006, El Messaoudi-Aubert et al., 2010). These observations have been 
confirmed in several independent studies that collectively imply that CK2 
associates with complexes based on CBX2, CBX4, CBX7, CBX8, RING2, RNF3 
and RNF159 (El Messaoudi-Aubert et al., 2010, Dietrich et al., 2007, Vandamme et 
al., 2011, Sanchez et al., 2007, Gao et al., 2012). CK2 has also been found in non-
canonical PRC1 complexes. For example, CK2 subunits were identified by mass 
spectrometry analysis of affinity purified Fblx10 (Sanchez et al., 2007), RYBP and 
YAF2 (Gao et al., 2012). However, until recently, there has been no documented 
validation of the interaction by, for example, immunoblotting, mapping of interaction 
domains, or binding between recombinant proteins (Vandamme et al., 2011, 
Sanchez et al., 2007). 
 
1.11.3 CK2 complex composition  
CK2 has been identified in all eukaryotic organisms investigated, in most tissues of 
higher eukaryotes, and in nearly every cellular compartment (Guerra and Issinger, 
1999, Faust and Montenarh, 2000). The CK2 holoenzyme is a heterotetramer that 
consists of two catalytic subunits (α) that bind a central dimer of non-catalytic of 
regulatory subunits (β) (Niefind et al., 2001). In contrast to other kinases, CK2 can 
efficiently use either ATP or GTP as a phosphoryl donor (Niefind et al., 1999). 
CK2α and α’ are encoded by the CSNK2A1 and CSNK2A2 genes respectively, 
which are located on different chromosomes (Pyerin and Ackermann, 2003). CK2β 
is encoded by CSNK2B. CK2α and α’ have very similar protein sequences except 
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for their C-termini, which vary in sequence and length (Bischoff et al., 2011). CK2α 
is reported to have an approximately 12-fold higher affinity for CK2β than CK2α’ 
(Olsen et al., 2008). 
 
Although CK2 tetramers are very stable, there is evidence that CK2 catalytic and 
regulatory subunits can act independently in vivo (Bibby and Litchfield, 2005). For 
example, immunofluorescence has identified subcellular populations of CK2β that 
do not co-localise with CK2α or α’ (Krek et al., 1992), and populations of CK2α and 
α’ that do not co-localise with CK2β (Faust et al., 2001). Furthermore, live cell 
imaging of GFP-CK2α and GFP-CK2β, has demonstrated that CK2 subunits are 
independently imported into the nucleus and can move independently within the 
nucleus (Martel et al., 2001, Filhol et al., 2003). These findings suggest that 
interactions between CK2 catalytic and regulatory subunits are more dynamic in 
vivo then previously appreciated. Furthermore, CK2β has been shown to associate 
with, and regulate the activity of, other kinases, including c-Mos (Chen et al., 1997) 
and A-Raf (Hagemann et al., 1997). 
 
1.11.4 Regulation of CK2 activity and substrate specificity 
Unlike most protein kinases, CK2 is constitutively active. The isolated and 
holoenzyme-bound forms of CK2α have conserved active segment conformations 
and are both catalytically active (Boldyreff et al., 1994, Grankowski et al., 1991, 
Niefind et al., 2001). CK2β can modulate the basal activity of the catalytic subunits 
but the effects appear to be context dependent. For most substrates CK2β 
increases the basal activity of CK2α but there are examples, such as calmodulin, 
where the presence of CK2β can be inhibitory to substrate phosphorylation (Marin 
et al., 1999a). In addition to the positive regulatory domain within its C-terminus of 
CK2β, CK2β contains an acidic loop towards its N-terminus. This acidic loop might 
negatively regulate CK2 by inhibiting binding of potential substrates; the CK2 
consensus is acidic. Alternatively, as this loop binds polyamines that can increase 
the basal activity of CK2α in vitro, in certain contexts, it could positively regulate 
CK2 activity (Niefind et al., 2001, Litchfield, 2003).  
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In addition to modulating CK2 catalytic activity, CK2β can be important for 
mediating substrate interactions and specificity. For example, CK2 associates with 
p53 via the CK2β, which binds the C-terminus of p53. Interestingly, phosphorylation 
of p53 by CK2 repels the interaction between these proteins (Filhol et al., 1992). 
There are situations in which the action of the holoenzyme can be influenced by 
interactions with other proteins. For example, the FACT complex, which facilitates 
transcription through nucleosomes (Orphanides et al., 1998), has been shown to 
bind CK2 following exposure to UV radiation. This interaction can modulate the 
specificity of CK2 and promote phosphorylation of p53 over other CK2 substrates 
(Keller et al., 2001). Another example is the association of CK2α with Pin1, which 
catalyses prolyl cis/trans isomerisation at pSer/Thr-Pro motifs and thereby 
regulates the conformation of its substrates (Lu and Zhou, 2007). Pin1 has been 
shown to inhibit CK2 phosphorylation of topoisomerase IIα (Messenger et al., 
2002).  
 
CK2α and CK2β are phosphorylated by CDK1 during mitosis (Litchfield et al., 1995, 
Litchfield et al., 1992) and these modifications can regulate cell-cycle phase-
specific substrate interactions. For example, the association of Pin1 with CK2α is 
dependent on the phosphorylation of CK2α at its C-terminus, which occurs in 
mitosis (Messenger et al., 2002). Phosphorylation of CK2 can also affect CK2 
stability. Both CK2α and CK2β contain autophosphorylation sites and 
autophosphorylation of CK2β can prevent ubiquitination and proteasome-mediated 
degradation of CK2β (Zhang et al., 2002). Interestingly CK2β contains a sequence 
with similarity to the destruction box of cyclin B, which confers mitosis-specific 
proteolysis to cyclin B. However, this putative destruction box alone does not affect 
CK2β stability (Zhang et al., 2002, Glotzer et al., 1991, King et al., 1996). 
 
1.11.5 CK2 consensus sites 
The minimal consensus sequence described for CK2 is S/T-x-x-D/E/pS/pT (where 
underlining denotes the residue targeted by CK2 (serine being more common than 
threonine) and pS/pT describes a phosphorylated serine or threonine serving as a 
specificity determinant) (Marin et al., 1986, Meggio and Pinna, 2003, Meggio et al., 
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1984). CK2 can also phosphorylate tyrosine in vitro (Marin et al., 1999b). Although 
any acidic amino acid or pS at position n+3 is the best predictor of a CK2 target site, 
the majority also have a negatively charged side chain at n+1 and multiple acidic 
residues are commonly found in region n-4 to n+7 (Meggio and Pinna, 2003). 
There are limitations to using the minimal consensus for the identification of novel 
CK2 target. For example, p53 is efficiently phosphorylated at Ser392 by CK2 
despite the fact that it does not conform to the consensus sequence, although there 
is an aspartic acid at n-1 and n+1 (Meggio et al., 1994).  
 
Almost any protein sequence is likely to contain the CK2 consensus (Litchfield, 
2003). Given this, its constitutive activity, and ubiquitous expression, it is not 
surprising that CK2 has an extensive repertoire of substrates – over 300 were 
documented in a recent comprehensive review (Meggio and Pinna, 2003). The 
catalogue of CK2 substrates includes transcription factors, proteins affecting the 
structure of DNA/RNA, proteins implicated in RNA synthesis or translation, 
signalling proteins, viral proteins and a few metabolic enzymes. However, the 
catalogue compiled by Meggio and colleagues has been criticised due to the lack 
of rigorous testing to determine whether the substrates are phosphorylated in vivo 
(Litchfield, 2003).  
 
Each mammalian PcG protein contains multiple CK2 consensus sequences (Table 
1.2), but there is currently no evidence that CK2 phosphorylates these proteins. 
Several PcG proteins are phosphorylated. For example, MBLR is phosphorylated 
at Ser32 during mitosis, probably by CDK7 (Akasaka et al., 2002). EZH2 is 
phosphorylated by CDK1 and CDK2 at Thr350 and this phosphorylation is 
important for effective recruitment of PRC2 to target loci (Zeng et al., 2011). 
Moreover, BMI1 is phosphorylated at mitosis and the phosphorylation of BMI1 
correlates with its dissociation from chromatin (Voncken et al., 1999). Interestingly, 
Mel18 is phosphorylated at multiple sites, one of which, Ser 254, lies within a CK2 
consensus (Elderkin et al., 2007).   
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Human PcG protein No of CK2 consensus sites 
HPH1 10 
HPH2 9 
HPH3 10 
NSCP1 5 
MEL18 8 
RNF3 5 
BMI1 8 
RNF159 4 
MBLR 3 
CBX2 16 
CBX4 9 
CBX6 6 
CBX7 3 
CBX8 8 
RING1 9 
RING2 13 
 
Table 1.2 Number of CK2 consensus sites within the human PcG proteins 
 
 
1.11.6 Importance of CK2 for cell viability and its role in tumorigenesis 
Many studies in mammalian cells have demonstrated that CK2 is required for cell-
cycle progression (Pepperkok et al., 1991, Lorenz et al., 1993, Pepperkok et al., 
1994). It is hardly surprising, therefore, that elevated levels of CK2, which typically 
correlate with increased CK2 activity, are associated with both highly proliferative, 
normal and cancerous tissue (Faust and Montenarh, 2000, Faust et al., 1999). 
Indeed, CK2 is reported to be upregulated in all cancers examined to date and 
expression can relate to disease severity and serve as a prognostic indicator 
(Tawfic et al., 2001, Guerra and Issinger, 1999, Faust et al., 1996, Laramas et al., 
2007, Gapany et al., 1995, O-Charoenrat et al., 2004). Although CK2 is not an 
oncogene in the classical sense, its upregulation contributes to the transformation 
potential of oncogenes such as c-myc and Tal-1, and loss of p53 (Kelliher et al., 
1996, Landesman-Bollag et al., 1998, Channavajhala and Seldin, 2002). 
Conversely, CK2 levels are low in brain tissue preparations from 
neurodegenerative disorders such as in Alzheimer’s disease (Iimoto et al., 1990). 
Furthermore, there is evidence that CK2 levels decrease at senescence. 
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Specifically, CK2 activity and levels of CK2α decrease during replicative and H2O2-
induced senescence and CK2 inhibition can induce senescence in human 
fibroblasts and mesenchymal stem cells (Ryu et al., 2006, Wang and Jang, 2009). 
 
The ability of CK2 to promote cellular transformation may result from its capacity to 
protect cells from apoptosis. Normal cells overexpressing CK2α show resistance to 
chemical-mediated apoptosis (Guo et al., 2001) and siRNA of CK2α promotes 
apoptosis of cells following IR treatment (Yamane and Kinsella, 2005). In cancer 
cells, chemical inhibition or siRNA-mediated knockdown of CK2 has been shown to 
induce apoptosis (Wang et al., 2005). A number of compounds have been used to 
inhibit CK2 including DRB (Blaydes and Hupp, 1998), emodin, apigenin 
(Channavajhala and Seldin, 2002) and TBB (Sarno et al., 2001). Of these, TBB 
demonstrates the highest selectivity for CK2. CK2 inhibitors are currently in clinical 
trials for treatment of various cancer types (for example: (Pierre et al., 2011)). 
There is evidence that the anti-apoptotic function of CK2 is at least in part due to its 
phosphorylation of proteins such as Max (Krippner-Heidenreich et al., 2001), Bid 
(Desagher et al., 2001) and HS1 (Ruzzene et al., 2002). The phosphorylation of 
these proteins by CK2 protects them from caspase cleavage. Furthermore, 
phosphorylation of ARC (apoptosis repressor with caspase recruitment domain) is 
required for ARC to exert its inhibition of caspase 8 (Li et al., 2002). 
 
CK2α-/- mouse embryos have a marked reduction in CK2 activity despite the 
presence of CK2α’ and die in mid-gestation (Lou et al., 2008). CK2β is also 
essential for mouse development; knockout of CK2β causes postimplantation 
lethality (Buchou et al., 2003). Conditional knockout studies have shown that CK2β 
is essential for viability of mouse ES cells and primary MEFs (Buchou et al., 2003). 
In contrast deletion of CK2α’ is well tolerated. CK2α’-/- mice are viable but the 
males have defects in spermatogenesis and are infertile (Xu et al., 1999). This 
probably reflects the restricted expression of CK2α’, which is predominantly found 
in the brain and testes of mice, contrasting the ubiquitous expression of CK2α 
(Guerra et al., 1999, Faust and Montenarh, 2000).  
 
Chapter 1 Introduction 
 49 
1.11.7 CK2 in the DNA damage response 
The importance of CK2 for cell viability and for protection against apoptosis may 
also be partly explained by its function in the DDR. Phosphorylation of XRCC1 by 
CK2 stabilises the interaction of XRCC1 with DNA ligase IIIα, a complex involved in 
the DNA ligation stage of both base-excision repair (BER) and SSB repair (Parsons 
et al., 2010). A recent study has shown that CK2 is involved in promoting HR. 
Phosphorylation of Rad51 (a recombinase that catalyses homologous pairing and 
strand transfer during HR) by Polo-like kinase 1 (Plk1), primes Rad51 for 
phosphorylation by CK2 during the cell cycle and in response to DNA damage. 
CK2 phosphorylation of Rad51 promotes binding of Rad51 to Nbs1, facilitating 
Rad51 recruitment to sites of DNA damage (Yata et al., 2012). Furthermore, CK2 
has been shown to directly phosphorylate HP1β during the DDR. The 
phosphorylation of HP1β disrupts its interaction with H3K9me3 and serves to 
mobilise HP1β from chromatin. Mobilisation of HP1β from chromatin appears to 
facilitate the phosphorylation of H2AX (Ayoub et al., 2008). CK2 phosphorylates 
threonine 51 (T51) within the chromodomain of HP1β, which lies within an atypical 
but highly acidic consensus (TXEXEE). Interestingly, T51 of HP1β is conserved in 
the chromodomains of CBX4, 6, 7 and 8 and is replaced with a serine in CBX2. 
This raises the tantalising possibility that CK2 might phosphorylate the CBX 
chromodomains and disrupt their interaction with H3K27me3. 
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1.12  Thesis aims 
At the inception of this thesis, CK2 had been identified as a prominent auxiliary 
protein that co-purified with mCbx7 (Nicholls, 2006). The aim of this thesis was to 
investigate the functional relevance of this interaction. Specifically, we set out to 
answer the following questions: 
 
• Which PRC1 component is responsible for the interaction with CK2?  
 
• Does CK2 phosphorylate components of the PRC1 complex? 
 
• Is CK2 required for the ability of PRC1 proteins to repress target genes such 
as INK4a and to extend the lifespan of HDFs? 
 
• Is CK2 important for the role of PRC1 proteins in the DDR? 
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Chapter 2. Materials & Methods 
2.1 Molecular biology 
2.1.1 Oligonucleotides 
All oligonucleotides were ordered from Sigma and are listed in Table 2.1. 
Oligonucleotides were supplied with –OH groups at both the 5’ and 3’ ends. Melting 
temperatures (Tm) of oligonucleotides were calculated by the suppliers. 
Oligonucleotides were used as primers for polymerase chain reaction (PCR) 
amplification or DNA sequencing.  
 
Name Sequence (5’ - 3’) 
CK2α shRNA1 forward (fwd) GATCCCCGTGTGTCTTAGTTACATCATTCAAGAGATGATGTAA
CTAAGACACACTTTTTGGAAA 
CK2α shRNA1 reverse (rev) AGCTTTTCCAAAAAGTGTGTCTTAGTTACATCATCTCTTGAATG
ATGTAACTAAGACACACGGG 
CK2α shRNA2 fwd GATCCCCCCGTTGCTTGTGGATTTATTTCAAGAGAATAAATCC
ACAAGCAACGGTTTTTGGAAA 
CK2α shRNA2 rev AGCTTTTCCAAAAACCGTTGCTTGTGGATTTATTCTCTTGAAAT
AAATCCACAAGCAACGGGGG 
CK2α‘ shRNA1 fwd GATCCCCGGGAATCATGCACAGGGATTTCAAGAGAATCCCTG
TGCATGATTCCCTTTTTGGAAA 
CK2α‘ shRNA1 rev AGCTTTTCCAAAAAGGGAATCATGCACAGGGATTCTCTTGAAA
TCCCTGTGCATGATTCCCGGG 
CK2α‘ shRNA2 fwd GATCCCCGATCCTGACAGACTTTGATTTCAAGAGAATCAAAGT
CTGTCAGGATCTTTTTGGAAA 
CK2α‘ shRNA2 rev AGCTTTTCCAAAAAGATCCTGACAGACTTTGATTCTCTTGAAAT
CAAAGTCTGTCAGGATCGGG 
CK2β shRNA1 fwd GATCCCCGCCATGGTGAAGCTCTACTTTCAAGAGAAGTAGAG
CTTCACCATGGCTTTTTGGAAA 
CK2β shRNA1 rev AGCTTTTCCAAAAAGCCATGGTGAAGCTCTACTTCTCTTGAAA
GTAGAGCTTCACCATGGCGGG 
CK2β shRNA2 fwd GATCCCCGGAGTCGTTATTGTGGTGGTTCAAGAGACCACCAC
AATAACGACTCCTTTTTGGAAA 
CK2β shRNA2 rev AGCTTTTCCAAAAAGGAGTCGTTATTGTGGTGGTCTCTTGAAC
CACCACAATAACGACTCCGGG 
mCbx7-T140A fwd AACTCCGTCACCGTCGCCTTCCGCGAGGCTCAA 
mCbx7-T140A rev TTGAGCCTCGCGGAAGGCGACGGTGACGGAGTT 
mCbx7-T140D fwd AACTCCGTCACCGTCGACTTCCGCGAGGCTCAA 
Chapter 3. Interaction of CK2 with PRC1 
 
 52 
mCbx7-T140D rev TTGAGCCTCGCGGAAGTCGACGGTGACGGAGTT 
mCbx7-V137A fwd ATCACCGCCAACTCCGCCACCGTCACCTTCCGC 
mCbx7-V137A rev GCGGAAGGTGACGGTGGCGGAGTTGGCGGTGAT 
mCbx7-V137AT140A fwd AACTCCGCCACCGTCGCCTTCCGCGAGGCTCAA 
mCbx7-V137AT140A rev TTGAGCCTCGCGGAAGGCGACGGTGGCGGAGTT 
mCbx7-V137AV139AT140A fwd GCCAACTCCGCCACCGCCGCCTTCCGCGAGGCT 
mCbx7-V137AV139AT140A rev AGCCTCGCGGAAGGCGGCGGTGGCGGAGTTGGC 
mCbx7-V137D fwd ATCACCGCCAACTCCGACACCGTCACCTTCCGC 
mCbx7-V137D rev GCGGAAGGTGACGGTGTCGGAGTTGGCGGTGAT 
mCbx7-V137DT140D fwd AACTCCGACACCGTCGACTTCCGCGAGGCTCAA 
mCbx7-V137DT140D rev TTGAGCCTCGCGGAAGTCGACGGTGTCGGAGTT 
mCbx7-V137DV139DT140D fwd GCCAACTCCGACACCGACGACTTCCGCGAGGCT 
mCbx7-V137DV139DT140D rev AGCCTCGCGGAAGTCGTCGGTGTCGGAGTTGGC 
mCbx7-V139A fwd GCCAACTCCGTCACCGCCACCTTCCGCGAGGCT 
mCbx7-V139A rev AGCCTCGCGGAAGGTGGCGGTGACGGAGTTGGC 
mCbx7-V139D fwd GCCAACTCCGTCACCGACACCTTCCGCGAGGCT 
mCbx7-V139D rev AGCCTCGCGGAAGGTGTCGGTGACGGAGTTGGC 
pBABE fwd CGTCTCTCCCCCTTGAACC 
pBABE rev CTGCCTGCTGGGGAGGCC 
pcDNA6 fwd (T7) AATACGACTCACTATAG 
pcDNA6 rev (BGH) TAGAAGGCACAGTCGAGG 
pGEX-6P1 fwd GGGCTGGCAAGCCACGTTTGGTG 
pGEX-6p1 rev CCGGGAGCTGCATGTGTCAGAGG 
pRetroSuper fwd TACATCGTGACCTGGGAAGC 
pRetroSuper rev TAAAGCGCATGCTCCAGACT 
Table 2.1 Oligonucleotides  
 
2.1.2 Plasmid vectors 
Plasmid vectors were propagated from laboratory stocks and used to clone new 
constructs. In addition, constructs were kindly provided by other laboratories, as 
acknowledged in the relevant sections. Commonly used vectors are described 
below. 
 
pBABE  This vector is based on the Moloney leukaemia virus 
(Morgenstern and Land, 1990). When transfected into a packaging cell line this 
vector allows for the production of ecotropic retroviruses. The gene of interest is 
under the control of a long-terminal repeat (LTR) promoter. The vector contains an 
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ampicillin resistance gene for selection in bacteria, and puromycin, hygromycin or 
bleomycin resistance genes for selection of mammalian cells.  
 
pRetroSuper  This vector is based on the pMSCV retroviral plasmid and the 
pSUPER shRNA plasmid for expression of shRNAs (Brummelkamp et al., 2002). 
shRNA targeting the gene of interest is expressed from an RNA polymerase III-
dependent promoter. The vector contains an ampicillin resistance gene for 
selection in bacteria and a puromycin resistance gene for selection of mammalian 
cells. 
 
pcDNA6/V5-HisB This vector is derived from pcDNA3.1. It is designed for stable 
or transient expression of the gene of interest in mammalian cells. The gene of 
interest is under the control of a CMV promoter allowing for high levels of 
expression. The vector contains an ampicillin resistance gene for selection in 
bacteria, and a blasticidin resistance gene for selection of mammalian cells. 
  
 
pGEX-6P1  This vector allows for the expression a protein attached to the 
C-terminus of GST. Between the protein and GST lies a prescission protease 
cleavage site, allowing for the removal of the GST tag if required. An internal 
lactose repressor gene allows for control of high level gene expression from the tac 
promoter. Chemical induction of gene expression occurs when IPTG releases lac 
repressor from the tac promoter. The vector contains an ampicillin resistance gene 
for selection in bacteria.  
 
1.1.1 Amplification of DNA by PCR 
DNA was routinely amplified using the following 50µl PCR reaction mix: 1x Pfu 
Ultra HF Reaction buffer (Agilent), 0.2mM deoxynucleotide triphosphates (dNTPs) 
(Pharmacia Biotech), 1µM Primer 1, 1µM Primer 2, 50ng DNA, 2.5 units Pfu Ultra 
HF polymerase (Agilent). The ‘basic’ PCR cycle program used was as follows: 
 
1. 94oC for 5 minute (denaturation (denaturation of plasmid DNA and 
primer:template complexes))  
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2. 94oC for 30 seconds (cyclical denaturation)  
3. Tann (primers) for 30 seconds (primer annealing (annealing of primers to 
template))  
4. 72oC for 2 minutes (extension (amplification of plasmid in a template-
directed manner by DNA polymerase)) 
5. Cycle steps 2-4, 34 more times 
 
Annealing temperature of primers (Tann) was approximated at 3-4oC less than the 
Tm of the primers. The elongation time of the reaction at 72oC was adjusted 
according the length of expected product (2 minutes/kb). 
 
2.1.3 Site-directed mutagenesis by over-lap extension 
The cloning strategy for site-directed mutagenesis by over-lap extension is outlined 
in Figure 2.1. PCR 1 used the routine PCR reaction mix and the basic PCR cycle 
program. DNA fragments were separated by gel electrophoresis and visualised 
using a UV transilluminator as described below. PCR 2 used the following 50µl 
PCR reaction mix: 1x Pfu Ultra HF Reaction buffer (Agilent), 2.5 units Pfu Ultra HF 
polymerase (Agilent), 0.2mM dNTPs (Pharmacia Biotech), 1µM Primer 1, 1µM 
Primer 2, 1/10th PCR 1 product AB and 1/10th PCR 1 product BC. PCR 2 used the 
following ‘2cycles3’ program: 
 
1. 94oC for 3 minutes (denaturation)  
2. 94oC for 30 seconds (cyclical denaturation)  
3. Ramp to 45oC for 1 minute (0.1oC/second) (annealing)  
4. 72oC for 5 minutes (extension) 
5. Cycle steps 2-4, 4 more times 
6. 94oC for 30 seconds (denaturation) 
7. Tann (Primers) for 30 seconds (Primer annealing)  
8. 72oC for 5 minutes (extension)  
9. Cycle steps 6-9, 29 more times 
10. 72oC for 15 minutes 
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The DNA fragment product of PCR 2 was separated by gel electrophoresis and 
visualised using a UV transilluminator before being subject to restriction enzyme 
digestion and ligation into cut vector as described below.  
 
 
Figure 2.1 Schematic diagram of site-directed mutagenesis by over-lap extension 
DNA and synthetic oligonucleotides are represented by lines with half arrows 
indicating the 5’ to 3’ orientation. Black lines represent the pGEX-6P1 vector, blue 
lines represent the mCbx7 sequence and the orange lines represent the site of 
mutagenesis. Oligonucleotides are denoted by lower-case letters and PCR 
products are denoted by pairs of upper-case letter corresponding to the 
oligonucleotide primers used to generate that product. The boxed portion 
represents the intermediate step taking place during PCR 2, where the denatured 
fragments anneal at the overlap for extension by DNA polymerase to form the 
mutant fusion product, which is amplified in the presence of primers a and d. 
 
 
a
db
c
Mutant  fusion  product  
PCR  product  CD
PCR  product  AB
PCR  1
PCR  2
a
d
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2.1.4 Cloning shRNA expression vectors 
Short hairpin RNA (shRNA) template inserts were created by annealing 
complementary oligonucleotides to create a synthetic DNA duplex for cloning. 
Unique siRNA target sites within mRNA nucleotides were identified using the 
GenScript siRNA Target Finder. Accession numbers used were: NM_001895 
(CK2α), NM_001896 (CK2α’) and NM_001320 (CK2β). The unique 19 nucleotide 
siRNA target sequence (SeqA1) generated by the GenScript program and its 
reverse-compliment counterpart (SeqA2) were entered into a template 
oligonucleotide sequence as follows: 
shRNA fwd: ................GATCCCC(SeqA1)TTCAAGAGA(SeqA2)TTTTTGGAAA 
shRNA rev:. AGCTTTTCCAAAAA(SeqA1)TCTCTTGAA(SeqA2)GGG…………. 
SeqA1 and SeqA2 were separated by a loop region, which facilitated short hairpin 
structure folding upon expression. The sticky ends at the periphery of the 
oligonucleotide, allowed for ligation into the pRetroSuper vector. Oligonucleotides 
used to clone shRNAs against CK2α, CK2α’ and CK2β are specified in Table 2.1. 
 
Oligonucleotides were diluted to 1µg/µl in water. 3µl shRNA fwd primer and 3µl 
shRNA rev primer were mixed with 44µl annealing buffer heated to 94oC for 4 
minutes and then incubated ay 70oC for 10 minutes. 3µl annealed primers were 
mixed with 50ng pRetroSuper vector previously cut with restriction enzymes HindIII 
and BglII (New England Biolabs (NEB)), 1µl 10x T4 DNA ligase buffer and 400 
units T4 DNA ligase (NEB). This ligation mix was incubated at room temperature 
for 30 minutes before transformation of competent bacteria (described below) 
 
2.1.5 Restriction digests and ligation of plasmids 
Plasmid DNA or PCR products were digested with restriction enzymes to produce 
DNA fragments. These fragments were subsequently used in ligation reactors, 
either as the recipient vector or insert DNA. Digestion was set up in a total volume 
of 30µl using 1 unit restriction enzyme (NEB) for 1µg DNA (typically 2µg was used), 
100µg/ml BSA (NEB) and 1x digestion buffer (NEB) chosen to provide optimal 
conditions for the restriction enzymes in question. Digests were incubated for 
between 30 minutes and 1 hour at 37oC. Fragments were resolved by agarose gel 
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electrophoresis, purified from the gel, and DNA concentration was determined 
(described below). 
 
Ligation reactions were set up in a total volume of 10µl with 1µl 10x T4 DNA ligase 
buffer, 400 units T4 DNA ligase (NEB) and a 3:1 ratio of insert:vector DNA e.g. 
150ng insert DNA and 50ng vector DNA (although this did vary depending on 
fragment size). Ligation reactions were left for 1 hour at room temperature or 
overnight at 16oC and 5µl was subsequently used to transform bacteria. A control 
reaction containing cut vector only was set up to determine background colony 
formation as a consequence of self-ligated plasmid. 
 
2.1.6 Agarose gel electrophoresis and gel extraction 
0.5-2% agarose gels (Invitrogen) (depending on the size of DNA fragment to be 
resolved) containing 50ng/ml ethidium bromide (Sigma) were cast using the Hoefer 
system. Once set, the gel was placed in an electrophoresis tank containing 1x TAE 
running buffer and samples were loaded alongside 10µl of pre-diluted molecular 
weight markers (Trackit 1Kb plus (Invitrogen)). 6x DNA loading buffer was added to 
DNA samples to allow visualisation of the gel front and assist sinking of samples 
into the wells. Electrophoresis was performed at 100V. Following sufficient 
separation, DNA fragments were visualised by a UV transilluminator (UVP BioDoc-
IT). Relevant DNA fragment sizes were excised and recovered using the QIAquick 
Gel Extraction kit (Qiagen) according to manufacturer’s instructions. DNA was 
typically eluted in 30µl EB. 
 
2.1.7 DNA sequencing 
DNA sequencing was performed by LRI Equipment Park using ABI PRISM Dye 
Terminator Cycle Sequencing kit (Applied Biosystems). PCR reactions contained 
low-level dye-labelled dideoxynucleotide triphosphate (ddNTP) terminators in a 
pool of dNTPs. Random incorporation of these ddNTP terminators caused 
premature termination of DNA polymerase. The products of such a PCR varied in 
length and were each labelled with one of the four ddNTPs. Sequencing reactions 
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contained 8µl big-dye terminator (BDT) 3.1 mix (Applied Biosystems), 3.2pmol 
sequencing primer and 250ng DNA, made up to a final volume of 20µl. The PCR 
cycling program used was as follows: 
 
1. 96oC for 1 minute (denaturation)  
2. 96oC for 10 seconds (cyclical denaturation)  
3. Ramp to 50oC for 5 seconds (1oC/second)  
4. Ramp to 60oC for 4 minutes (1oC/second) 
5. Cycle steps 2-4, 24 more times 
 
PCR products were purified using DyeEx 2.0 Spin kit (Qiagen), according to 
manufacturers instructions, to remove unincorporated dye-labelled ddNTPs. 30µl 
elute containing purified DNA was dried in a vacuum centrifuge (DNA Speed Vac 
Savant) and pellets were then processed by the LRI Equipment Park. This 
processing involved separation of PCR products using the Applied Biosystems 
Prism 3730 system. Sequences were analysed using MacVector software 
(Accelrys) and ddNTP fluorescence traces were confirmed manually. DNA 
sequencing was analysed using MacVector software (Accelrys).  
 
2.1.8 Production of chemically competent bacteria 
DH5α competent E. coli bacteria were thawed from -80oC stocks on ice. 20µl 
competent DH5α were inoculated into 10ml L-Broth (LB) and incubated, shaking at 
200rpm overnight at 37oC alongside 10ml LB without DH5α (control). If the control 
‘culture’ was clear of bacteria the following day then 100ml LB was inoculated with 
1ml overnight DH5α culture and incubated shaking at 200rpm, at 37oC until it 
reached an optical density measured at a wavelength of 600nm (OD600) of 0.5. 
Bacteria were pelleted at 3000rpm for 10 minutes at 4oC and supernatant was 
discarded. Cells were gently resuspended in 50ml ice-cold 100mM MgCl2 and then 
pelleted at 3000rpm for 10 minutes at 4oC. After supernatant had been discarded, 
DH5α cells were gently resuspended in 100ml ice-cold 100mM CaCl2 and left on 
ice for 60-90 minutes. After the cells were pelleted at 3000pm for 10 minutes at 4oC, 
the supernatant was discarded and cells were resuspended in 8ml ice-cold 85mM 
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CaCl2 with 15% glycerol. 100µl aliquots were snap frozen in liquid nitrogen and 
stored at -80oC. 
 
2.1.9 Transformation of chemically competent bacteria 
Top10 One Shot (Invitrogen) or DH5α chemically competent bacteria (stored at -
80oC) were thawed on ice. 10-50ng DNA in a total volume of 5µl was added to 50µl 
thawed bacteria and flicked to mix. The bacteria/DNA mix was incubated on ice for 
30 minutes then transferred to a 42oC water bath for 45 seconds and immediately 
transferred back to ice for 2 minutes. Bacteria were subsequently incubated 
shaking at 200rpm with 500µl LB for 1 hour at 37oC. 50µl-250µl bacteria were 
spread on LB agar plates containing the selective drug (100µg/ml ampicillin) (LB 
AMP) and incubated overnight at 37oC. 
 
2.1.10 Small-scale preparation of plasmid DNA (miniprep) 
Small-scale preparation of plasmid DNA was used to screen bacterial colonies to 
identify those expressing successfully ligated plasmids. Single colonies picked from 
the transformation plate were inoculated in 5ml LB AMP and incubated overnight 
shaking at 200rpm, at 37oC. Bacteria were pelleted by centrifugation at 6000g for 
10 minutes and supernatant was discarded. Plasmid preparation was then 
performed using the QIAprep Spin Miniprep kit (Qiagen) by following the 
manufacturers protocol and using the solutions provided. Bacterial cells were lysed 
under alkaline conditions. The lysate was subsequently neutralised and adjusted to 
high-salt binding conditions. the lysate was cleared by centrifugation (13,200rpm) 
and applied to a silica-gel membrane, which adsorbed DNA but not RNA, cellular 
proteins or metabolites. This membrane was washed in buffer containing 80% 
ethanol to remove salt. Pure plasmid DNA was eluted with 50µl EB. 
 
2.1.11 Large-scale preparation of plasmid DNA (maxiprep) 
100ml LB AMP was inoculated with 200µl overnight mini-culture and incubated 
overnight shaking at 200rpm, at 37oC. Alternatively, a scrape sample of a glycerol 
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stock of bacteria was inoculated in 100ml LB AMP and incubated overnight shaking 
at 200rpm at 37oC. This glycerol stock was made by mixing 500µl 60% filtered 
glycerol with 500µl of overnight mini-culture and snap freezing the mix in liquid 
nitrogen for subsequent storage at -80oC. Bacteria in the 100ml culture that had 
been incubated overnight shaking at 200rpm, at 37oC, were pelleted at 6000g for 
15 minutes and supernatant was discarded.  
 
Large-scale preparation of plasmid DNA was performed using the QIAfilter Plasmid 
Maxi kit (Qiagen) by following the manufacturer’s protocol and using the solutions 
provided. Bacterial cells were lysed under alkaline conditions. Lysate was 
subsequently neutralised and debris removed using a QIAfilter cartridge (Qiagen). 
The remaining solution was loaded into a pre-equilibrated QIAGEN-tip by gravity 
flow. Salt and pH conditions ensured only DNA was adsorbed. The QIAGEN-tip 
was washed with medium-salt buffer to remove any remaining contaminants. 
Plasmid DNA was then eluted with high-salt buffer. Eluted plasmid DNA was 
desalted, concentrated by isopropanol precipitation and washed with 70% ethanol 
at room temperature. Purified DNA was briefly air-dried and re-dissolved in 500µl-
1ml TE.  Plasmid DNA concentration was determined using a spectrophotometer 
(Nanodrop (Thermo Scientific)), which measured absorbance of 260nm wavelength 
light in 1µl of eluted DNA. 
	  
2.2 Cell culture 
All cell types used were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(GIBCO) supplemented with 10% foetal bovine serum (FBS) (PAA) and the 
antibiotics penicillin and streptomycin, which will together be referred to as 
‘medium’. AsiSI-ER-HA-U20S cells were grown in the continued presence of 
1µg/ml puromycin. Cells were grown as monolayers in plastic tissue culture dishes 
at 37oC in 5% CO2. Just prior to confluency, cells were washed in 37oC PBSA and 
incubated with diluted trypsin (between 1:2 and 1:10 trypsin (0.25% Trypsin-EDTA 
(Gibco)):PBSA depending on cell type) at 37oC. When cells began to detach from 
the plate medium was added to neutralise the trypsin and cells were seeded into 
new culture dishes. For cell lines, cells were generally split at a ratio 1:4 and 1:8. 
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For primary human fibroblasts, cells were split either 1:2 or 1:4 and new passage 
numbers (+1 or +2 respectively) were recorded accordingly.  
 
2.2.1 Cell lines and primary fibroblasts 
293T    Ad5/SV40 large T-transformed HEK293 (ATCC number 
CRL-1573) 
U2OS Human osteosarcoma cell line (ATCC number HTB-96) 
AsiSI-ER-HA-U20S  Clonal U20S cell line that stably expressed AsiSI-ER 
fusion protein ((Iacovoni et al., 2010)) 
FDF  Human foetal dermal fibroblasts (Brookes et al., 2004) 
Hs68  Human neonatal foreskin fibroblasts (ATCC number 
CRL-1635) (Ohtani et al., 2001) 
IMR90  Foetal lung fibroblast strain (ATCC number CCL-186) 
(Nichols et al., 1977) 
TIG3  Foetal lung fibroblast strain (ATCC number CRL-9609) 
(Provided by E.Hara) 
ESC  Human endometrial stromal cells (fibroblast) (Brookes et 
al., 2004) 
Table 2.2 Description of cell lines and primary fibroblasts 
 
2.2.2 Storage and recovery of cells 
Prior to storage, cells were released from the tissue culture dish using trypsin, as 
previously described, and resuspended in medium. Cells were pelleted at 750g for 
5 minutes and resuspended in freezing medium (50% FCS, 10% DMSO and 40% 
medium) before being transferred to Cryovials (Corning Incorporated). Cryovials 
were placed in a freezing container (Nalgene) containing isopropanol, which 
ensured cells were gradually frozen (-1oC/minute) when placed at -80oC. Once 
frozen, cells were transferred to liquid nitrogen tanks. Cells were recovered from 
liquid nitrogen storage by placing the Cryovial directly in a 37oC water bath to thaw 
(typically 1 minute). Cells were then transferred into 10ml medium and pelleted at 
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750g to remove DMSO. Cell pellets were resuspended in medium and seeded into 
a culture dish. 
 
2.2.3 Transfection of cell lines 
12 hours prior to transfection, approximately 4x106 cells were seeded into a 
100mm-diameter culture dish (BD Falcon) in a total volume of 10ml medium.  
 
2.2.3.1 Lipofectamine 2000 transfection  
Transfection Mix A (1.5ml OptiMem (Gibco) and 10µg plasmid DNA) and 
Transfection Mix B (1.5ml OptiMem and 30µl Lipofectamine 2000 (Invitrogen)) were 
incubated alone for 5 minutes and then mixed together and incubated at room 
temperature for a further 20 minutes. During this incubation, the medium bathing 
293T cells was replaced with DMEM only. Transfection Mix A/B was then added to 
the cells. Cells were harvested for protein or RNA extraction 24 hours after 
transfection. 
  
2.2.3.2 Calcium phosphate transfection for production of amphotropic virus 
10µg of plasmid DNA was combined with 2µg pCG-VSV-G and 8µg pCG-Gag-Pol 
DNA (for retrovirus) or pCMV ∆8.2 (for lentivirus), mixed with 60µl 2M CaCl2, and 
made up to 500µl with water. 500µl 2x HBS was added to the DNA mix in a drop-
wise manner and solution was incubated at room temperature for 30 minutes 
without mixing. The solution was added to 293T cells in a drop-wise manner evenly 
over the plate. Cells were incubated under normal conditions for 10-14 hours 
before the medium was replaced with 10ml fresh medium. 24 hours later virus was 
harvested and used to infect HDFs.  
 
2.2.4 Viral infection of human diploid fibroblasts (HDFs) 
HDFs were split 1:4, 24 hours prior to infection into a 100mm-diameter culture dish. 
Amphotropic virus was collected from medium bathing 293T cells and filtered 
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through a 0.45µm Millex-HV filter (Millipore). For retroviral infection the total 10ml of 
virus-containing medium was added directly to the HDFs (with previous medium 
removed). For lentiviral infection the harvested virus was first diluted 1:5. 32-48 
hours post-infection HDFs were washed and fresh medium was applied containing 
0.75µg/ml Puromycin (Invitrogen). Selection efficiency was monitored against a 
plate of uninfected HDFs.  
 
2.2.5 Chemical treatment of cells in culture  
2.2.5.1 Tamoxifen (4OHT) induction of ER-fusion protein translocation 
4OHT causes the translocation of ER-fusion proteins from the cytosol to nucleus. 
4OHT (300µM in methanol) was diluted to a working concentration of 300nM in cell 
medium. Control medium contained an equivalent volume of methanol. AsiSI-ER-
HA-U20S cell line and AsiSI-ER-HA-Hs68 HDF cells (both stably expressing HA-
tagged AsiSI-ER fusion protein) were grown to near confluency and incubated with 
4OHT or control medium for 4 hours. After this incubation, cells were fixed for 
immunofluorescence or chromatin immunoprecipitation (see below). 
 
2.2.5.2 TBB and DRB inhibition of CK2 
TBB and DRB are chemical inhibitors of protein kinase CK2. TBB (Sigma-Aldrich) 
(60mM in DMSO) was diluted to a working concentration of 300µM in cell medium. 
Control medium contained an equivalent volume of DMSO. HDF cells were 
incubated with TBB or control medium for 6 or 12 hours before harvesting. 
 
DRB (Sigma-Aldrich) (30mM in ethanol) was diluted to 75µM in cell medium. 
Control medium contained an equivalent volume of ethanol. 293T cells were 
incubated with DRB for 3 hours before harvesting.  
 
2.2.6 Harvesting cells 
Cells were released from the culture dish using trypsin, as previously described, 
and resuspended in medium. Cells were pelleted at 750g for 5 minutes and 
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washed twice in 10ml ice-cold PBSA. The washed cell pellet was resuspended in 
1ml ice-cold PBSA, transferred to a 1.5ml microcentrifuge tube and pelleted. The 
cell pellet was then either snap frozen in liquid nitrogen and stored at -80oC or 
immediately lysed for protein or RNA extraction. 
 
2.3 RNA techniques 
2.3.1 Preparation of total cellular RNA 
Total RNA was purified using the Qiagen RNeasy kit according to the 
manufacturer’s protocol for mammalian cells. Harvested cells were lysed in 600µl 
lysis buffer containing 2-Mercaptoethanol to inactivate RNases. Lysates were 
homogenised by passing them through a QIAshredder spin column (Qiagen) at 
13,200rpm for 1 minute. 70% ethanol was added to the samples, which were then 
transferred to RNeasy spin columns. RNA was bound to the silica gel of the 
RNeasy spin column by centrifugation at 13,200rpm, washed to remove 
contaminants and eluted in RNase-free water. The Nanodrop spectrometer was 
used to determine the RNA concentration (by measuring sample absorbance at a 
wavelength of 260nm) and to check the purity of the RNA. 
 
2.3.2 Reverse transcription PCR (RT-PCR) 
RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcription 
kit (Applied Biosystems) according to the manufacturers instructions. Random 
hexamers were used, as opposed to oligo(dT)16, to prime cDNA synthesis. 2µg 
RNA was used in a 50µl reaction mix that contained RNase inhibitors. The reaction 
mix was heated to 65oC for 10 minutes to initiate the reaction, held at 42oC for 30 
minutes for reverse transcription and then heated to 95oC for 5 minutes to 
inactivate the reverse transcriptase. The cDNA product was used for Quantitative 
Real-Time PCR (see below). 
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2.3.3 Quantitative Real-Time PCR (qPCR) of cDNA 
Primers were typically designed to be 20-24mers with 50-60% GC content, a Tm ≥ 
60oC and no more than three consecutive repeats of the same base. Exonic 
regions where forward and reverse primers anneal were either separated by a 
large intron in genomic sequence or spanned an intron/exon boundary. This 
prevented potential amplification of cDNA in the PCR. Products were designed to 
be around 150bp. Correct product size was verified by agarose gel electrophoresis 
alongside a H2O control qPCR. High specificity of a qPCR reaction corresponded to 
a single sharp peak in the dissociation curve at a temperature above 80oC in the 
presence of cDNA but not in an H2O control. These curves were also assessed to 
ensure primer-dimers were not formed during the qPCR reaction. Primers used are 
detailed in Table 2.3. 
 
Every cDNA:Primer mix reaction combination was performed in triplicate. A primer 
set measuring changes of a reference gene invariant under experimental condition 
(β tubulin or RPS17) was used as an internal control so as to allow relative 
quantification of mRNA levels between samples. Each well of a MicroAMP fast 
optical 96-well Reaction plate (Applied Biosystems) contained the follow reaction 
mix: 1µl cDNA, 11µl sterile water, 0.5µl Primer mix (10µM fwd primer and 10µM rev 
primer), and 12.5µl Express qPCR Supermix with Premixed ROX (Invitrogen), 
which is based on SYBR green incorporation and includes ROX passive reference 
dye. Reaction mixes were transferred from master mixes of A) cDNA and sterile 
water and B) Express qPCR Supermix and Primer mix. Wells were sealed with 
MicroAMP Optical Adhesie Film (Applied Biosystems), centrifuged to remove any 
bubbles and PCR cycling was carried out in a 7500 FAST Real-Time PCR machine 
(Applied Biosystems). The following cycling protocol was used: 
 
1. 95oC for 15 seconds (hotstart of the polymerase) 
2. 95oC for 3 seconds (cyclical denaturation) 
3. 60oC for 30 seconds (primer anneal and extension) 
4. Fluorescence read 
5. Cycle steps 2-4, 39 times 
6. Dissociation stage 
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Data were analysed using SDS software (Applied Biosystems) and exported to 
Excel.  
 
Name Sequence (5’ – 3’) 
CBX7 fwd CGGAAGGGTAAAGTCGAGTATC 
CBX7 rev TCGGACCTCTCTTCCTATACCC 
CK2α fwd CTTCTCAGGGGAGGCAGGA 
CK2α rev CACACTTCCACAAGAGCCACT 
CK2α’ fwd’ CACTTTTCCATAAGCAGAACAAGA 
CK2α’ rev TACATTCGGAAGTGAGGTTTGATA 
CK2β fwd AAAAGTACCAGCAAGGAGACTTTG 
CK2β rev GTGTCTTGATGACTTGGGTGTGTA 
Cyclin D2 fwd ATTGCTCTGTGTGCCACCGAC 
Cyclin D2 rev GGCATCACAAGTGAGCGAGCT 
GAS1 fwd TCTCGACAGCTGTTCATTTCC 
GAS1 rev GCAGAAGGTCCCCTTTCG 
IGFBP5 fwd GGTTTGCCTCAACGAAAAGA 
IGFBP5 rev AGATCTTGGGGGAGTAGGTCTC 
p16 fwd CGGTCGGAGGCCGATCCAG 
p16 rev GCGCCGTGGAGCAGCAGCAGC 
RPS17 fwd GCACCAAAACCGTGAAGAAG 
RPS17 rev TCTTGTTGCGGAGCTTTTTG 
TGFB2 fwd CCAAAGGGTACAATGCCAAC 
TGFB2 rev CAGATGCTTCTGGATTTATGGTATT 
β tubulin fwd ATGGATCCCCAACAATGTCA 
β tubulin rev TCCTGGATGGCTGTGCTATT 
Table 2.3 List of primers used to amplify cDNA (previously generated from 
mature mRNA) 
 
2.3.4 qPCR of DNA purified from ChIP 
DNA purified from ChIP assays (Chapter 2.4.9) was also analysed by qPCR in 
essentially the same way as cDNA prepared from cellular mRNA (Chapter 2.3.3). 
However, 2µl DNA was used per well and therefore only 10µl sterile water. Primer 
sets to measure reference gene expression were not included on the plate. Primers 
to amplify genomic DNA had been verified previously in the lab, these are detailed 
in Table 2.4. In addition, dissociation curves were checked for each qPCR reaction 
as described for qPCR of cDNA.   
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Name Sequence (5’ – 3’)  
CDKN2A-1 fwd GGAACCTAGATCGCCGATGTA 
CDKN2A-1 rev TGTTTTACGCGTGGAATGCAC 
CDKN2A-2 fwd GTGGGTCCCAGTCTGCAGTTA 
CDKN2A-2 rev CCTTTGGCACCAGAGGTGAG 
CDKN2A-3 fwd GGAGCGATGTGATCCGTTATC 
CDKN2A-3 rev TGAAATCCCAATCGTCTTCCAC 
CDKN2A-5 fwd CTCAAAGCGGATAATTCAAGAGC 
CDKN2A-5 rev AAGCCTTAAGAACAGTGCCACAC 
CDKN2A-7 fwd AGAGGGTCTGCAGCGG 
CDKN2A-7 rev TCGAAGCGCTACCTGATTCC 
CDKN2A-9 fwd CAAGCTTCCTTTCCGTCATGC 
CDKN2A-9 rev GCCAGAGAGAACAGAATGGTCAGAGCCA 
Table 2.4 List of primers used to amplify DNA (purified by ChIP) 
 
2.4 Biochemistry 
2.4.1 Preparation of total cell lysate 
Harvested cells were lysed with approximately 10 x cell pellet volume ice-cold 
NP40 lysis buffer (1) for 10 minutes on ice. The lysate was cleared of nuclear 
debris by centrifugation at 13,200rpm for 10 minutes at 4oC and supernatant was 
collected on ice. Protein concentration was determined by Bradford assay. Protein 
Assay Dye Reagent (Bio-Rad) was diluted 1:5 in water and 995µl was transferred 
to a microcentrifuge. 5µl protein lysate or BSA standard of known concentration 
(0.125-20µg/µl) was added to the diluted Dye Reagent, the solution was vortexed 
and transferred to a plastic cuvette (Sarstedt). The solution was then incubated for 
15 minutes at room temperature before absorbance was measured at a wavelength 
of 595nm using an Ultrospeco-2000 spectrometer (Pharmacia Biotech). Protein 
lysate concentrations were estimated from a standard curve calculated from 
absorbance values of BSA standards of known concentration.  
 
2.4.1.1 Phosphatase treatment of cell lysates 
Harvested cells were lysed with approximately 10 x cell pellet volume ice-cold 
Tween lysis buffer, incubated for 15 minutes on ice and sheared by passing 
Chapter 3. Interaction of CK2 with PRC1 
 
 68 
through a 23G gauge needle. The lysate was cleared of nuclear debris by 
centrifugation at 13,200rpm for 10 minutes at 4oC and the supernatant was 
collected on ice. Protein concentration was determined by Bradford assay as 
described above. The lysate was treated with 4,000 units Lambda Protein 
Phosphatase NEB) per mg protein in 1x NEBuffer and 1mM MnCl2, for 45 minutes 
at 30oC and was then fractionated by SDS-PAGE prior to immunoblotting.  
 
2.4.2 SDS-PAGE   
Polyacrylamide gels (8x10x1.5cm (small) or 15x15x1.5cm(large)) were poured 
using the Protean system (Bio-Rad) or the Hoefer system respectively. Running 
gels were cast from a mix of 375mM TrisHCl pH 8.8, 0.1% SDS, 0.1% APS, 0.04% 
TEMED and 8-15% acrylamide (type) depending on the molecular weight of the 
protein of interest. Following polymerisation of the running gel, the stacking gel 
containing 5% acrylamide in 375mM TrisHCl pH 6.8, 0.1% SDS, 0.1% APS and 
0.1% TEMED was poured. A comb was inserted before polymerisation to create 
wells to hold protein samples. Protein samples were boiled for 5 minutes in 1x 
Laemmli buffer and loaded into the wells of a cast polyacrylamide gel. Molecular 
weight markers (12-225kDa) (Amersham) were loaded into a well alongside protein 
samples to later identify proteins of interest according to their molecular weight. For 
small gels, electrophoresis was performed in 1x running buffer in a Protean tank 
(BioRad) at a constant current of 30mA per gel until desired fractionation was 
achieved. For large gels, electrophoresis was performed in 1x running buffer in a 
Hoefer tank at a constant current of 80mA at 4oC until desired fractionation was 
achieved.  
 
For fractionation of 32P-containing samples and for samples to be subsequently 
analysed by mass spectrometry, the NuPAGE system (Invitrogen) was used. 
Samples were loaded into a precast 10%, 12% or 4-12% NuPAGE Bis-Tris gel 
(Invitrogen) and run in 1x NuPAGE MOPS running buffer (Invitrogen). Gels were 
run at a constant current of 30mA per gel until desired fractionation was achieved.  
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2.4.3 Gel Coomassie staining 
Following SDS-PAGE, gels were fixed in fixing solution for 30 minutes before being 
submerged in Coomassie stain solution overnight, at room temperature. The gel 
was destained in destaining solution until the gel background was clear. Gels were 
stored in 3% acetic acid. 
 
2.4.4 Immunoblotting and stripping 
Following fractionation by SDS-PAGE, protein was transferred from small 
acrylamide gels to Protran nitrocellulose membrane (Whatman) using the Protean 
system (BioRad). The membrane was soaked in transfer buffer, placed on top of 
the running gel and sandwiched between 3mm filter paper (Whatman) and sponge 
pads (Biorad) within a cassette (Biorad). The closed cassette was inserted into the 
Protean transfer module. Proteins were transferred at room temperature at 100V 
for 60-90 minutes depending on the size of the protein of interest, or at 4oC at 30V 
overnight. Protein from large acrylamide gels was transferred to Protran 
nitrocellulose membrane (Whatman) using semi-dry transblot apparatus (Atto Corp). 
The membrane was soaked in transfer buffer and placed on top of 3mm filter paper. 
The acrylamide gel was laid on top of the membrane and 3mm filter paper was laid 
on top of the gel. This sandwich was placed between the electrode plates. Proteins 
were transferred at 270mA for 60 minutes. 
 
Following transfer, the nitrocellulose membrane was incubated with Blocking buffer 
for 1 hour at room temperature or overnight at 4oC. Primary antibodies used are 
listed in Table 2.5. Blocked membranes were incubated with primary antibodies 
against the protein/epitope of interest that were diluted in Blocking buffer. These 
incubations were either overnight at 4oC or for 1 hour at room temperature 
depending on the antibody. Membranes were then subject to 3 x 10 minute washes 
in PBST. The relevant secondary antibody (HRP-conjugated anti-rabbit, anti-mouse 
or anti-goat IgG (Amersham)) was then applied to the washed membrane (1:2,000, 
previously diluted in Blocking buffer) and left to incubate for 1 hour at room 
temperature. The membrane was then subjected to further 3 x 10 minute washes in 
PBST. Excess PBST was blotted from the membrane, which was then laid on 
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flattened Saran Wrap (Dow). Antibody complexes on the membrane were detected 
by the addition of a 1:1 mix of enhanced chemiluminescence (ECL) reagents 1 and 
2 (Amersham Pharmacia Biotech). ECL was left on the membrane sandwiched 
between Saran Wrap for one minute before excess was blotted off and the 
membrane was placed in a Hypercassette (Amersham Pharmacia Biotech) within 
fresh Saran Wrap. Hyperfilm (GE Healthcare) was then exposed to the membrane 
in the cassette for anywhere between 20 seconds and 24 hours depending on the 
amount of protein of interest and the sensitivity of the antibody. After exposure, the 
film was developed in an automatic x-ray film processor (model JP-33 (JPI 
Healthcare Solutions). A 14C-labelled ruler strip within the cassette was used to 
position the developed film relative to the membrane. Occasionally it was 
necessary to remove the previous primary antibody signal before re-probing the 
membrane with a different primary antibody. On these occasions, the membrane 
was incubated with stripping buffer at 50oC for 30 minutes, washed extensively with 
PBST before being re-blocked in Blocking buffer.  
 
2.4.5 Antibodies 
2.4.5.1 Antibody generation 
A peptide representing the C-terminus of CBX7 was synthesised on a branched 
lysine core (MAP) by the LRI Peptide Synthesis facility. This peptide sequence was 
FREAQAAEGFFRDRSGKF. This antigen was used by Pettingill Technology Ltd 
(PTL) to immunize a pair of rabbits. The terminal bleed was collected 77 days after 
immunisation. The terminal bleed was subsequently IgG purified by LRI Cell 
services.  
 
2.4.5.2 Commonly used antibodies 
Primary antibodies that were used for the work presented in this thesis are listed in 
Table 2.5. 
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Antigen Origin / Source Product 
number 
Species and 
Type 
Dilution for 
Immunoblotting 
and Immuno-
fluorescence 
BMI1 Cell Signalling 6964 Rabbit mAb 1:500 
BMI1 Millipore 05-637 Mouse mAb 1:500 
β-tubulin Santa Cruz sc-9140 Rabbit pAb 1:1000 
CK2a Cell Signalling 2656 Rabbit pAb 1:1000 
CK2a Bethyl A300-198A Rabbit pAb 1:1000 
CK2a Santa Cruz sc-12738 Mouse mAb 1:100 
CK2a’ Santa Cruz sc-6481 Goat pAb 1:500 
CK2b Santa Cruz sc-12739 Mouse mAb 1:100 
FLAG (HRP) Sigma A8592 Mouse mAb 1:4000 
Histone H3K27me3 Millipore 07-449 Rabbit pAb 1:1000 
HA Santa Cruz sc-805 Rabbit pAb 1:1000 
HPH2 LRI 1615 Rabbit pAb 1:500 
CBX7 Abcam 21873 Rabbit pAb 1:1000 
Histone H3 Abcam 1791 Rabbit pAb 1:4,000 
p16 LRI JC8 Mouse mAb 1:5 
p18 Novus Biologicals NB120-
3216 
Mouse mAb 1:200 
RING2 Haruhiko Koseki  
(Atsuta et al., 2001) 
MAb3-3 Mouse mAb 1:500 
RING1 Cell Signalling 2820 Rabbit pAb  
Mel18 Santa Cruz 10744 Rabbit pAb 1:500 
Phospho-Pol II 
(Ser2) 
Covance MMS-129R Mouse mAb 1:500 
IgG Abcam 46540 Rabbit pAb  
IgG Abcam 18413 Mouse  
γH2AX Millipore 05-636 Mouse mAb 1:1000 
γH2AX Cell Signalling 9718 Rabbit mAb 1:1000 
53BP1 Santa Cruz sc-22760 Rabbit pAb 1:200 
Phospho-MEK 
(Ser217/221) 
Cell Signalling 9121S Rabbit pAb 1:1000 
PARP Cell Signalling 9532 Rabbit mAb 1:1000 
Phospho-CBX7 
(Thr119) 
Emily Bernstein 
(Mount Sinai School 
of Medicine) 
 Rabbit pAb 1:1000 
β-actin Sigma A5441 Mouse mAb 1:2000 
Table 2.5 List of commonly used primary antibodies 
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2.4.6 Phosphoenrichment assay  
Harvested cells were lysed and the lysate was fractionated to separate 
phosphorylated and non-phosphorylated proteins using the TALON PMAC 
Phosphoprotein Enrichment kit (Clontech) according to the manufacturers 
instructions. Harvested cells were lysed by incubating in 30µl Buffer A (Clontech) 
for each mg of cells, on ice for 10 minutes. The lysate was cleared at 10,000g for 
20 minutes at 4oC to pellet any insoluble material. Some cleared lysate was 
reserved for later analysis (Input). A maximum of 8mg cleared lysate was loaded 
into an equilibrated Phosphoprotein Affinity column (Clontech) and was incubated 
rotating end-over-end for 20 minutes at 4oC. This allowed phosphorylated proteins 
in the lysate to bind the Phosphate Metal Affinity Chromatography (PMAC) resin 
(Clontech) of the column. The column was then left to stand upright for 5 minutes at 
room temperature to allow the resin to settle. The column top and end caps were 
then removed and non-phosphorylated proteins, that had not bound the resin, were 
collected in the flow-through. The column was washed four times with Buffer A 
(Clontech). 4 x 1ml Buffer B (Clontech) were added to the column to elute 
phosphorylated proteins from the resin. Elutes were pooled and stored on ice 
immediately after elution. Flow-through and eluted samples were fractionated by 
SDS-PAGE alongside input samples equivalent to 2% volume of cell lysate loaded 
on the PMAC column. 
 
2.4.7 Immunoprecipitation 
Harvested cells were lysed in 10 x NP40 lysis buffer 2 on ice for 10 minutes. The 
lysate was cleared at 13,200rpm for 15 minutes. 60µl equilibrated beads 
(previously resuspended to a 50% slurry) per 1ml of lysate, were added to the 
cleared lysate and incubated rotating end-over-end for 1 hour at 4oC. The beads 
used were dependent on the primary antibody to be used for immunoprecipitation 
of the protein of interest. Pierce Protein G agarose (ThermoScientific) beads were 
used for mouse monoclonal antibodies and Pierce Protein A agarose 
(ThermoScientific) beads were used for rabbit polyclonal antibodies. Following this 
incubation, beads (and any bound proteins) were pelleted at 13,200rpm for 5 
minutes at 4oC and pre-cleared lysate was transferred to a fresh microcentrifuge 
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tube. Pre-cleared lysate was incubated with 5µg primary antibody rotating end-
over-end at 4oC overnight. Typically 1mg (at a concentration of around 1mg/ml) 
pre-cleared protein was used per immunoprecipitation. 10% of the input was set 
aside for later analysis. Non-specific Rabbit control IgG ChIP-grade or Mouse 
control IgG ChIP-grade antibodies (Abcam) were used to immunoprecipitate lysate 
as a negative control. Antibody amounts per immunoprecipitation are detailed in 
table 4. Following the overnight incubation, 60µl fresh equilibrated beads 
(previously resuspended to a 50% slurry), per 1ml of lysate, were added to the 
lysate containing immune complexes and incubated rotating end-over-end for 2-3 
hours. The beads were then pelleted (along with any immune complexes) at 
2,000rpm, washed four times in 1ml ice-cold lysis buffer and then once in ice-cold 
PBSA. Immune complexes were eluted from beads by boiling for 5 minutes in 
100µl 2x Laemmli sample buffer, pelleting beads at 13,200rpm and removing the 
supernatant. Input and immunoprecipitated proteins were fractionated by SDS-
PAGE prior to immunoblotting.  
 
For the immunoprecipitation of HA/FLAG epitope-tagged proteins, no pre-clearing 
of the lysate was required. 30µl of a 50% slurry of anti-FLAG M2-agarose affinity 
gel (Sigma) or anti-HA-agarose (Sigma) beads were added directly to cleared 
lysate and incubated rotating end-over-end for 2 hours and 30 minutes. The beads 
were subsequently washed four times in 1ml lysis buffer before eluting with 
200µg/ml FLAG or HA peptide in a total volume of 150µl, by rotating end-over-end 
for 30 minutes at 4oC. Beads and peptide were pelleted at 13,200rpm before 
removing eluted protein and boiling this in 1x Laemmli sample buffer. 
 
2.4.8 Gel filtration 
Whole cell lysate and immune complexes were fractionated using Superose 6 
High-Resolution (HR) 10/30 Gel Filtration Column (GE Healthcare) according to the 
manufacturer’s instructions. Gel filtration separates molecules according to size as 
they pass through gel filtration medium packed within a column. Smaller molecules 
will diffuse into pores of the matrix and therefore take longer to travel the length of 
the column. The molecular weight (MW) range over which molecules are efficiently 
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separated is determined by the choice of gel filtration medium. Superose 6 HR 
10/30 gel filtration column (GE Healthcare), enables high-resolution fractionation of 
protein complexes between 5 kDa and 5 MDa. This column was initially calibrated 
using the HMW and LMW calibration kit (GE Healthcare) according to the 
manufacturer’s instructions. 
 
For analysis of whole cell lysate, harvested cells were lysed in CHAPS lysis buffer 
for 20 minutes on ice. The lysate was subjected to two rounds of clearing at 
13,200rpm to remove any aggregates of insoluble material. The protein 
concentration of the lysate was measured and adjusted to a maximum of 
12.5mg/ml. For analysis of immune complexes, it was necessary to amend the 
immunoprecipitation protocol (detailed above) slightly to perform the final wash 
steps with 1ml CHAPS lysis buffer and to elute the immune complexes in this buffer 
(the Superose 6 column may not be compatible with NP40 containing buffer 
(Goedele Maertens (personal communication)). Immunoprecipitation was 
performed with starting material equating to approximately 5 x confluent 100mm-
diameter culture dishes of 293T cells. 
 
200µl of eluted immune complexes or 200µl whole cell lysate (≤ 12.5µg/ml) was 
loaded onto the Superose 6 HR 10/30 Gel Filtration Column (GE Healthcare) that 
had been previously equilibrated with CHAPS lysis buffer. Protein run through the 
column was collected in 0.5ml fractions at 4oC. 10% Trichloroacetic acid (TFA) was 
added to each 500µl fraction and incubated overnight rotating at 4oC to precipitate 
proteins. The following day, samples were centrifuged at 13,200rpm for 30 minutes 
at 4oC, supernatant was removed and the pellet of precipitated protein was 
vortexed with 500µl ice-cold acetone. This acetone wash was repeated twice more. 
After the final wash, acetone was removed and the pellet was vacuum dried for 5 
minutes. The pellet was subsequently boiled for 5 minutes in 2x Laemmli sample 
buffer. Proteins were fractionated by SDS-Page prior to immunoblotting. 
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2.4.9 Fixed chromatin immunoprecipitation (ChIP) 
Cells to be used for chromatin immunoprecipitation (ChIP) were treated with 
formaldehyde, a reversible DNA-protein cross-linking agent, before they were 
harvested. Cells were incubated by rocking with 1% formaldehyde at room 
temperature for 10 min. The reaction was then quenched by addition of glycine to a 
final concentration of 125 mM and incubation at room temperature for 5 min. Cells 
were scraped from culture dishes and transferred to 225ml conical tube (BD 
Falcon). Cells were pelleted at 2,000rpm for 5 minutes at 4oC. The pellets were 
resuspended in 10 x pellet volume of ice-cold ChIP swelling buffer (containing the 
following inhibitors: 5mM NaF, 1mM PMSF, 1x protease inhibitor cocktail (Roche), 
25mM β-glycerophosphate and 1mM Na3VO4), incubated on ice, rocking for 10 
minutes and homogenised with 50 strokes of a tight pestle (Wheaton). Nuclei were 
pelleted at 4,400rpm for 5 minutes at 4oC. The supernatant was discarded and 
nuclei were resuspended in 5 x pellet volume of ChIP sonication buffer (containing 
the following inhibitors: 5mM NaF, 1mM PMSF, 1x protease inhibitor cocktail, 
25mM β-glycerophosphate and 1mM Na3VO4). The chromosomal DNA was then 
sheared using a BioRuptor waterbath sonicator (Diagenode). Sonication was 
performed at the high setting for intervals of 30 seconds of sonication followed by 
30 seconds rest (to keep samples cool) over three 12 min periods. Ice in the 
waterbath was replaced after each 12-minute cycle. After the first cycle, the 
concentration of DNA was roughly estimated by adding 2µl chromatin to 98µl 0.1M 
NaOH and using the Nanodrop sepctrometer to estimate the DNA concentration of 
the sample (as described previously). Following this measurement, samples were 
adjusted to equivalent concentrations to ensure equivalent sonication efficiency 
between different conditions. After the sonication cycles were complete, chromatin 
was centrifuged at 13,200rpm for 15 minutes at 4oC and supernatant was 
transferred to a fresh 2ml microcentrifuge tube. DNA concentration was again 
measured using the Nanodrop spectrometer and samples were adjusted to a DNA 
concentration of 1.667µg/µl.  
 
Immunoprecipitation of the protein of interest was performed using 300µg 
chromatin by essentially the same protocol as previously described. However, 
immunoprecipitation was carried out in ChIP sonication buffer and following 
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incubation of the relevant agarose beads with immune complexes, beads were 
washed with 1 x 1ml ChIP sonication buffer, 1 x 1ml ChIP wash buffer A, 1 x 1ml 
ChIP wash buffer B and 2 x 1ml ChIP TE buffer. Following these washes, the 
beads were resuspended in 100µl ChIP elution buffer, incubated at 65oC for 5 
minutes and then rotated end-over-end for 15 minutes. The beads were then 
pelleted at 2,000rpm for 3 minutes and the elute was transferred to a fresh 1.5ml 
microcentrifuge tube. This elution step was repeated once more, with the spin 
being performed at 13,200rpm to collapse the beads, and elutes were pooled. 
Inputs were brought up to 200µl with ChIP TE buffer. 6.4µl 5M NaCl and 4µl 
1mg/ml DNase-free RNase A (Qiagen) was added to both the elutes and input 
samples, which were subsequently incubated at 65oC overnight to reverse the 
formaldehyde-induced protein-DNA cross-linking. 
 
Reverse cross-linked samples were cooled and DNA was purified using the 
QIAquick PCR Purification kit (Qiagen) according to the manufacturer’s instructions. 
DNA was typically eluted in 30-60µl EB buffer (Qiagen). DNA was subject to qPCR 
analysis as previously described. The sonication efficiency of chromatin was 
confirmed by analysing DNA fragment sizes on a 1% agarose gel. The target DNA 
fragment size range was 0.5 – 1 kb.  
 
2.4.9.1 ChIP-seq and bioinformatics analysis 
Library preparation and Solexa genome-wide sequencing was performed by the 
LRI Advanced Sequencing Facility. Typically 60µl of DNA was submitted to the LRI 
Advanced Sequencing Facility at a minimum concentration of 0.2µg/µl. To obtain 
enough DNA, parallel ChIPs were performed and DNA elutes were subsequently 
pooled and concentrated. Input DNA was used as a control for the ChIP seq 
analysis. Sequence alignments were performed using Novoalign (version 2.07.14) 
allowing for a single base mismatch per read. Reads were mapped to the human 
genome (assembly hg19). Peak calling was performed using MACS (version 
1.4.0rc2).  
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2.4.10 Production of recombinant protein 
BL21 E. coli were transformed with pGEX-6P1 vector contain the gene of interest. 
To check the efficiency of protein production following IPTG induction, 3-4 clones 
were analysed by the small-scale protein production protocol. Large-scale protein 
production was performed for successful clones.  
 
2.4.10.1 Small-scale production of recombinant protein 
20ml LB AMP was inoculated with a single colony and incubated at 37oC overnight, 
with shaking at 200rpm. Subsequently, 50ml LB AMP was inoculated with 1ml of 
the overnight culture and incubated at 37oC, with shaking at 200rpm, until culture 
reached an OD600 between 0.4 and 0.6 (log growth phase). 1ml culture was 
removed, pelleted at 4,400rpm and resuspended in 2x Laemmli sample buffer (SB). 
1mM IPTG was added to the remaining culture to induce protein expression. The 
culture was subsequently incubated at 37oC, shaking at 200rpm, and 2ml samples 
were removed after 2, 3 and 4 hours. These 1ml samples were pelleted at 
4,400rpm, and resuspended in Xml 2x Laemmli sample buffer (where X is 100x(OD 
post-IPTG/OD pre-IPTG). Samples were fractionated by SDS-PAGE and evaluated 
by Coomassie staining. 
 
2.4.10.2 Large-scale production of recombinant protein  
500ml LB AMP was inoculated with 10ml overnight culture and incubated at 37oC, 
with shaking at 200rpm, until culture reached an OD600 between 0.4 and 0.6 (log 
growth phase). 1mM IPTG was added to induce protein expression and culture was 
incubated shaking at 200rpm, at 37oC for a further 2 hours. Bacteria were pelleted 
at 4,400rpm at 4oC for 10 minutes. The bacterial pellet was resuspended in 5 
volumes GST lysis buffer, incubated for 10 minutes on ice and sonicated on ice at 
medium intensity (Soniprep 150) for 3 cycles of 20 seconds on/20 seconds off. The 
lysate was cleared at 13,200pm for 10 minutes. Cleared lysate was incubated with 
equilibrated glutathione sepharose 4B beads (GE Healthcare) (100µl per 100ml 
culture) for 30 minutes at room temperature. The beads were washed 4 times with 
10 x bead volume of ice-cold GST lysis buffer (beads were pelleted at 500g).  
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Protein was eluted in 3 x 500µl GST elution buffer (containing 10mM reduced 
glutathione) for every 1ml beads. The elute was concentrated with microcon filter 
devices (Ultracel YM-10 membrane) (according the manufacturer’s instructions), 
which also removed any excess glutathione. Alternatively, protein was eluted from 
beads using PreScission protease (GE Healthcare) to cleave the GST tag from the 
protein. In this case, beads were equilibrated with GST cleavage buffer before 
incubation with 80 units PreScission protease per 1ml beads, and GST cleavage 
buffer to a total volume of 1ml. The beads were incubated for 4-24 hours at 4oC. 
Beads, GST and PreScission protease were pelleted at 500g, whilst purified protein 
was recovered in solution. Purified protein was analysed by SDS-PAGE alongside 
a series of BSA standards of known concentration (0.1-6mg/ml). This gel was 
subsequently stained by the Coomassie staining protocol described previously.  
 
2.4.11 GST pull-down assay 
Whole cell lysates were prepared from harvested cells NP40 lysis buffer 1, as 
described previously. 5mg lysate was precleared by incubation with 60µl GST 
glutathione sepharose 4B (GS4B) beads (GE Healthcare) (previously washed in 
lysis buffer and resuspended to a 50% slurry), rotating end-over-end for 1 hour at 
4oC. Beads were pelleted at 13,200rpm and 5mg precleared lysate was incubated 
with 10µg purified GST-tagged protein and 50µl fresh 50% slurry of GS4B beads 
for 2 hours, rotating end-over-end at 4oC. 10% of the input was set aside for later 
analysis. The beads were pelleted at 500g, washed four times in 1ml GST lysis 
buffer, and the proteins were eluted in 60µl GST elution buffer (containing 10mM 
reduced glutathione). The beads were pelleted at 13,200rpm and the elute was 
boiled with 1x Laemmli sample buffer. Input and proteins recovered from the GST 
pull-down were fractionated by SDS-PAGE prior to immunoblotting. 
 
2.4.12 Peptide array synthesis 
Peptide arrays were generated by the LRI Peptide Synthesis facility. Peptide arrays 
were made from 20mer peptides. For peptide-
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array was advanced from the previous by 1 or 2 residues (as specified in the figure 
legend) in the C-terminal direction of the protein being represented. For peptide 
substitution arrays each peptide had an amino acid of the wild-type peptide 
substituted for one of the 20 common amino acids. Peptide arrays were comprised 
of 600 or 777 peptides spots (the latter spot diameters being smaller than the 
former).  Peptide arrays were synthesised on an Intavis Multipep Peptide 
Synthesiser (Intavis Bioanalytical Instruments AG, Cologne, Germany). Each 
amino acid was coupled by activating its carboxylic acid group with 
diisopropylcarbodiimide in the presence of hydroxybenzatriazole. Individual aliquots 
of the 20 common amino acids (which are N-terminally protected) were spotted 
onto a cellulose membrane (100mm x 150mm) that had been derivatised to have 8-
10 ethylene glycol spacers between the cellulose and an amino group. Peptide 
synthesis was accomplished by cycles of coupling amino acids, washing and then 
removing the temporary N-terminal protecting group. Once the required number of 
cycles was complete, the membrane was subjected to various wash steps to 
remove side chain protecting groups and TFA salts. Loading was 400nmol/cm2. For 
a 4mm diameter spot this equates to 50nmol peptide per spot.  Membranes were 
dried and stored at -20oC before use.  
 
2.4.13 Peptide array kinase assay 
The peptide array was hydrated in 50% methanol and blocked for 2 hours in 1ml 
Kinase assay buffer at room temperature. Blocking solution was drained and the 
peptide array was incubated with 6125 units of recombinant CK2α or CK2a’ 
(Calbiochem) and 3.75µCi [γ-32P] ATP (PerkinElmer) in 1ml Kinase assay buffer for 
2 hours at 37oC. 1 unit of CK2α is defined as the amount of enzyme that will 
catalyse the transfer of 1.0pmol phosphate from ATP to the synthetic CK2 
substrate RRRDDDSDDD per minute at 37oC, pH 8.5. The membrane was 
subsequently washed by 5 x 10 minute incubations with 75mM H3PO4 and 5 x 10 
minute incubations with PBSA before exposing for autoradiography. 
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2.4.14 Peptide array binding assay 
The peptide array was hydrated in 50% methanol and blocked for 2 hours in 1ml 
Binding assay buffer at room temperature. Blocking solution was drained and the 
peptide array was incubated with 2µg recombinant CK2α (Calbiochem) in 1ml 
Binding assay buffer, or Binding assay buffer alone as a negative control. This 
incubation was carried out at room temperature for 2 hours. The membrane was 
subsequently washed by 5 x 10 minute incubations with TBST and subjected to 
immunoblotting. 
 
2.4.15 In vitro kinase assay and analysis by 32P incorporation 
2µg recombinant protein substrate was incubated with 100 units of CK2 
holoenzyme (Calbiochem) and 1.5µCi [γ-32P] ATP in 20µl Kinase assay buffer for 
30 minutes at 30oC. 1 unit of CK2 holoenzyme is defined as the amount of enzyme 
that will catalyse the transfer of 1.0pmol phosphate from ATP to the synthetic CK2 
substrate RRRDDDSDDD per minute at 30oC, pH 7.5. The reaction was boiled in 
1x Laemmli buffer for 5 minutes to stop the reaction. Proteins were fractionated by 
SDS-PAGE. Subsequently, the gel was subjected to Coomassie staining and then 
vacuum dried. 32P labelled proteins were detected by autoradiography.  
 
2.4.16 In vitro kinase assay and analysis by mass spectrometry 
2µg recombinant protein substrate was incubated with 100 units of CK2 
holoenzyme (Calbiochem) in 20µl Kinase assay buffer for 30 minutes at 30oC. The 
reaction was boiled in 1x Laemmli buffer for 5 minutes to stop the reaction. Proteins 
were fractionated by SDS-PAGE. The gel was then subjected to Coomassie 
staining as described previously. The band of recombinant protein substrate, made 
visible by the Coomassie stain, was excised and added to a 1.5ml microcentrifuge 
tube with 50µl HPLC water. These samples were kept at 4oC and analysed by the 
LRI Protein Analysis and Proteomics service. Samples were digested using Trypsin 
or Asp-N endoproteases. LC-MS/MS analysis of the resulting peptides was 
performed using an LTQ-Orbitrap XL (Thermo Scientific) machine. MASCOT 
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software was used for database searching for identification of peptides. Scaffold 
software was used for data analyses.  
 
2.4.17 β-galactosidase assay 
HDFs in culture dishes were washed twice in 37oC PBSA and then incubated for 3-
5 minutes with 37oC fixing solution at room temperature. Cells were then washed 
twice with 37oC PBSA and incubated with staining solution at 37oC for 12-16 hours 
in the culture dish sealed with parafilm. After staining, cells were washed twice in 
PBSA and once in methanol. Cells were then stored dry in sealed culture dishes at 
room temperature and submerged in PBSA for visualisation using a Ziess Axiovert 
25 inverted microscope microscopy. 
 
2.4.18 Immunofluorescence 
Approximately 103 cells were seeded into each well of a 12-well culture plate (BD 
Falcon) containing No 1.5 coverslips. 24 hours after cells were seeded they were 
washed once in 37oC PBSA for 1 minute and then fixed in 37oC 3.7% formaldehyde 
in PBSA for 15 minutes at room temperature. Cells were then subjected to 4 x 20 
second washes in 37oC PBSA (hereafter referred to as ‘wash’). Cells were 
permeabilised in 0.1% Triton X-100 in PBSA for 15 minutes at room temperature 
before washing. Four drops of Image-iT FX Signal Enhancer (Molecular Probes) 
was added to each well and incubated for 30 minutes at room temperature in a 
humid atmosphere. After incubation, cells were washed and blocked for one hour in 
3% BSA in PBSA. Cells were then incubated with primary antibody (previously 
diluted in 3% BSA in PBSA) overnight at 4oC or for 1 hour at room temperature. 
After washing, the relevant fluorescein-coupled (Alexa Fluor 488 or 555), highly 
cross-adsorbed, secondary antibody (previously diluted in 3% BSA in PBSA) was 
applied and incubated for 30-60 minutes at room temperature in the dark. Cells 
were washed and coverslips were mounted onto glass microscopy slides 
(76x26x1mm) using ProLong Gold Antifade reagent with DAPI (Invitrogen). 
Coverslips were left to cure before confocal microscopy analysis. 
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2.4.19 Confocal microscopy  
Images were acquired using a 40x/1.3 DIC Plan Apochromat lens under oil 
immersion and a Zeiss LSM invert 710 microscope using sequential scanning. Zen 
2009 software (Zeiss) was used. DAPI was excited using a 405nm laser line, Alexa 
Fluor 488 was excited using a 488nm laser line and Alexa Fluor 555 was excited 
using a 561nm laser line. Spatial sampling was 0.04µm per pixel in the X/Y plane 
and between 0.2µm and 0.3µm per pixel in the Z plane. The pinhole aperture was 
set to 1 airy unit. Images were deconvoluted using Huygens Essential software 
(Scientific Volume Imaging (SVI)). Imaris 7.6 software (Bitplan) was used for 
colocalisation analysis of deconvoluted images. Colocalisation analysis was 
performed using automatically selected intensity thresholds within a region of 
interest (set by the DAPI channel) to generate Pearson’s correlation coefficient 
values. 
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2.4.20 Solutions 
Solutions were made up to the appropriate concentration in water (unless 
otherwise stated). To sterilise solutions (if required) they were either autoclaved or 
filtered though 0.22µm Stericup Filter Units (Millipore). LRI Media services provided 
clean glassware, PBSA, L-Broth (LB), and LB-Agar. Chemicals were generally 
purchased from Sigma-Aldrich. Water was purified using a Millipore reverse 
osmosis system.  
 
Molecular biology solutions 
 
1x TAE running buffer  40mM Tris acetate (pH 7.6) 
     5mM Sodium acetate 
     1mM EDTA 
 
6x DNA loading buffer  60% Sucrose 
     0.1% Bromophenol blue 
 
Annealing buffer   30mM HEPES-KOH (pH 7.4) 
100mM Potassium acetate 
2mM Magnesium acetate 
 
L-Broth (LB)    1% NaCl 
     0.5% yeast extract 
     1% NP40 
      
 
Cell culture solutions 
 
2x HBS    50mM HEPES (pH 7.0) 
     280mM NaCl 
     10mM KCl 
     1.5mM Na2PO4 
     12mM dextrose 
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Biochemistry solutions 
 
SDS-PAGE running buffer  25mM Trizma base 
     192mM Glycine 
     0.1% SDS 
 
Transfer buffer   25mM Trizma base 
     192mM Glycine 
     20% Methanol 
 
6x Laemmli sample buffer  375mM TrisHCl (pH 6.8) 
     10% SDS 
     10% 2-Mercaptoethanol 
     0.04% bromophenol blue 
     50% glycerol 
 
Coomassie stain solution  0.1% Coomassie Brilliant Blue R250 
     50% Methanol 
     10% Acetic acid 
 
Gel fixing/destaining solution 50% Methanol 
     10% Acetic acid    
     
 
PBSA     8.06 mM Na2HPO4 
     0.8% NaCl 
1.47 mM KH2PO4 
     0.025% KCl (pH 7.2) 
 
PBSA-Tween (PBST)  PBSA 
     0.2% Tween 
 
Blocking buffer   PBSA 
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     0.2% Tween 
5% dried milk (Marvel) or bovine serum albumin 
(BSA) (Sigma) 
 
Stripping buffer   62.5mM TrisHCl (pH 6.8) 
5% 2-Mercaptoethanol 
     2% SDS 
 
NP40 lysis buffer (1)   50mM TrisHCl (pH 7.5) 
     120mM NaCl 
     5mM EDTA 
     0.5% NP40 
1mM PMSF (added fresh) 
1mM DTT (added fresh) 
2mM Na3VO4 (added fresh) 
100mM NaF 
1x protease inhibitor cocktail (Roche) (added 
fresh) 
 
NP40 lysis buffer (2)   50mM TrisHCl (pH 8.0) 
     150mM NaCl 
     1mM EDTA 
     1% NP40 
1x protease inhibitor cocktail (Roche) (added 
fresh) 
 
CHAPS lysis buffer   50mM TrisHCl (pH 8.0) 
     0.5% CHAPS 
     150mM NaCl 
     1mM EDTA 
1mM PMSF (added fresh) 
1x protease inhibitor cocktail (Roche) (added 
fresh) 
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Tween lysis buffer   20mM HEPES (pH 7.5) 
     150µM NaCl 
     0.1% Tween 
     1mM EDTA 
     10% Glycerol 
     1mM DTT (added fresh) 
1x protease inhibitor cocktail (Roche) (added 
fresh) 
 
ChIP swelling buffer 25mM HEPES pH 7.9 
 1.5mM MgCl2 
 10mM KCl 
 0.1% NP-40 
 
ChIP sonication buffer  50mM HEPES pH 7.9 
     140mM NaCl 
     1mM EDTA 
     1% Triton X-100 
     0.1% Na-deoxycholate 
     0.1% SDS 
 
ChIP wash buffer A   50mM HEPES pH 7.9 
     500mM NaCl 
     1mM EDTA 
     1% Triton X-100 
     0.1% Na-deoxycholate 
     0.1% SDS 
 
ChIP wash buffer B   20mM Tris pH 8.0 
     1mM EDTA 
     250mM LiCl 
     0.5% NP-40 
     0.5% Na-deoxycholate 
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ChIP TE buffer 10mM Tris pH 8.0 
1mM EDTA  
  
ChIP elution buffer 50mM Tris pH 8.0 
 1mM EDTA 
 1% SDS 
 
GST lysis buffer   10mM TrisHCl pH 7.6 
     500mM NaCl 
     0.5% NP40 
     5mM EDTA 
 
GST elution buffer   50mM TrisHCl pH 8.0 
10mM reduced glutathione 
 
GST cleavage buffer   50mM TrisHcl pH 7.5 
150mM NaCl 
1mM EDTA 
1mM DTT (added fresh) 
      
Kinase assay buffer 20mM TrisHCl pH 7.5 
 5mM EGTA 
 1mM DTT (added fresh) 
20mM MgCl2 
100µM ATP 
 25mM β-glycerophosphate 
 
Binding assay buffer 20mM TrisHCl pH 7.5 
 0.1% Tween 
 5mM EGTA 
 1mM DTT (added fresh) 
 
 
 
Chapter 3. Interaction of CK2 with PRC1 
 
 88 
 
Microscopy solutions 
 
β-galactosidase staining solution 1mg/ml X-gal in dimethylformamide 
40mM Citric acid/Sodium phosphate buffer (pH 
6.0) 
5mM Potassium ferricyanide 
5mM Potassium ferrocyanide 
150mM NaCl 
2mM MgCl 
 
Citric acid/ 
Sodium phosphate buffer 2:1 ratio of 0.1M Citric acid solution:0.2M 
Sodium phosphate solution 
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Chapter 3. Interaction of CK2 with PRC1 
3.1 Introduction 
As discussed in Chapter 1.1.1, several auxiliary proteins, which are not encoded by 
recognised PcG genes, consistently co-purify with the core PRC1 components. 
Although some of these auxiliary proteins have been shown to contribute to the 
function or regulation of PRC1 (El Messaoudi-Aubert et al., 2010, Maertens et al., 
2010), it is not clear that they are present in stoichiometric amounts. CK2 is an 
interesting example, because the enzyme is itself a complex and all three subunits 
have been identified in PRC1-like complexes. Specifically, mass spectrometry 
identified CK2 subunits in PRC1-like complexes affinity purified via CBX2, CBX4, 
CBX7, CBX8, RING2, RNF3 and RNF159, (El Messaoudi-Aubert et al., 2010, 
Dietrich et al., 2007, Vandamme et al., 2011, Sanchez et al., 2007, Gao et al., 
2012). However, CK2 is a relatively abundant and ubiquitous protein that has been 
detected in a number of other types of complex, including those involved in the 
DNA damage response (Keller et al., 2001). 
 
At the inception of this thesis, only one study had sought to confirm the mass 
spectrometry data by immunoblotting for CK2 in a RING2-based complex (Sanchez 
et al., 2007). We therefore set out to confirm the presence of CK2 in PRC1 
complexes and to explore the direct protein-protein interactions that might be 
responsible. 
 
3.2 Association of CK2 with PRC1 complexes 
3.2.1 Association of CK2 and PRC1 proteins 
A previous graduate student in the lab, James Nicholls, had identified all three CK2 
subunits in a complex purified from 293T cells transduced with TAP-tagged mouse 
Cbx7 (Nicholls, 2006). To confirm and extend this observation, FLAG tagged (C-
terminal) versions of human CBX2, CBX4, CBX6, CBX7 and CBX8 were expressed 
in 293T cells and the cell lysates were immunoprecipitated with anti-FLAG agarose, 
fractionated by SDS-PAGE, and immunoblotted for CK2 subunits. FLAG-tagged 
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CBX proteins were mostly resolved as two or more differently migrating bands 
(Figure 3.1A). This may reflect the use of different methionines as alternative 
translation start sites as each CBX protein contains two or more methionines within 
its sequence. Although there was some variability in the levels of the CBX proteins 
achieved by transient transfection, it was clear that both the α and α’ subunits of 
CK2 co-precipitated with all five CBX proteins (Figure 3.1A). As expected, 
endogenous RING2 was also detected in the immunoprecipitates. It was difficult to 
draw conclusions regarding differential binding affinities between CK2 and CBX-
complexes. It appeared that more CK2 was co-precipitated with CBX2-FLAG than 
any of the other CBX-FLAG proteins. This was especially striking considering the 
relatively low level of RING2 that co-precipitated with CBX2-FLAG. However, not 
only was there some variability in the expression of the CBX proteins but the levels 
of endogenous RING2, used as a positive control in this experiment, varied 
substantially in the transfected 293T cells. This is unlikely to reflect differences in 
loading, as the CK2 signals appear well balanced. A more likely explanation is that 
overexpression of CBX proteins affects the stability of RING2, perhaps to varying 
degrees. Although interesting, this issue would be difficult to resolve by standard 
approaches that rely on transient over-expression and the analyses of endogenous 
proteins is very dependent on the efficacy of the available antibodies. 
 
Endogenous co-IP is the gold standard for demonstrating a biologically relevant 
interaction between two proteins. Although attempted, it was not possible to 
recover CK2 subunits from IPs of endogenous CBX7 (data not shown). Of the 
laboratory’s panel of antibodies against PRC1 proteins, anti-RING2 (gifted by 
Haruhiko Koseki) has demonstrated the greatest efficiency for purifying its target 
(personal communication with various members of the Molecular Oncology 
laboratory). Anti-RING2 was therefore used to immunoprecipitate RING2-
complexes from 293T lysate. Purified proteins were fractionated by SDS-PAGE 
and immunoblotted for CK2 subunits. Figure 3.1B shows that all three endogenous 
CK2 subunits co-precipitated with endogenous RING2.  
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Figure 3.1 Co-immunoprecipitation of CK2 with FLAG-tagged CBX proteins and 
endogenous RING2 
A) pcDNA6 plasmids encoding FLAG-tagged CBX2, 4, 6, 7 or 8 (generated by 
Marc Rodriguez-Niedenfuhr) were transfected into 293T cells using 
lipofectamine. After 24 hours cells were harvested and cell lysate was subject to 
immunoprecipitation (IP) using anti-FLAG M2 agarose (Sigma). Purified 
proteins were fractionated by SDS-PAGE alongside input samples equivalent to 
1/10th volume of lysate used for the IP. Immunoblotting was performed against 
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CK2α, CK2α‘, RING2, and FLAG. The image is representative of two biological 
replicates B) 293T cells were harvested and lysate was subject to IP using anti-
RING2 antibody and Protein G agarose (Thermoscientific). Purified proteins 
were fractionated by SDS-PAGE alongside an input sample equivalent to 1/10th 
volume of lysate used for the IP. Immunoblotting was performed against CK2α, 
CK2α‘, CK2β, RING2, and CBX7. The image is representative of three 
biological replicates.  
 
 
3.2.2 Interaction of CK2 and CBX7 in a high molecular weight complex 
The co-precipitation data were consistent with reports from other groups showing 
CK2 to purify with CBX2, CBX4, CBX8 and RING2 complexes (Dietrich et al., 2007, 
Vandamme et al., 2011, Sanchez et al., 2007). However, these studies did not 
indicate whether the interaction between CK2 and PcG proteins takes place in the 
context of a PRC1 complex. To address this issue, and exclude the possibility that 
CK2 interacts with free, monomeric PcG proteins, gel filtration was used to 
estimate the molecular weight of CK2-CBX7 protein complexes.  
 
A Superose 6 HR 10/30 gel filtration column (GE Healthcare), which enables high-
resolution fractionation of protein complexes between 5 kDa and 5 MDa, was 
calibrated using a series of protein standards whose elution was monitored by UV  
(Appendix: Figure 8.1). Although these protein standards were those 
recommended for the calibration of this column, it is important to note that the 
largest monomeric protein was thyroglobulin (669 kDa). As a consequence, the 
size of protein complexes larger than 669 kDa cannot be estimated with any 
confidence. To analyse the endogenous complexes, a sample of 293T whole cell 
lysate, containing approximately 2mg of protein, was applied to the Superose 6 
column. The proteins in each fraction were concentrated by precipitation with 
trichloroacetic acid (TCA) fractionated by SDS-page, and detected by 
immunoblotting. As shown in Figure 3.2A, endogenous CBX7 was recovered in a 
size range between 43 and 440 kDa, with the majority in a peak at approximately 
200 kDa. The apparent CBX7 doublet will be discussed in Chapter 4.2. The 
predicted molecular weight of human CBX7 is 28 kDa and that of a canonical 
PRC1 complex comprising CBX7, MEL18, HPH2 and RING2 is 194 kDa. 
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Interestingly, endogenous RING2 also shows a peak at about 200 kDa although its 
distribution suggests that it is also present in much larger complexes. 
The predicted molecular weight of the human CK2 holoenzyme is between 132 
kDa and 140 kDa, depending on the contributing subunits. However, the majority of 
the endogenous CK2 eluted in a peak at around 550 kDa and extended into a 
much higher size range (Figure 3.2A). There was little if any signal equivalent to 
free holoenzyme but some of the protein was clearly detectable in the fractions 
containing CBX7 and RING2. These data would be consistent with the idea that 
CK2 associates with CBX7 in the context of a PRC1 complex but is not definitive. 
 
A number of studies have used a similar approach to characterise the molecular 
weight of complexes containing endogenous PcG proteins (Gao et al., 2012, 
Sanchez et al., 2007, Vandamme et al., 2011, Tavares et al., 2012, Maertens et al., 
2010). For example, endogenous CBX7 has been observed in complexes of 
around 75-158 kDa in mESCs (Tavares et al., 2012) and 158-500 kDa in HDFs 
(Maertens et al., 2010), whereas CBX8 complexes appear to be somewhat larger 
(Dietrich et al., 2007, Maertens et al., 2010). There is broad agreement that 
endogenous RING proteins are distributed in two different sizes of complex, 
although the composition of these complexes has not been determined (Sanchez 
et al., 2007, Vandamme et al., 2011, Tavares et al., 2012).  
 
One of the problems with this approach is that the endogenous proteins are rarely 
present in sufficient quantities to allow further analysis of potential complexes, for 
example by immunoprecipitation and immunoblotting of individual fractions. An 
alternative strategy is to perform the immunoprecipitation prior to gel filtration. 
Unfortunately, it was not possible to recover CK2 subunits from IPs of endogenous 
RING2 in sufficient quantities for such analysis (data not shown). However, this 
approach was possible using CBX7-FLAG precipitates from transiently transfected 
293T cells. Figure 3.2B shows that the majority of CBX7-FLAG was present in 
large complexes in excess of 669 kDa. Some CBX7-FLAG was also found in 
smaller complexes around 440 kDa. Importantly, the endogenous RING2 that co-
precipitated with FLAG-CBX7 showed the same distribution as FLAG-CBX7. All 
three CK2 subunits co-purified with the larger species of CBX7 complexes but were 
not detected in the 440 kDa size range.  
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It was surprising that FLAG-CBX7 complexes were much larger than endogenous 
CBX7 given that the FLAG epitope only adds 1 kDa. However, others have 
observed a similar phenomenon (Vandamme et al., 2011). It is possible that 
endogenous CBX7 can also form these larger complexes but that levels were too 
low to detect. In light of these discrepancies, it is unclear how biologically relevant 
the FLAG-tagged complexes are and the size of endogenous CBX7-CK2 
complexes remains undetermined. However, these data do suggest that the 
interaction of CK2 with CBX7 can take place within the context of a high molecular 
weight complex above 669 kDa, a size consistent with PRC1-like complexes.  
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Figure 3.2 Gel filtration of 293T cell lysate and CBX7-FLAG complexes  
A) 2mg 293T cell lysate was applied to a Superose 6 column and flow through 
was collected in 500µl fractions. Protein was precipitated from fractions 20-36 
using TCA, fractionated by SDS-PAGE and immunoblotting was performed 
against CK2α, CK2α‘, CK2β, RING2, and CBX7. The image is representative of 
three biological replicates B) Purified CBX7-FLAG complexes were applied to 
the Superose 6 column. Flow though was collected in 500µl fractions. Protein 
was precipitated from fractions 20-33 with TCA, fractionated by SDS-PAGE and 
immunoblotting was performed against CK2α, CK2α‘, CK2β, RING2, and 
FLAG. The image is representative of two biological replicates. 
    20      21      22        23      24      25    26      27      28      29    30    31      32      33      34      35      36  
158  kDa
RING2
CK2`
CK2_’
CK2_
CBX7
669  kDa 440  kDa 43  kDa 29  kDaA
B
Fraction
    20      21      22        23      24      25    26      27      28      29    30    31      32      33   Fraction
158  kDa669  kDa 440  kDa
RING2
CK2`
CK2_’
CK2_
FLAG
Chapter 3. Interaction of CK2 with PRC1 
 
 96 
3.3 Interaction of CK2 with the Pc box domain of CBX proteins 
3.3.1 Binding of CK2α  to C-terminal peptides representing the Pc box of 
CBX7 
Although CK2 has been found in a variety PcG complexes, little attention has been 
paid to the protein(s) responsible for the direct interaction with CK2. To address 
this question, recombinant CK2α (Calbiochem) was used to probe synthetic 
peptide arrays of CBX7, BMI1, HPH2 and RING2 (examples representing the Pc, 
Psc, Ph, and Sce protein families respectively). These arrays represented the 
protein of interest as a series of overlapping 20-mers. Peptide arrays can be used 
to test whether a direct interaction is possible between protein A and a peptide 
representing a domain of protein B. The result can suggest that protein A and B 
directly interact, and also, the domain of protein B wherein this interaction occurs. 
Duplicate arrays were incubated with or without recombinant CK2α and the bound 
protein was detected by immunoblotting.  
 
Low-level signals of CK2α were detected on all four arrays (Figure 3.3 and Figure 
3.4). However, these signals were generally confined to discrete peptides scattered 
throughout the entire protein and, although we cannot rule out some contribution to 
CK2 binding, they are not consistent with a defined interaction domain. The notable 
exception was a series of 20 consecutive peptides (spots H1-H20 in Figure 3.4A) 
that correspond to amino acids 210-249 of CBX7. This C-terminal region of CBX7 
contains the conserved Pc box domain (Figure 3.4B) and peptides that contain the 
complete Pc box are highlighted by the blue bar (Figure 3.4A). One amino acid, 
Ile230, was common to all peptides bound by CK2α.  
 
Four other regions of the CBX7 peptide array demonstrated binding to CK2 that 
could be consistent with these also representing CK2 interaction domains: I) 
Peptides A23-30, corresponding to amino acids 23-49 within the conserved 
chromodomain of CBX7, II) Peptides C21-30, corresponding to amino acids 80-108 
of CBX7, III) Peptides E25-30 corresponding to amino acids 145-169 of CBX7, IV) 
Peptides F7-18 corresponding to amino acids 157-187 of CBX7. Although the 
signals were generally weaker relative to the C-terminal domain, it is possible that 
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there are multiple binding sites for CK2 within the CBX7 protein or that, in the 
context of the tertiary CBX7 structure, CK2 may contact these regions 
simultaneously.  
 
Taken together, the peptide array data suggest that CK2 interacts directly with 
CBX7 via the C-terminal Pc box but does not make stable contacts with other 
components of the PRC1 complex when tested in isolation. This would be 
consistent with recently published observations that CK2 does not interact directly 
with BMI1 or RING2 and that the Pc box of CBX4 is necessary for the direct 
interaction with CK2 (Vandamme et al., 2011). However, these authors concluded 
that the interaction involved the β rather than the α subunit of CK2, which will be 
discussed further in Chapter 7. 
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Figure 3.3 Binding of CK2α  to peptide arrays of HPH2, RING2 and BMI1 
Peptide arrays of HPH2, RING2 and BMI1 were incubated with recombinant 
CK2α. After extensive washing, immunoblotting was performed against CK2α to 
detect CK2α bound to array peptides. Position A1 of each array corresponds to 
N-terminal amino acids 1-20 of each protein. Each 20-mer peptide in the array 
was advanced from the previous by two residues in the C-terminal direction. 
The last peptide corresponds to the 20 amino acids at the C-terminus of each 
protein.  
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Figure 3.4 Binding of CK2α  to a peptide array of CBX7 
A) A peptide array of CBX7 was incubated with recombinant CK2α. After 
extensive washing, immunoblotting was performed against CK2α to detect 
CK2α bound to array peptides. Position A1 of the array corresponds to N-
terminal amino acids 1-20 of CBX7. Each 20-mer peptide in the array was 
advanced from the previous by one residue in the C-terminal direction. The last 
peptide, at position H22, corresponds to the C-terminal amino acids 232-251. 
The image is representative of two biological repeats. B) A schematic alignment 
of the Pc box in CBX proteins and conserved domains found within RYBP and 
YAF2.  
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3.3.2 CK2 binding to the Pc box of other CBX proteins 
To investigate whether CK2α also binds to the Pc box of other CBX proteins, 
additional peptide arrays were generated to represent CBX6 and CBX8. As before, 
the arrays were incubated with recombinant CK2α and the bound CK2α was 
detected by immunoblotting. Although the data were less compelling than the 
original CBX7 array, binding of CK2α was observed at peptides containing the 
complete Pc box, highlighted by the blue bar in Figure 3.5. These data suggest that 
the ability of the Pc box to interact directly with CK2 is conserved among the CBX 
proteins. 
 
RYBP (RING1 and YY1 interacting protein) has recently been shown to bind to the 
same surface of RING2 as the CBX proteins (Wang et al., 2010) and it has been 
proposed that RYBP-PRC1 and CBX-PRC1 represent functionally distinct 
complexes (Tavares et al., 2012, Gao et al., 2012). Although RYBP and CBX 
proteins share little sequence homology (11% identity between CBX7 and RYBP at 
the amino acid level), some residues in the CBX Pc box are conserved in RYBP 
(Figure 3.4B) and the corresponding domains in each protein are predicted to 
interact with RING2 via similar structural folds (Wang et al., 2010). To test whether 
CK2 can also interact with the relevant domain in RYBP, a peptide array of RYPB 
was generated and used in a binding assay with recombinant CK2α. Figure 3.5 
shows that CK2α was able to bind peptides at the N-terminus of RYBP and also 
peptides sharing conserved residues with the Pc box of CBX proteins. The blue bar 
highlights peptide spots containing the domain of RYPB similar to the Pc box of 
CBX proteins. These data suggest that CK2 might directly interact with RYBP as 
well as CBX proteins and are consistent with work showing that CK2 co-purifies 
with TAP-tagged versions of RYBP and YAF2 from 293T cells (Gao et al., 2012). 
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Figure 3.5 Binding of CK2α  to peptide arrays of CBX6, CBX8, and RYBP 
Peptide arrays of CBX6, CBX8 and RYBP were incubated with recombinant 
CK2α. After extensive washing, immunoblotting was performed against CK2α to 
detect CK2α bound to array peptides. Position A1 of each array corresponds to 
N-terminal amino acids 1-20 of each protein. Each 20-mer peptide in the array 
was advanced from the previous by one residue in the C-terminal direction. The 
last peptide corresponds to the 20 amino acids at the C-terminus of each 
protein. 
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3.4 Mapping the critical CK2 binding residues within the Pc 
box of CBX7 
3.4.1 Identifying CBX7 Pc box residues that interact with CK2 
To identify residues in the Pc domain of CBX7 that are critical for the interaction 
with CK2, a peptide array was generated in which amino acids 218-237 
(SEVTVTDITANSITVTFREA) of CBX7, encompassing the entire Pc box domain, 
were individually substituted in turn with one of the 20 common amino acids. A 
binding assay was performed, with or without recombinant CK2α,  and the bound 
protein was detected by immunoblotting. Binding of CK2 to the 
SEVTVTDITANSITVTFREA peptide was largely unaffected by the substitution of 
the first twelve residues (Ser218-Ser229) and the last three residues (Arg235-
Ala237) in this sequence, suggesting that these residues were not important for the 
interaction of CBX7 with CK2 (Figure 3.6). Notable exceptions were the 
replacement of some of the residues with either proline (Row P) or cysteine (Row 
C), which resulted in a loss of CK2α binding. Proline is unable to occupy many of 
the main-chain conformations adopted by other amino acids and is often found 
within very tight turns in protein structures. The substitution of a residue to proline 
is therefore likely to have introduced a kink in the peptide structure. The propensity 
of cysteine to form disulphide bonds could also have meant that cysteine 
substitutions altered peptide conformation. Loss of CK2 binding, to peptides 
containing proline or cysteine substitutions, may therefore be due to a significant 
change in the structure of these peptides, as opposed to the importance of the 
substituted residue for the interaction with CK2. 
 
A notable feature of the data was that replacing certain residues in the peptide with 
different alternatives seemed to have a consistent effect on the binding of CK2α. 
Most strikingly, the substitution of Val232 with any of 15 different amino acids 
resulted in reduced or loss of CK2α binding. The only exceptions are proline and 
asparagine, and the aliphatic amino acids leucine and isoleucine, which are 
biochemically similar to valine.  Substitutions of Ile230, Thr233, and to a certain 
extent Phe234, also resulted in the disruption of CK2α binding to the peptide. In 
particular mutating these residues to charged amino acids, such as histidine and 
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aspartic acid resulted in a loss of CK2α binding. Taken together these results 
indicate that four residues within this peptide are important for CK2 binding: Ile230, 
Val232, Thr233 and Phe234. 
 
3.4.2 Designing CBX7 point mutants 
The peptide binding data suggested that it might be possible to design a minimally 
mutated version of full length CBX7 that is unable to bind to CK2. This would 
obviously be an ideal tool for testing the functional importance of the interaction 
between these proteins. However, before introducing mutations into the full-length 
cDNA, it was important to consider how the four residues identified in the context of 
a 20-mer peptide (Ile230, Val232, Thr233 and Phe234) relate to the 3-dimensional 
structure of CBX7. Specifically, would these residues be available to interact with 
CK2 and how might they affect the interaction between CBX7 and RING2?  
 
The crystal structure of the C-terminus of CBX7 bound to the C-terminal domain of 
RING2 has been solved at a resolution of 1.7Å (PDB ID 3GS2, (Wang et al., 2010)). 
Interestingly, residues 218-237 of CBX7 form an antiparallel beta sheet that, in 
combination with residues in RING2, generates an extended intermolecular beta 
sheet that packs against the central helix in the C-terminal domain of RING2 (see 
Figure 3.7). Critically, Phe234 of CBX7 participates in a key hydrophobic stacking 
interaction with residue Tyr262 of RING2. Mutation of this residue was therefore 
likely to disrupt the interaction between CBX7 and RING2 and negate the 
participation of CBX7 in a functional PRC1 complex. Similarly, Val232 is one of four 
residues clustered around Phe234 that pack against a hydrophobic pocket in 
RING2. The side chain of Val232 can also be seen to point towards RING2, making 
it likely that is involved in the interaction (Figure 3.7). In contrast, the side chains of 
both Ile230 and Thr233 point out from the CBX7-RING2 interface suggesting they 
are not involved in the interaction between these proteins and in principle could be 
available to make additional protein contacts. Hydrophobic amino acids such as 
isoleucine are generally buried within protein structures and it is unusual to find a 
surfaced exposed aliphatic side chain unless it is involved in an inter-molecular 
interaction.   
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Figure 3.6 Binding of CK2α  to a substitution array of CBX7(218-237) 
A peptide array in which residues 218-237 of CBX7 (left-right axis) were 
individually changed to one of the 20 common amino acids (top-bottom axis). 
This array was incubated with recombinant CK2α. After extensive washing, 
immunoblotting was performed to detect CK2α bound to array peptides.   
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Together, these considerations suggested that Ile230 and Thr233 could contribute 
to a docking site for CK2 and that mutation of these residues might abrogate 
binding of CBX7 to CK2 while maintaining its ability to interact with RING2. They 
were therefore selected as targets for mutagenesis. Although the substitution of 
Val232 was predicted to affect the interaction of CBX7 with RING2, given the 
strength of the peptide array data implying a role for this residue in the interaction 
with CK2, it was also included as a target.  
 
Recombinant human CBX7 has proved difficult to produce in bacteria (personal 
communication from Jesus Gil, Janice Rowe and Lucas de Breed) and is less 
stable than mouse Cbx7 (mCbx7) (personal communication from Marc Rodriguez-
Neidenführ). The human protein contains a stretch of 92 amino acids that is not 
present in mCbx7 but otherwise there is 89% sequence identity between the two 
homologues. Importantly, the C-terminal Pc box is highly conserved (Figure 3.7).  
Because of these considerations, it was decided to generate mutations in mCbx7 
rather than the human protein, and to use mCbx7 for further functional investigation 
of the interaction with CK2. Previous work in the lab has shown that mCbx7 can 
extend the lifespan of human fibroblasts by repressing INK4a (Maertens et al., 
2009) and can interact with human PRC1 proteins when expressed in 293T cells 
(El Messaoudi-Aubert et al., 2010). As depicted in Figure 3.8, the critical residues 
in human CBX7 identified in the peptide arrays (Ile230, Val232 and Thr233) 
correspond to Val137, Val139 and Thr140 in mCbx7. 
 
The wild-type mCbx7 cDNA was cloned into the pGEX-6P1 vector to introduce an 
N-terminal GST tag. Using this plasmid as a template, PCR-based site-directed 
mutagenesis (Chapter 2.1.3) was used to make the following substitutions: 
1) V137A/D  
2) V139A/D 
3) T140A/D 
4) V137A/D T140A/D 
5) V137A/D V139A/D T140A/D  
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Figure 3.7 CK2 interacting residues of CBX7 in the context of a CBX7-RING2 
complex 
The crystal structure of the C-terminus of CBX7 (cyan) and the C-terminus of 
RING2 (yellow). Key residues important for an interaction with CK2 are 
highlighted, Ile230 (indigo), Val232 (purple), Thr233 (pink). Images were 
created using PyMol from PDB ID 3GS2 (Wang et al., 2010). The conservation 
of these residues between the human CBX proteins, mCbx7, dPc, YAF2 and 
RYBP is shown in the ClustalW sequence alignment below. 
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Figure 3.8 Conservation of Pc box residues important for CK2 binding 
Schematic diagram of the chromodomain and Pc box of human CBX7 and the 
conservation of these domains in mouse Cbx7 (mCbx7). The stretch of 92 
amino acids unique to CBX7 (Arg83-Gln175) is indicated. CK2 interacting 
residues in the Pc box of CBX7 (Ile230, Val232, Thr233) and mCbx7 (Val137, 
Val139 and Thr140) are highlighted.   
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3.4.3 Testing the CK2 binding potential of mCbx7 point mutants 
The plasmids encoding the GST-mCbx7 variants were transduced into an 
appropriate strain of E. coli and protein expression was induced by addition of 
IPTG (Appendix: Figure 8.2 and Figure 8.3). The fusion proteins were purified on 
glutathione sepharose beads and their concentrations were adjusted to 0.1mg/ml. 
The ability of these fusion proteins to interact with CK2 subunits and RING2 was 
analysed in a standard GST pull-down assay with 293T cell lysate. 
 
Wild-type mCbx7 showed the expected interaction with the α, α’ and β of CK2 and 
with RING2 (Figure 3.9). The V137A, V139A and T140A single substitutions and 
even the V137AT140A double substitution had no discernible effect on the binding 
of CK2 to mCbx7. However, the V137AV139AT140A triple substitution showed a 
reduced ability to bind to CK2. Interestingly, the single substitutions in which 
Val137, Val139 and Thr140 were replaced with aspartic acid rather than alanine 
(V137D, V139D and T140D) did cause a decrease in the binding of CK2 to mCbx7, 
with V139D demonstrating the strongest effect. CK2 binding to the V137DT140D 
double mutant was very weak and with the triple substitution, V137DV139DT140D, 
binding to CK2 was essentially abolished. The different effects of the alanine and 
aspartic acid substitutions are consistent with peptide array data (Figure 3.6) and 
can be explained by the properties of these residues. As alanine is non-polar and 
only weakly hydrophobic, replacing a wild-type residue with alanine will test 
whether the physiochemical properties of that particular amino acid are critical for 
the tested function. In contrast, aspartic acid is a negatively charged, hydrophilic 
amino acid with very different physiochemical properties compared to valine and 
threonine. Thus, aspartic acid is a more disruptive substitution that could have a 
stronger effect on the interface involved in intra-molecular interactions.  
 
To ensure that the loss of CK2 binding to mCbx7-V137DT140D and mCbx7-
V137DV139DT140D was not due to protein misfolding, the melting point (Tm) of 
the variants was compared to that of wild-type mCbx7 by differential scanning 
fluorimetry (DSF) (Figure 3.10). All of the proteins had a Tm within one degree 
centigrade of each other, giving high confidence that the mutant proteins are folded 
in the same manner as wild-type mCbx7 (Helen Walden, personal communication). 
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Collectively, the data suggested that residues Val137, Val139 and Thr140 in 
mCbx7 are indeed important for its interaction with CK2 and that it is possible to 
abrogate binding to CK2 by changing all three of these residues to aspartic acid. 
Unfortunately, the substitutions also disrupted the interaction of mCbx7 with RING2 
and BMI1, although not with HPH2 (Figure 3.9). This is an interesting distinction 
that warrants further investigation and is discussed in more detail in Chapter 7. It is 
also important to note that these experiments did not determine whether the 
mutated residues are absolutely required for the direct interaction between mCbx7 
and either CK2 or RING2. It is possible that they disrupt the interaction with an, as 
yet, unspecified protein or domain that promotes the formation of the CBX7-CK2 or 
CBX7-RING2 complex (see discussion in Chapter 7).   
 
3.5 Conclusions 
The results described in this chapter demonstrate that CK2 can associate with all 
five members of the CBX family and that, in the case of CBX7, this interaction 
takes place in high molecular weight complexes that would be consistent with 
PRC1. It was further shown that CK2 could directly interact with residues in the C-
terminus of CBX proteins that coincide with the conserved Pc box domain. Three 
residues within the Pc box of mCbx7, Val137, Val139 and Thr140, were shown to 
be necessary for the interaction with endogenous CK2. Interestingly, these three 
residues were also necessary for the interaction of mCbx7 with both BMI1 and 
RING2. The specific interaction of CK2 with CBX proteins suggested that CK2 
might phosphorylate these proteins. The next chapter describes efforts to 
investigate this possibility.  
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Figure 3.9 GST pull-down of mutant mCbx7 proteins from 293T cell lysate 
5mg pre-cleared 293T cell lysate was incubated with 10µg GST, GST-mCbx7, 
or GST-mCbx7 mutant proteins (A) alanine mutants B) aspartic acid mutants), 
as indicated. GST pull-down was performed as described in methods. Proteins 
recovered from the pull-down were fractionated by SDS-PAGE alongside input 
samples equivalent to 1/100th of the volume of cell lysate used for the pull-
down. Immunoblotting was performed against CK2α, CK2α‘, CK2β, RING2, 
BMI1 and HPH2. GST and GST-mCbx7 proteins are indicated and asterisks 
highlight suspected degradation products. Images are representative of two 
biological repeats. 
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Figure 3.10 Thermal denaturation of mCbx7 (wild-type) and mCbx7 point mutants  
Differential scanning fluorimetry (DSF) was used to determine thermal 
denaturation curves for GST-mCbx7 (wild-type, V137DT140D, and 
V137DV139DT140D). Data are representative of three technical repeats. Each 
thermal denaturation curve is coloured according to the key, and the melting 
point (Tm) of each protein is noted in the figure.  
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Chapter 4. Phosphorylation of CBX7 
4.1 Introduction 
Phosphorylation can enhance or disrupt protein-protein and protein-DNA 
interactions. The association of CK2 with CBX proteins suggested that CK2 could 
influence the function of PRC1 complexes, either by phosphorylating a component 
of PRC1 or acting in conjunction with PRC1 to phosphorylate a protein at its site of 
action. However, as discussed in Chapter 1.11.5, investigating candidate CK2 
substrates is challenging due to their large number. The CK2 consensus sequence, 
S/T-x-x-D/E (Marin et al., 1986, Meggio and Pinna, 2003, Meggio et al., 1984), is 
present in most protein sequences (Litchfield, 2003)). Indeed, each human PRC1 
protein contains multiple CK2 consensus sequences (Table 1.2). Importantly, 
although an interaction between CK2 and the PRC1 complex has been extensively 
reported, no CK2 substrates have been identified among the known PcG proteins. 
 
CK2 is constitutively active and although this activity can be modulated by the 
CK2β subunits, in a substrate and context dependent manner, a main facet its 
regulation is via substrate interactions (Chapter 1.11.4). Given the specific 
interaction between CK2 and the Pc box domain of CBX proteins described in 
Chapter 3, we hypothesised that the CBX proteins might be phosphorylated by 
CK2. Within CBX7, there are three residues that lie within CK2 consensus 
sequences: Ser40, Thr221 and Thr233 (Figure 4.1). The Thr233 residue is a 
particularly interesting candidate because of its location in the Pc box of CBX7. The 
equivalent residue in mCbx7, Thr140, (Figure 3.8) is one of the three residues in 
the Pc box that are important for the interaction of mCbx7 with CK2 and RING2. A 
fourth residue, Thr41, was also of interest as a candidate CK2 target. Although 
Thr41 does not lie within a CK2 consensus, the equivalent residue in the 
chromodomain of HP1β, Thr51, is phosphorylated by CK2 during the DNA damage 
response. Phosphorylation of Thr51 disrupts the interaction of HP1β with H3K9me3 
and serves to mobilise HP1β from chromatin (Ayoub et al., 2008). Thr41 of CBX7 
may therefore be an atypical CK2 target site and its phosphorylation could affect 
the interaction of CBX7 with chromatin. Given these precedents, we decided to 
investigate whether CBX7 itself is a substrate for CK2 phosphorylation. 
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Figure 4.1 Candidate CK2 phosphorylation sites within mCbx7 and CBX7 
CBX7 (251 amino acids) and mCbx7 (158 amino acids) proteins are 
represented by this schematic. Regions containing the chromodomains and Pc 
boxes are indicated (yellow and blue boxes, respectively). Dashed lines show 
the 92 amino acid stretch of CBX7 (Arg83-Gln175) that is not conserved in 
mCbx7. Candidate CK2 target residues are indicated.  
 
 
4.1.1 CK2 phosphorylation of mCbx7 in vitro 
To determine whether CBX7 could be phosphorylated by CK2 in vitro, purified 
recombinant mCbx7 was used as a substrate in a kinase assay with recombinant 
CK2 and [γ-32P]ATP. The wild-type GST-mCbx7 fusion protein was expressed in E. 
coli using the pGEX-6P1 plasmid as described in Chapter 3.  Following purification 
on glutathione sepharose beads, the intact mCbx7 protein was released from the 
beads by cleavage with PreScission protease. The production and recovery of 
recombinant proteins was assessed by SDS-PAGE and Coomassie staining of the 
gel. The purified mCbx7 appeared as a band of the expected size at around 24kDa 
and its provenance was confirmed by immunoblotting with an antibody that 
recognises mCbx7 (Appendix: Figure 8.4). 
 
Incubation of purified mCbx7 with recombinant CK2 and [γ-32P]ATP resulted in the 
incorporation of radioactive label, suggesting that CK2 was able to phosphorylate 
mCbx7 in vitro (Figure 4.2). Importantly, incorporation of 32P was dependent on the 
addition of CK2, demonstrating that other kinases, which might have been present 
as contaminants of the purification, were not responsible for the phosphorylation of 
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mCbx7. 32P was also incorporated into CK2α as expected; the α and β subunits of 
the CK2 holoenzyme are known to be autophosphorylated (Zhang et al., 2002). 
However, under the conditions used, autophosphorylation of the β-subunit was not 
detectable.  
 
Substrate interactions can be important for the regulation of CK2 activity (Chapter 
1.11.4). We therefore set out to test whether mCbx7 variants, which show impaired 
binding to CK2 (Chapter 3.4.3), could be phosphorylated. Two mCbx7 mutants, 
mCbx7-T140D and mCbx7-V137DV139DT140D were expressed in E. coli, purified, 
and subsequently cleaved from their N-terminal GST-tag, as described above for 
wild-type mCbx7. Purified mCbx7 (Wild-type, T140D and V137DV139DT140D) or 
recombinant Cdc37 (ProSpec), were incubated with recombinant CK2 and [γ-
32P]ATP, and proteins were subsequently fractionated by SDS-PAGE. Coomassie 
staining of the gel revealed equivalent loading of wild-type and mutant mCbx7 
species. 32P incorporation of wild-type mCbx7 was comparable to 32P incorporation 
of Cdc37, a known target of CK2 phosphorylation (Miyata and Nishida, 2005) 
(Figure 4.3). 32P incorporation of mCbx7-T140D was slightly less than that of wild-
type mCbx7. This could be a consequence of the slightly abrogated binding of CK2 
to this mutant (Chapter 3.4.3). Alternatively, it could also suggest that Thr140 is a 
CK2 target. However, as 32P incorporation was not completely abolished by the 
T140D mutation, this result would suggest that CK2 is able to phosphorylate 
additional residues under these conditions. Surprisingly, 32P incorporation into 
mCbx7-V137DV139DT140D was greater than wild-type mCbx7. Evidence in 
Chapter 3.4.3 suggested this mutant would be unable to bind CK2.  It is possible 
that the increased 32P incorporation could be a consequence of phosphorylation at 
a novel CK2 consensus site, Ser136, found in this mutant. These data suggest that 
either CK2 binds mCbx7-V137DV139DT140D under these conditions, or that the 
binding of CK2 to mCbx7 is uncoupled from its ability to phosphorylate mCbx7. 
These points will be discussed further in Chapter 7. 
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Figure 4.2 In vitro phosphorylation of CBX7 by CK2 
Kinase assays were performed using purified mCbx7, CK2 holoenzyme and [γ-
32P]ATP in the combinations indicated. Kinase assay products were fractionated 
by SDS-PAGE and Coomassie stained overnight. Autoradiography was used to 
detect 32P in the Coomassie stained gel. Arrows indicate phosphorylated CK2α 
and mCbx7. Image is representative of three biological repeats. 
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Figure 4.3 CK2 phosphorylation of mCbx7 (wild-type, T140D and 
V137DV139DV140D) and Cdc37 
Kinase assays were performed using purified mCbx7 (wild-type, T140D and 
V137DV139DT140D) or Cdc37 (ProSpec), CK2 holoenzyme and [γ-32P]ATP 
when indicated. Kinase assay products were fractionated by SDS-PAGE and 
Coomassie stained overnight. Autoradiography was used to detect 32P in the 
Coomassie stained gel. Arrows indicate phosphorylated mCbx7 proteins and 
Cdc37. Image is representative of two biological repeats. 
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4.1.2 Identifying CK2 phosphorylated peptides within CBX7 
To try to identify the residue(s) in mCbx7 phosphorylated by CK2, the in vitro 
kinase assay was repeated in the presence of unlabelled ATP and the products 
were submitted for analysis by mass spectrometry (MS). Samples that had been 
treated with or without CK2 were submitted and two enzymatic digestions were 
performed on each. Although the coverage of mCbx7-derived peptides was good, 
the MS analyses did not identify any phosphorylated residues within mCbx7.  This 
was disappointing, given the clear evidence for 32P labelling of mCbx7 in the in vitro 
kinase reaction. However, if only a small percentage of the mCbx7 was 
phosphorylated in the reaction, the MS analyses may not have been sufficiently 
sensitive to identify sub-stoichiometric amounts of phosphopeptides.  
 
As the MS analysis was inconclusive, it was decided to take an alternative 
approach. A synthetic peptide array, representing the sequence of human CBX7 as 
a series of overlapping 20-mers, was used as the substrate in an in vitro kinase 
assay with [γ-32P]ATP and recombinant CK2. Autoradiography was used to detect 
32P-bound to the array (Figure 4.4A). Interestingly, 32P labelling was observed in 
four discrete regions of the array, in patterns consistent with phosphorylation of 
adjacent peptides. However, these 32P-labelled peptide spots did not contain 
candidate CK2 target residues. Furthermore, some of the 32P-bound peptides did 
not contain a serine or threonine residue (A17-21), and although these peptides did 
contain tyrosine, it is very rare to find tyrosine phosphorylation attributable to CK2 
(Meggio and Pinna, 2003). Taken together, these data suggested that 32P 
incorporation did not reflect phosphorylation of the peptides by CK2.  
 
As ATP is negatively charged, it was conceivable that the signals on the array 
represented direct binding of [γ-32P]ATP to positively charged peptides. A crude 
estimate of the charge was obtained by simply counting the difference between the 
number of acidic (aspartate and glutamate) and basic (histidine, arginine and 
lysine) residues in each peptide. As represented in Figure 4.4B, there was a 
striking correlation between the peptides with an excess of positively charged 
residues and those labelled by [γ-32P]ATP on the array. To confirm this 
interpretation, a duplicate array was used in an in vitro kinase assay in the absence 
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of CK2. The 32P signal was detected on the same positively charged peptides 
implying that it did not represent phosphorylation by CK2 (Figure 4.5). 
  
This was an unexpected finding as, in other studies, peptide arrays have been 
successfully used to identify sites of phosphorylation. For example, similar peptide 
arrays were used at the LRI to determine the CK2 phosphorylation site in TEL2 
(Horejsi et al., 2010). Importantly, the conditions used in the TEL2 study were 
adopted here for the in vitro kinase assay on the CBX7 array. Presumably, the 
signal to noise ratio for a true phosphorylation event would be great enough to 
negate the background signal obtained from binding of [γ-32P]ATP to positively 
charged peptides. A positive control peptide on these arrays would have been 
useful to test this hypothesis. The implication is either that CK2 can only 
phosphorylate CBX7 in the context of the full-length protein or that CBX7 is not a 
substrate for phosphorylation by CK2.  
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Figure 4.4 In vitro kinase assay of CBX7 peptide array with CK2 
A) A peptide array of CBX7 was incubated under kinase assay conditions with 
recombinant CK2α and [γ-32P]ATP. After extensive washing, autoradiography 
was used to detect 32P bound to the array. Position A1 of the array corresponds 
to N-terminal amino acids 1-20 of CBX7. Each 20-mer peptide in the array was 
advanced from the previous by one residue in the C-terminal direction. The last 
peptide, at position H22, corresponds to the C-terminal amino acids 232-251. 
B) A diagram showing the number of positive side-chains minus the number of 
negative side chains within each peptide of the CBX7 array used in A. Peptide 
positions are coloured according to the key shown in the diagram. 
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Figure 4.5 In vitro kinase assay of CBX7 peptide array in the absence of CK2 
A) A peptide array of CBX7 was incubated under kinase assay conditions with 
[γ-32P]ATP but in the absence of recombinant CK2. After extensive washing, 
autoradiography was used to detect 32P bound to the array. Position A1 of the 
array corresponds to N-terminal amino acids 1-20 of CBX7. Each 20-mer 
peptide in the array was advanced from the previous by two residues in the C-
terminal direction. The last peptide, at position D26, corresponds to the C-
terminal amino acids 232-251. B) A diagram showing the number of positive 
side-chains minus the number of negative side chains within each peptide of 
the CBX7 array used in A. Peptide positions are coloured according to the key 
shown in the diagram. 
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4.2 Evidence for phosphorylation of endogenous CBX7 
To assess whether endogenous CBX7 is phosphorylated, the TALON phosphate 
metal affinity chromatography (PMAC) resin was used to separate cell lysates into 
fractions containing phosphorylated proteins (that had bound to the resin) and 
fractions containing non-phosphorylated proteins (which did not bind to the resin). 
Phospho-enrichment was performed on lysates from control cells (treated with 
ethanol) and from cells treated with the CK2 inhibitor DRB, to investigate whether 
CBX7 phosphorylation status was dependent on CK2 activity. 
 
In addition to CK2, DRB is known to target additional kinases, such as P-TEFb. 
Inhibition of P-TEFb by DRB blocks transcriptional elongation by Pol II; leading to a 
decrease in the Ser2-phosphorylated form of RNA polymerase II (phospho-Pol II 
(Ser2)) levels (Nechaev and Adelman, 2011). As expected, β-actin was recovered 
exclusively in the non-binding fraction whereas phospho-Pol II (Ser2) was 
exclusively in the bound fraction (Figure 4.6). Less phospho-Pol II (Ser2) was 
recovered in the bound fraction from DRB-treated cells, confirming DRB had 
blocked transcriptional elongation. 
 
Figure 4.6 shows that endogenous CBX7 was bound to the PMAC resin in both the 
control and DRB-treated samples. Moreover, the amount of phosphorylated CBX7 
recovered under both conditions was equivalent. This result suggests that if 
endogenous CBX7 is indeed phosphorylated by CK2, as implied by the in vitro 
kinase assay, then CK2 is not the only kinase to do so. RING2 was also recovered 
as a phosphorylated protein in both the presence and the absence of DRB, and 
therefore similar conclusions apply. One caveat in this experiment is the 
discrepancy between the amount of CBX7 recovered in the phosphorylated fraction 
and the input.  Although CBX7 was not detected in the flow-through, it could have 
been lost during the extensive washing of the column between loading and elution.  
This did not appear to be an issue with RING2 and phospho-Pol II (Ser2) but it is 
conceivable that the extent of phosphorylation and the position of these 
modifications in the protein can affect the affinity of the protein for PMAC resin.  
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Endogenous CBX7 is resolved into two differently migrating bands when 
fractionated by SDS-PAGE under optimal conditions. This doublet is apparent in 
Figure 4.6 but is more convincing in Figure 4.7. To investigate whether the doublet 
reflected a phosphorylation event, 293T cell lysate was treated with lambda 
phosphatase to remove this modification from all cellular proteins. Following SDS-
PAGE and immunoblotting, CBX7 was still resolved as a doublet (Figure 4.7). 
Phosphorylated-MEK served as a positive control to show that lambda 
phosphatase treatment had been effective. This result suggests that the 
endogenous CBX7 doublet is not due to phosphorylation. Overexpressed mCbx7-
FLAG and mCbx7-HA are resolved as doublets but the bands are markedly 
different in size as opposed to those of endogenous CBX7. CBX7-FLAG can also 
be resolved as two differentially migrating bands, although the smaller of these, 
migrating to around 26 kDa, is often only visible after FLAG-immunoprecipitation 
(Figure 3.1). Following lambda phosphatase treatment, the higher migrating bands 
of mCbx7-FLAG, mCbx7-HA and CBX7-FLAG were detected at equivalent 
amounts to untreated lysate, suggesting that they are not a consequence of 
phosphorylation. As mCbx7 and CBX7 have a conserved methionine position 55, 
and CBX7 has an additional methionine at position 86, the different sizes of these 
C-terminally tagged proteins probably reflect translation from alternative start 
codons.  
  
Chapter 4. Phosphorylation of CBX proteins 
 
 124 
 
Figure 4.6 Phosphorylation status of CBX7 following CK2 inhibition 
293T cells were treated with ethanol or 75mM DRB for 3h and then lysed. 
Lysate was loaded into phosphate metal affinity chromatography (PMAC) resin 
columns. Non-phosphorylated proteins did not bind to the resin and were 
collected in the flow-thorough. After extensive washing of the column, 
phosphorylated proteins bound to the resin were eluted. Flow-through and 
eluted samples were fractionated by SDS-PAGE alongside input samples 
equivalent to 2% volume of cell lysate loaded on the PMAC column. 
Immunoblotting against CBX7, RING2, β-Actin and phospho-Pol II (Ser2) was 
performed. Image is representative of two biological repeats. 
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Figure 4.7 Lambda phosphatase treatment of cell lysate 
pcDNA6 plasmids encoding CBX7-FLAG, mCbx7-FLAG or mCbx7-HA 
(generated by Marc Rodriguez-Niedenfuhr) were transfected into 293T cells 
using lipofectamine. After 24 hours, cells were lysed and treated with lambda 
phosphatase (4,000 U per mg protein lysate) for 45 minutes at 30°C. The 
untreated and lambda phosphatase treated lysates were fractionated by SDS-
PAGE.  Immunoblotting was performed against FLAG, HA, CBX7 (Ab21873), 
phospho-MEK(Ser217/221) and β-tubulin. 
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4.3 CK2-independent phosphorylation of mCbx7 
Figure 4.6 suggested that endogenous CBX7 is phosphorylated and that some 
level of phosphorylation can occur independently of CK2 activity. In agreement with 
this, residue Thr119 of mCbx7, which does not lie within a CK2 consensus site, 
was found to be phosphorylated when mCbx7 was expressed in 293T cells (Emily 
Bernstein, personal communication). Phosphorylation of Thr119 was determined by 
mass spectrometry and the Bernstein laboratory developed a phospho-specific 
antibody against this residue of mCbx7. The phospho-specific antibody developed 
by the Bernstein laboratory was validated in two ways. Firstly, a peptide 
competition assay was performed using unphosphorylated or phosphorylated 
mCbx7 peptides. This assay showed that the antibody was specifically blocked by 
the phosphorylated mCbx7 peptide. Secondly, the antibody was validated by its 
failure to detect Cherry-tagged mCbx7 following lambda phosphatase treatment of 
the cell lysate. These experiments to validate the phospho-specific antibody were 
performed by the Bernstein laboratory; the data is not shown in this thesis. It is 
important to note that the mass spectrometry analysis of mCbx7, carried out by the 
Bernstein laboratory, did not reveal any phosphorylation at putative CK2 target 
residues.  
 
A collaboration was established with the Bernstein laboratory to investigate the 
functional implications of Thr119 phosphorylation. Our work specifically focused on 
understanding whether Thr119 phosphorylation affected the ability of mCbx7 to 
repress the INK4a tumour suppressor gene.  Over-expression of mCbx7, including 
the TAP-tagged version, can extend the replicative lifespan of HDFs via the 
repression of INK4a (Nicholls, 2006).  Conversely, shRNA-mediated knockdown of 
CBX7 causes up-regulation of INK4a and premature senescence (Maertens et al., 
2009). 
 
Retrovirus-based vectors encoding phospho-ablating and phospho-mimicking 
mutants of mCbx7 at Thr119 (mCbx7T119A-FLAG-Cherry-LPC and mCbx7T119E-
FLAG-Cherry-LPC respectively) were provided by the Bernstein laboratory. They 
were packaged into amphotropic particles and used to infect the TIG3 and ESC 
strains of human fibroblasts (Brookes et al., 2004). Previous studies in the 
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laboratory have shown that ectopic expression of PRC1 components can have 
variable effects, depending on the strain of human fibroblasts, and TIG3 and ESC 
are two distinctive examples (Sharon Brookes, personal communication). As both 
the LPC vector and the Cherry tag had not been previously tested in the lab, cells 
were also infected with mCbx7-FLAG in pBABE, and the pBabe vector alone, 
which had both been previously validated (data not shown). 
 
Following infection and drug selection, the expression of the different versions of 
mCbx7 was assessed by immunoblotting with an antibody against the C-terminal 
FLAG epitope. As shown in Figure 4.8, similar levels of expression were achieved 
with each construct and in both cell backgrounds. Immunoblotting with an antibody 
that recognises mCbx7 identified the relevant bands on the gel and their sizes were 
consistent with the addition of FLAG and Cherry epitopes. Full-length protein 
species are indicated in Figure 4.8. The provenance of lower migrating bands 
detected by the anti-FLAG antibody have not resolved but may be a consequence 
of translation from alternative start codons as previously discussed (Chapter 4.2) 
Importantly, immunoblotting with an antibody against phospho-Thr119 confirmed 
the phosphorylation of wild-type Cbx7, expressed from either vector (lanes 2 and 4), 
but was not sensitive enough to detect endogenous CBX7. The phospho-mimicking 
and phospho-ablating mutants were not detected by the phospho-Thr119 antibody.  
 
The cell lysates were also analysed for the expression of p16INK4a at both the 
protein and RNA level. Wild-type mCbx7, expressed from either the pBABE or LPC 
vectors, caused the expected down-regulation of endogenous p16INK4a in both TIG3 
and ESC cells, and comparable effects, relative to the loading control, were 
observed with the T119A and T119E mCbx7 mutants (Figure 4.8). INK4a RNA 
levels were also reduced to equivalent amounts following the overexpression of 
mCbx7-T119A, -T119E and wild-type mCbx7 proteins (Figure 4.9). The ability of 
mCbx7 to repress transcription of INK4a therefore appears to be intact in mCbx7-
Thr119 phospho-mimicking and phospho-ablating mutants.  
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Figure 4.8 p16INK4a levels in HDFs following expression of mCbx7 mutants  
Retrovirus-based vectors (pBABE, mCbx7-FLAG-pBABE (generated by Marc 
Rodriguez-Niedenfuhr), Cherry-FLAG-LPC, mCbx7-Cherry-FLAG-LPC, 
mCbx7T119A-Cherry-FLAG-LPC or mCbx7T119E-Cherry-FLAG-LPC 
(generated by Mooki Wu)) were packaged into amphotropic particles and used 
to infect TIG3 (A) and ESC (B) cells. 14 days post-infection infection, cells were 
lysed and protein was fractionated by SDS-PAGE. Immunoblotting was 
performed against FLAG, p16INK4a, phospho-mCbx7(T119) and β-tubulin. Single 
asterisks indicate full-length Cherry-FLAG-tagged mCbx7 species. Double 
asterisks indicate full-length FLAG-tagged mCbx7 species. Images are 
representative of two biological repeats.  
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Figure 4.9 INK4a RNA levels in HDFs following expression of mCbx7 mutants 
Retrovirus-based vectors (pBABE, mCbx7-FLAG-pBABE (generated by Marc 
Rodriguez-Niedenfuhr), Cherry-FLAG-LPC, mCbx7-Cherry-FLAG-LPC, 
mCbx7T119A-Cherry-FLAG-LPC or mCbx7T119E-Cherry-FLAG-LPC 
(generated by Mooki Wu)) were packaged into amphotropic particles and used 
to infect TIG3 (A) and ESC (B) cells. 14 days post-infection, cells were lysed, 
and the RNA was extracted and reverse transcribed. INK4a and β-tubulin cDNA 
was amplified by qPCR and CT values of INK4a were normalised to β-tubulin. 
The fold change of INK4a mRNA following the overexpression of mCbx7 (wild-
type, T119A or T119E), relative to control samples is shown. Data correspond 
to the average and standard deviation of three technical replicates and are 
representative of two biological repeats.  
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Recent work in the laboratory has suggested that CBX proteins function within 
Polycomb bodies that contain multiple variants of PRC1, and that the genes 
encoding CBX proteins are themselves subject to regulation by PRC1 (O'Loghlen 
et al., 2012, Bracken et al., 2006, Pemberton et al.). Further experiments were 
therefore performed to assess whether the contribution of mCbx7-Thr119 phospho-
mimicking and phospho-ablating mutants to p16INKa regulation was concomitant 
with the physical association of these mutants to INK4a. In human fibroblasts, 
endogenous PRC1 proteins have a well-characterised binding pattern across the 
INK4a-ARF-INK4b region as documented by chromatin immunoprecipitation (ChIP) 
and PCR with multiple primer sets (Maertens et al., 2009, Dietrich et al., 2007, 
Bracken et al., 2007, Pemberton et al.). An initial test was performed to confirm that 
mCbx7-FLAG expressed from the pBABE vector showed the expected binding 
pattern at INK4a following ChIP with anti-FLAG agarose (Figure 4.10A). Peak 
binding was observed with primer sets 5 and 7, which correspond to the first exon 
of INK4a, whereas binding was minimal at ARF and INK4b. No signal was detected 
with cells infected with the empty vector. 
 
In cells expressing FLAG-Cherry-tagged wild-type mCbx7, T119A-mCbx7 and 
T119E-mCbx7 from in the LPC vector, very similar binding patterns were observed 
following ChIP with anti-FLAG agarose (Figure 4.10B).  Although the enrichment 
relative to input was lower than observed with the pBABE vector, this applied to the 
wild-type construct and could reflect interference by the additional Cherry epitope in 
these constructs. These data suggest that the T119A and T119E mutations did not 
impair the ability of mCbx7 to associate with INK4a in either TIG3 or ESC cells. 
 
Finally, the mCbx7-Thr119 phosphomimicking and phosphoablating mutants were 
assessed for their ability to extend the lifespan of cells in which they are expressed. 
Previous work in the laboratory had shown that wild-type mCbx7 has a substantial 
impact on replicative lifespan of ESC cells but only a marginal effect in TIG3 cells 
(Sharon Brookes, personal communication). The reasons for these differences 
remain unclear but were recapitulated in the experiments described in Figure 4.11. 
Importantly, the ability of the T119A and T119E mutants to delay senescence was 
indistinguishable from that of wild-type mCbx7.  
 
Chapter 4. Phosphorylation of CBX proteins 
 
 132 
Taken together, these data imply that a phosphorylation event at Thr119 of mCbx7 
is unlikely to affect the ability of mCbx7 to function as a component of PRC1. It 
remains conceivable that phosphorylation of Thr119 alters a property of mCbx7 
that was not assessed or is only apparent at specific target genes. However, the 
Bernstein lab have more recently looked at global changes in gene expression by 
microarray analyses and found no significant differences between the effects of 
mCbx7T119A, mCbx7T119E and wild-type mCbx7 proteins.  
 
4.4 Conclusions 
Data presented in this chapter suggest that mCbx7 can be phosphorylated by CK2 
in vitro. However, the target residue could not be identified. This called into 
question the extent of in vitro CBX7 phosphorylation by CK2 and therefore the 
likelihood of CBX7 being an endogenous substrate of CK2. It also meant that it was 
not possible to mutate any identified CK2 target residues and test the function of 
phosphorylation. Both endogenous CBX7 and RING2 were shown to be phospho-
proteins and this status was not altered by CK2 inhibition. This suggested CBX7 
and RING2 are both substrates for other kinases. 
 
A CK2-independent phosphorylation site of mCbx7 (Thr119) was identified by 
Emily Bernstein’s laboratory and, in collaboration, we sought to investigate the 
functional implications of this phosphorylation. Specifically, our work tested the 
recruitment and activity of phospho-mimicking and phospho-ablating mCbx7 
mutants. Data here indicate that phosphorylation of mCbx7 at Thr119 is not 
important for PRC1 repression of INK4a. 
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Figure 4.10 ChIP of mCbx7 (wild-type, T119A or T119E) at INK4a-ARF-INK4b 
Retrovirus-based vectors (pBABE, mCbx7-FLAG-pBABE (generated by Marc 
Rodriguez-Niedenfuhr), Cherry-FLAG-LPC, mCbx7-Cherry-FLAG-LPC, 
mCbx7T119A-Cherry-FLAG-LPC or mCbx7T119E-Cherry-FLAG-LPC 
(generated by Mooki Wu)) were packaged into amphotropic particles and used 
to infect TIG3 (A and B) and ESC (D and E) cells. Cells were fixed 14-days 
post-infection and chromatin was subject to sonication and chromatin 
immunoprecipitation (ChIP) with anti-FLAG agarose (Thermoscientific). Purified 
DNA was isolated from bound protein and amplified by qPCR using primer sets 
at positions within the INK4a-ARF-INK4b locus (detailed in C). Graphs show the 
percentage enrichment of FLAG tagged protein relative to input DNA at the 
indicated primer sets. Data are representative of two biological repeats. 
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Figure 4.11 Life span chart of HDFs following expression of mCbx7 mutants 
Retrovirus-based vectors (pBABE, mCbx7-FLAG-pBABE (generated by Marc 
Rodriguez-Niedenfuhr), Cherry-FLAG-LPC, mCbx7-Cherry-FLAG-LPC, 
mCbx7T119A-Cherry-FLAG-LPC or mCbx7T119E-Cherry-FLAG-LPC 
(generated by Mooki Wu)) were packaged into amphotropic particles and used 
to infect TIG3 (A) and ESC (B) cells. Population doublings were recorded until 
cells reached senescence. Graphs show cumulative population doublings as a 
function of time following infection.   
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Chapter 5. Importance of CK2 for PRC1 repression 
of target genes 
5.1 Introduction 
Chapters 3 and 4 have described attempts to identify sites in CBX7 that are 
phosphorylated by CK2 or other kinases, and to map domains or individual 
residues in CBX7 that are important for the interaction with CK2.  The hope was 
that by identifying the critical residues, it might be possible to generate mutant 
versions of CBX7 that are either insensitive to or do not interact with CK2, and to 
use these in functional assays.  If successful, this strategy would have enabled us 
to determine whether the presence of CK2 in the PRC1 complex reflects a role in 
transcriptional repression or the DNA damage response (DDR). 
 
An alternative approach, which the laboratory has applied to other PRC1-
associated proteins (USP7 and USP11 (Maertens et al., 2010), and MOV10 (El 
Messaoudi-Aubert et al., 2010)), would be to manipulate the levels or activity of 
CK2 and to assess the consequences for endogenous PRC1 function. The 
situation is of course complicated by the fact that CK2 is a tetramer of two catalytic 
subunits (α and α’) and two β subunits.  Although the latter are dubbed “regulatory” 
subunits, CK2 is constitutively active and the effect of the β-subunits on CK2 
activity is substrate and context-dependent (Chapter 1.11.4). Manipulation of CK2 
therefore requires either a reduction of CK2 protein levels or chemical inhibition of 
its catalytic activity. Interestingly, siRNA-mediated knockdown of CK2 catalytic 
subunits in human fibroblasts was reported to cause an increase in the proportion 
of senescence-associated β-galactosidase (SA-β-gal) positive cells. Furthermore, 
the same study showed that CK2 levels were reduced in senescent human 
fibroblasts (Ryu et al., 2006). These data suggested a link between CK2 levels and 
senescence, perhaps through some contribution to PRC1-mediated repression of 
INK4a.  
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5.2 CK2 levels at senescence 
To confirm the report that CK2 levels are decreased in senescent cells (Ryu et al., 
2006), Hs68 human fibroblasts were grown to replicative senescence and the 
levels of CK2 subunits were compared to those in proliferating Hs68 cells. The 
Hs68 cells achieved 67 population doublings and were judged to be senescent by 
several criteria. At 6 weeks after the final 1:2 split, the cultures had only reached 
~50% confluency although cell viability was sustained. The cells had a large, flat 
morphology, single, prominent nucleoli, and stained positive for SA-β-gal activity 
(Figure 5.1). In addition, the cells expressed increased levels of p16INK4a and 
decreased levels of p18INK4c and CBX7 (Figure 5.1), changes that are typically seen 
at senescence (Acosta et al., 2008, Gagrica et al., 2012, Gil et al., 2004). 
Interestingly, the levels of both CK2α’ and CK2β protein were decreased in 
senescent Hs68 cells, whereas those of CK2α remained constant. Two studies 
from Young-Seuk Bae’s laboratory have demonstrated that mRNA and protein 
levels of CK2α and α’ are decreased in senescent IMR90 cells, but expression of 
CK2β remains stable. The same work also showed that CK2α and CK2β protein 
levels were reduced in aged rat testis but only CK2β  decreased in aged rat liver 
(levels of CK2α’ were not reported) (Ryu et al., 2006, Kim et al., 2009). Taken 
together, the data suggest that there is a consistent reduction in the overall levels 
of CK2 subunits at senescence but that the effects on individual subunits might be 
context dependent.  
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Figure 5.1 CK2 levels in senescent fibroblasts 
Hs68 cells were harvested at PD32 and PD67. Equivalent amounts of cell 
lysate were fractionated by SDS-PAGE and immunoblotted with antibodies 
against p16INK4a, p18INK4c, CBX7, CK2α, CK2α’ and CK2β and β-tubulin. The 
band denoted by an asterisk is believed to be a background immunoreactive 
band. Image is representative of two biological repeats. 
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5.3 Expression from INK4a following CK2 knockdown 
To investigate whether long term knockdown of CK2 had a discernible effect on 
p16INK4a expression, short hairpin RNAs (shRNAs) were designed to individually 
target the CK2α, α’ and β subunits (CSNK2A1, CSNK2A2 and CSNK2B mRNA 
respectively). The relevant DNA sequences were cloned into the pRetroSuper 
vector (Chapter 2.1.4) and tested for their ability to knockdown the target CK2 
subunit in transiently transfected 293T cells. The two most effective shRNAs for 
each subunit were then introduced into Hs68 human fibroblasts by retroviral 
infection. Figure 5.2 shows that levels of CSNK2A1, CSNK2A2 and CSNK2B 
mRNA and CK2α, α’ and β protein were reduced following expression of the 
corresponding shRNAs. However, none of the CK2 shRNAs caused an increase in 
the levels of INK4a mRNA compared to the control (luciferase shRNA), except for a 
very slight increase noted following the knockdown of CSNK2A2 by shRNA2. If 
anything, a slight decrease in INK4a mRNA was observed, for example with both 
CSNK2A1 shRNAs, CSNK2A2 shRNA1 and CSNK2B shRNA2. These data are 
representative of two biological repeats and care was taken to ensure that the 
housekeeping gene RPS17 was an appropriate control following CK2 knockdown 
in human fibroblasts. The levels of p16INK4a protein remained relatively unchanged 
following CK2 knockdown, in agreement with the RNA data. Exceptions to this 
were slight increases in p16INK4a protein levels following CK2α knockdown by 
CSNK2A1 shRNA2 and CK2β knockdown by CSNK2B shRNA2.  
 
As de-repression of INK4a is generally accompanied by the loss of H3K27me3 at 
the locus (Maertens et al., 2009, Barradas et al., 2009, Agger et al., 2007), Hs68 
cells expressing shRNAs against CSNK2A1 or luciferase (control shRNA) were 
fixed and a ChIP of H3K27me3 was performed. Figure 5.3 shows that enrichment 
of H3K27me3 across INK4a-ARF-INK4b did not appear to change following CK2 
knockdown.  
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Figure 5.2 Levels of INK4a mRNA and p16INK4a following CK2 knockdown 
pRetroSuper plasmids encoding control shRNA (against luciferase) or shRNAs 
against CSNK2A1 (A) CSNK2A2 (B) or CSNK2B (C) (generated as detailed in 
materials and methods) were packaged into amphotropic particles and used to 
infect Hs68 cells. 14 days post-infection, cells were harvested. RNA was 
extracted and reverse transcribed. Gene of interest (GOI) (INK4a, CSNK2A1, 
CSNK2A2, CSNK2B) cDNA and RPS17 cDNA was amplified by qPCR and CT 
values of the GOI were normalised to RPS17. The fold change of GOI mRNA 
following knockdown of CSNK2A1, CSNK2A2 or CSNK2B, relative to control 
samples is shown. Data correspond to the average and standard deviation of 
three technical replicates and are representative of two biological repeats. For 
protein analysis, Hs68 cells were also harvested 14 days post-infection. 
Equivalent amounts of cell lysate were fractionated by SDS-PAGE and 
immunoblotted with antibodies against p16INK4a, CK2α, CK2α’ and CK2β and β-
tubulin.  
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Figure 5.3 H3K27me3 enrichment at INK4a-ARF-INK4b following CSNK2A1 
knockdown 
pRetroSuper plasmids encoding control shRNA (against luciferase) or shRNAs 
against CSNK2A1 (generated as described in materials and methods) were 
packaged into amphotropic particles and used to infect Hs68 cells. 14 days 
post-infection, cells were fixed and chromatin was subject to sonication and 
chromatin immunoprecipitation (ChIP) using anti-H3K27me3 and Protein A 
agarose (Thermoscientific). Purified DNA was isolated from bound protein and 
amplified by qPCR using primer sets at positions within the INK4a-ARF-INK4b 
locus. Graph shows the percentage enrichment of H3K27me3 relative to input 
DNA at the indicated primer sets. Data are representative of two biological 
repeats.  
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5.4 Repression of PcG protein targets following CK2 inhibition 
Although the shRNAs used to knockdown CK2 subunits were very effective, they 
did not completely eliminate protein expression. In addition, only one subunit at a 
time was targeted in any given population. It was therefore a concern that the 
residual CK2 activity following shRNA knockdown of one subunit would be 
sufficient for CK2 to still function effectively in PRC1. To address this issue, 4,5,6,7-
Tetrabromobenzotriazole (TBB), a ATP/GTP-competitive inhibitor of CK2 (Sarno et 
al., 2001), was used to eliminate its catalytic activity. A limitation of this approach is 
that TBB treatment can cause a loss of cell viability and, as a result, is typically only 
applied to cells for 24 hours. Studies in the Jurkat human leukaemia cell line have 
shown that CK2-mediated phosphorylation of HS1, Max and Bid protects these 
proteins from caspase cleavage (Krippner-Heidenreich et al., 2001); (Desagher et 
al., 2001) (Ruzzene et al., 2002). This anti-apoptotic activity of CK2 could, at least 
in part, explain cell death following CK2 inhibition by TBB.  
 
Human fibroblasts (FDF) were treated with 300µM TBB for 24 hours. Successful 
CK2 inhibition was indicated by detection of PARP cleavage. PARP cleavage is a 
result of the apoptotic program induced by CK2 inhibition (Figure 5.4). A sufficient 
proportion of the cells remained viable to allow an analysis of gene expression by 
qPCR. As changes in INK4a expression are rarely apparent at this time point, the 
analyses were conducted on a series of putative PRC1 target genes that had been 
identified in the lab by ChIP-seq and shRNA-mediated knockdown of CBX7. FDFs 
expressing either control or CBX7-specific shRNA that had been introduced by 
lentiviral infection (kindly provided by Sharon Brookes) were used as a control for 
these experiments, but in this case the RNA was extracted 10 days post infection. 
Figure 5.4 confirms that the levels of CBX7 mRNA were substantially reduced 
following expression of the CBX7 shRNA. As expected, the levels of INK4a and 
TGFB2 mRNA increased, consistent with release from PRC1-mediated repression. 
However, CBX7 knockdown also caused a decrease in the levels of GAS1 and 
IGFBP5 mRNA. These changes are in line with recent RNAseq data suggesting 
that the knockdown of CBX7 can have both positive and negative effects on the 
expression of PRC1-occupied genes (Sharon Brookes, personal communication). 
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In contrast to the effects of CBX7 knockdown, the levels of INK4a and GAS1 
mRNA remained unchanged following TBB treatment while the levels of TGFB2 
were reduced.  With the possible exception of IGFBP5, these data suggest that 
there is no correlation between the effects of CK2 inhibition and CBX7 knockdown. 
However, it is worth re-emphasising that the 24 hour restriction on TBB treatment 
limits the conclusions that can be drawn from such experiments. If CK2 inhibition 
did release PRC1-repression of the target genes, it is possible that a change in 
their expression would not be detected until later time points.  
 
5.5 Conclusions 
Data presented in this chapter confirm the relationship between decreasing CK2 
levels and senescence. This relationship was interesting given that the INK4a gene 
is a target of PRC1 repression. However, both CK2 knockdown and inhibition 
experiments suggested that PRC1 regulation of INK4a is not affected by CK2 
activity. Similarly, expression from other PRC1 target genes remained largely 
unaffected following CK2 inhibition. These data suggest that CK2 activity may not 
be relevant for PRC1 repression of target genes. However, it is important to note 
the significant limitations attached to CK2 knockdown and inhibition experiments. In 
light of these, the extent to which CK2 is important in PRC1 function remains 
uncertain. 
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Figure 5.4 Expression of PRC1 target genes following CK2 inhibition 
RNA was prepared from FDF cells expressing control or CBX7 shRNA, and 
from FDFs treated with DMSO (control) or the CK2 inhibitor, TBB. After reverse 
transcription, gene of interest (GOI) (CBX7 (A), INK4a (B), GAS1 (C), IGFBP5 
(D), TGFB2 (E)) cDNA and RPS17 cDNA was amplified by qPCR and CT 
values of the GOI were normalised to RPS17. The fold change of GOI mRNA 
following CBX7 knockdown or TBB treatment, relative to control samples is 
shown. Data correspond to the average and standard deviation of three 
technical replicates. F) FDFs treated with DMSO (control) or TBB, were lysed 
and equivalent amounts of lysate were fractionated by SDS-PAGE and 
immunoblotted with antibodies against PARP.  
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Chapter 6. PRC1 recruitment to double strand 
breaks 
6.1 Introduction 
Attempts to show that CK2 modulates the ability of PRC1 complexes to regulate 
transcription have proved equivocal. Although PcG proteins are classically 
associated with gene repression, they have recently been shown to localise at sites 
of DNA damage leading to the idea that they might also play a role in the DNA 
damage response (DDR). For example, Bmi1 null-MEFs show impaired recruitment 
of DDR proteins, such as 53BP1, at double-strand breaks (DSBs) and increased 
sensitivity to ionising radiation (Ismail et al., 2010). Interestingly, CK2 activity is 
important for both SSB and DSB repair. CK2 phosphorylation of the DDR proteins 
XRCC1, Rad51 and HP1β, affects their stability, their interaction with other DDR 
proteins and their interaction with DNA, respectively. Collectively, therefore, CK2 
promotes effective DNA repair (Parsons et al., 2010, Yata et al., 2012, Ayoub et al., 
2008).  
 
Given reports of specific and prompt recruitment of PcG proteins to DSBs (Chou et 
al., 2010, Ismail et al., 2010, Facchino et al., 2010, Ginjala et al., 2011), we 
hypothesised that the interaction between PRC1 and CK2 could serve to localise 
CK2 at sites of DNA damage and thereby promote DNA repair. Alternatively, CK2 
phosphorylation of a PRC1 protein during the DDR could be important for the 
mobilisation of PcG proteins to sites of DNA damage, either by affecting intra-
molecular interactions of PRC1, interactions with other DDR proteins or with DNA 
itself. In an effort to test this latter hypothesis, we set about to establish a system 
whereby the genome-wide binding of PRC1 complexes could be assessed before 
and after inducing DSBs at predicted sites. Such a system could be used to 
determine the extent of PRC1 mobilisation during an extensive assault on DNA 
integrity. In addition, by manipulating CK2 activity in this system, the contribution of 
CK2 to the PRC1 response during DNA damage could be assessed. 
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6.2 Establishing an inducible DNA damage system in HDFs 
To this end, we adopted an inducible DNA damage system based on a fusion 
between the AsiS1 restriction enzyme and a modified DNA binding domain from 
the oestrogen receptor. In cells that constitutively express the fusion protein, AsiS1 
activity can be induced by addition of 4-hydroxy tamoxifen (4OHT). AsiSI is an 8bp 
endonuclease that cuts DNA at the consensus sequence GCGATCGC, which 
occurs at 1219 sites in the human genome (data not shown). A clone of U2OS cells 
that express the fusion protein (herein referred to as AsiSI-ER-HA-U2OS), along 
with the plasmid construct AsiSI-ER-HA-pBABE, were kindly provided by Gaelle 
Legube. The U2OS system was used by the Legube laboratory to map genome-
wide enrichment of γH2AX at DSBs following 4OHT induction of AsiSI (Iacovoni et 
al., 2010).  
 
The AsiSI-ER-HA-pBABE plasmid was packaged as a retroviral particle and used 
to infect the Hs68 strain of human fibroblasts. Hs68 cells were chosen because the 
binding sites for multiple PRC1 components have been mapped by ChIP-seq 
(Emma Anderton, personal communication) and because DNA repair pathways 
should be intact in normal human fibroblasts. Following drug selection, the infected 
cells were treated with 4OHT and analysed by immunofluorescence with antibodies 
against HA, to detect HA-tagged AsiS1, and γH2AX, to detect DSBs.   
 
As shown in Figure 6.1, nuclear levels of HA-tagged AsiSI and the number of 
γH2AX foci increased significantly following addition of 4OHT to cells expressing 
the AsiSI-ER-HA fusion protein. This was evident in both the previously 
characterised AsiSI-ER-HA-U2OS cells and throughout the population of AsiSI-ER-
HA-Hs68 cells. Importantly, only very low levels of nuclear HA and γH2AX signals 
were detected in these cells in the absence of 4OHT, levels equivalent to those 
seen in uninfected Hs68 cells, implying that the system was not leaky. 
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Figure 6.1 Immunofluorescence of γH2AX foci following 4OHT induction of DNA 
damage by AsiSI. 
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A) AsiSI-ER-HA-U2OS cells were co-stained with DAPI following incubation 
with antibodies against γH2AX (red) and HA epitope (green), before and after 
4OHT treatment. Images were deconvoluted using Huygens Essential software 
and Imaris software was used to detect the number of γH2AX foci per nuclei. B) 
Quantification of HA intensity (voxels) and number of γH2AX foci in 20 
representative AsiSI-HA-ER-U2OS nuclei before and after 4OHT treatment. A 
student’s t-test was performed on the data using Prism 5.0 (GraphPad 
Software). A P value of >0.05 is considered statistically significant. *** indicates 
P<0.001. Error bars represent the standard deviation of the sample. C) Hs68 
cells and AsiSI-ER-HA-Hs68 cells were co-stained with DAPI following 
incubation with antibodies against γH2AX (red) and HA epitope (green), before 
and after 4OHT treatment. Imaris software was used to detect the number of 
γH2AX foci per nuclei. D) Quantification of HA intensity (voxels) and number of 
γH2AX foci in 20 representative Hs68 and AsiSI-HA-ER-Hs68 nuclei before and 
after 4OHT treatment. A student’s t-test was performed on the data using Prism 
5.0 (GraphPad Software). A P value of >0.05 is considered statistically 
significant. *** indicates P<0.001. Error bars represent the standard deviation of 
the sample.  
 
 
6.3 Co-localisation of PcG proteins at DSBs 
Having validated 4OHT induction of DSB in cells expressing the AsiSI-ER-HA 
fusion protein, the system was used to assess recruitment of PcG proteins to DSBs. 
Fixed cells were immunostained with antibodies against CBX7, BMI1, RING2, 
53BP1 and γH2AX and either Alexa Fluor 488 or Alexa Fluor 555-conjugated 
secondary antibodies. Nuclei were located by DAPI staining. To assess the degree 
of co-localisation between different antibody pairs, Z-stacked images of three 
representative nuclei were collected and the images were deconvoluted using 
Huygens Essential software. Co-localisation channels were generated using 
automatic thresholds in the region of interest (nucleus) as defined by the DAPI 
channel using Imaris software. Pearson’s correlation coefficients (PCCs) were 
calculated, again using the Imaris software, to estimate the extent of co-localisation. 
PCCs can range from -1 to +1: -1 indicating a perfect negative linear relationship 
between two variables, 0 indicating no linear relationship between variables, and 
+1 indicating a perfect positive linear relationship between variables. The 
interpretation of intermediate PCCs can be quite varied in different studies. For the 
purpose of this investigation, we assume values between 0 and 0.09 to mean no 
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co-localisation, between 0.1 and 0.29 to mean weak co-localisation, between 0.3 
and 0.7 to mean moderate co-localisation and between 0.7 and 1 to indicate strong 
co-localisation. 
 
Following 4OHT treatment of AsiSI-ER-HA-U2OS cells, 53BP1 and γH2AX showed 
moderate co-localisation (Figure 6.2A-B). BMI1 and RING2 were mostly detected in 
large nuclear spots, as described previously for PRC1 components in U2OS cells 
(Alkema et al., 1997, Cmarko et al., 2003, Saurin et al., 1998, Hernandez-Munoz et 
al., 2005). Although there was a faint signal in the co-localisation channels for 
BMI1-γH2AX and RING2-γH2AX, the PCCs suggested that neither of these PcG 
proteins co-localised with γH2AX (Figure 6.2A-B). Co-localisation images and 
PCCs for BMI1-MEL18 and RING1-RING2 provided strong evidence for the co-
localisation of these PRC1 proteins, giving confidence that the antibodies were 
appropriate for use in co-localisation studies (Figure 6.2C). Although the 
immunofluorescence signal for CBX7 appeared to be more dispersed compared to 
BMI1 and RING2, this could represent cross-reaction of the antiserum with another 
cellular protein(s), as there was no evidence for co-localisation with the PcG 
proteins. Even with the more diffuse staining, which would tend to bias the statistics 
towards a stronger correlation, only a weak co-localisation of CBX7 with γH2AX 
was suggested by the PCC.  
 
Following 4OHT treatment of AsiSI-ER-HA-Hs68 cells, 53BP1 showed strong co-
localisation with γH2AX (Figure 6.2D-E). The co-localisation channel signals and 
corresponding PCCs suggested a weak co-localisation of both BMI1 and CBX7 
with γH2AX, with the caveat that the CBX7 result should be treated with caution 
(Figure 6.2D-E). RING2 could not be detected in Hs68 cells, although this might 
reflect a need for further optimisation of fixation, blocking and antibody incubation 
conditions. Interestingly, the distribution of BMI1 in Hs68 cells, in dispersed nuclear 
speckles, was very different from the large bodies seen in U2OS cells. Although 
most immunofluorescence studies on human PRC1 proteins have been carried out 
in U2OS or 293T cells, the difference between primary and transformed cells was 
noted in one of the first reports on RING1 localisation (Saurin et al., 1998) and 
clearly warrants further investigation. 
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Figure 6.2 Detecting co-localisation of PcG proteins with γH2AX foci following 
4OHT induction of DNA damage by AsiSI 
A) U2OS AsiSI-ER-HA cells were co-stained with DAPI following incubation 
with antibodies against γH2AX (red) and 53BP1 or a PcG protein (BMI1, CBX7 
or RING2) (green), before and after 4OHT treatment. Images were 
deconvoluted using Huygens Essential software and Imaris software was used 
to generate a co-localisation channel (yellow). B-C) PCC values for co-
localisation of the indicated proteins in three representative nuclei. Error bars 
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represent the standard deviation of the sample. D) Hs68 cells and Hs68 AsiSI-
ER-HA cells were co-stained with DAPI following incubation with antibodies 
against γH2AX (red) and 53BP1 or a PcG protein (BMI1 or CBX7) (green), 
before and after 4OHT treatment. Images were deconvoluted using Huygens 
Essential software and Imaris software was used to generate a co-localisation 
channel (yellow). E) PCC values for co-localisation of the indicated proteins in 
three representative nuclei. Error bars represent the standard deviation of the 
sample. 
 
 
6.4 ChIP-seq analysis of CBX7 in HDFs following genome-wide 
DNA damage 
Taken together, the immunofluorescence data suggested that the inducible system 
established in AsiSI-ER-HA-Hs68 cells was functioning as expected, as shown by 
the appearance of γH2AX foci and recruitment of 53BP1 following addition of 4OHT. 
However, the co-localisation of PcG proteins with γH2AX foci was questionable as 
only a weak correlation was observed with some antibodies. As an alternative 
approach, and to get a higher resolution picture of events occurring at AsiSI cut 
sites, chromatin was isolated from AsiSI-ER-HA-Hs68 cells before and after 4OHT 
treatment with a view to doing ChIP-seq analyses. For continuity with other aspects 
of the study, it was decided to focus initially on CBX7.  
 
Although the anti-CBX7 antibody Ab21873 (Abcam) was not considered reliable for 
immunofluorescence, it has been thoroughly evaluated and shown to be effective 
for ChIP (Maertens et al., 2009, El Messaoudi-Aubert et al., 2010). Due to more 
recent batch-to-batch variation in its efficacy for ChIP experiments, we decided to 
generate our own antiserum against the same peptide used to generate Ab21873 
(Chapter 2.4.5.1). This peptide, FREAQAAEGFFRDRSGKF, represented amino 
acids 234-251 at the C-terminus of CBX7. The IgG fraction of the antiserum 
generated against this peptide was purified, and is hereafter referred to as HCHA1. 
To test the specificity of HCHA1, FLAG tagged CBX2, CBX4, CBX6, CBX7 and 
CBX8 proteins were expressed in 293T cells, immunoprecipitated with anti-FLAG 
agarose, fractionated by SDS-PAGE, and immunoblotting was performed using 
HCHA1 (Figure 6.3). Although endogenous CBX7 from 293T cell lysate was not 
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detected by HCHA1, it clearly detected CBX7-FLAG and importantly, did not bind 
FLAG-tagged CBX4, 6 or 8. Anti-FLAG antibody failed to detect CBX2-FLAG from 
transiently transfected 293T lysates, suggesting expression of CBX2-FLAG in 
these cells was very low. The reactivity of HCHA1 with CBX2 has therefore not 
been evaluated, although as HCHA1 was generated against the same peptide as 
the commercial Ab21873 antibody, it should not cross-react. The efficacy of 
HCHA1 for ChIP of endogenous CBX7 was assessed. ChIP was performed using 
between 2.5 and 20µg HCHA1 per 500µg sonicated chromatin. A parallel ChIP was 
performed using 5µg Ab21873 (Abcam) from a batch that had been previously 
validated for ChIP of CBX7 (Emma Anderton, personal communication). ChIP of 
CBX7 at INK4a was as effective using HCHA1 as Ab21873 (Figure 6.4). The 
amount of HCHA1 antibody used did not noticeably affect the levels of CBX7 
enrichment at the INK4a. Future ChIP experiments using HCHA1 were performed 
using 5µg of antibody per 500µg chromatin. 
 
Chromatin from AsiSI-ER-HA-Hs68 cells, treated with or without 4OHT, was 
subjected to ChIP using the HCHA1 antibody. After confirmation that enrichment of 
CBX7 was observed at INK4a-ARF-INK4b (data not shown), the samples were 
submitted for massively parallel DNA sequencing on the Illumina GAII platform. 
This sequencing generated between 21 and 27 million 36bp reads that could be 
mapped to the hg19 release of the human genome. Equivalent data (between 20 
and 24 million 36bp reads that could mapped to the hg19 release of the human 
genome) from ChIP of CBX7 using Ab21873 and chromatin from uninfected Hs68 
cells had already been obtained by Emma Anderton. The ChIP-seq data showed 
that equivalent levels of CBX7 enrichment were observed genome-wide in both the 
untreated and 4OHT treated of AsSI-ER-HA-Hs68 cells, and that the patterns were 
indistinguishable from those in uninfected Hs68 cells. Examples of known CBX7-
target genes (INK4a, GATA6, DLX1) are shown in Figure 6.5A-C. Thus, the 
induction of DSBs at AsiS1 sites did not appear to cause gross changes in the 
existing patterns of CBX7 binding. 
 
The more telling question was whether CBX7 was recruited to AsiS1 sites following 
4OHT treatment. Peaks identified by the MACS algorithm as showing significant 
CBX7 enrichment were scored for their position (+/- 10kb) relative to predicted 
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AsiS1 sites. Only one of these MACS peaks was found exclusively in 4OHT- 
treated AsiSI-HA-ER-Hs68 cells and not in the untreated or uninfected control cells 
(Figure 6.5D). As this is the only example out of 1219 potential AsiS1 sites, it has 
not been validated by conventional ChIP. At face value therefore, it appears that 
CBX7 is not recruited to DSBs generated by AsiS1 induction. As the AsiSI-HA-ER-
Hs68 cells represent a mixed population it is conceivable that different subsets of 
AsiSI sites are cut in different cells, thereby diluting the apparent enrichment of 
CBX7 at each site. However, the immunostaining for γH2AX, which was performed 
on the same batch of cells as those used for the ChIP-seq analysis, suggests that a 
considerable proportion of the AsiS1 sites must be cut in each cell. Another 
possible explanation is that canonical PRC1 complexes are not recruited to DSBs; 
much of the existing literature focuses on BMI1 and RING2, which can participate 
in alternative complexes. In hindsight, it would have been useful to perform ChIP-
seq with an antibody against a bona-fide DDR protein, such as 53BP1, or with 
RING2, for which we already have ChIP-seq data in uninfected Hs68 cells.  
 
6.5 Conclusions 
To investigate whether CK2 contributes to the non-canonical role of PRC1 in the 
DDR, a system was established to test PcG protein recruitment to DSBs. 
Specifically, the hope was be able to map genome-wide changes in PcG binding 
patterns by ChIP-seq following DNA damage. The sequence specific, inducible, 
DSB system was established and validated in Hs68 human fibroblasts. However, 
CBX7 recruitment to DSBs could not be detected by immunofluorescence or ChIP-
seq. Furthermore, BMI1 and RING2, both previously reported to be recruited to 
DSBs, at best only showed weak co-localisation with DSBs as determined by PCC 
values.  
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Figure 6.3 HCHA1 antibody detection of FLAG-tagged CBX7 
pcDNA6 plasmids encoding FLAG-tagged CBX2, 4, 6, 7 or 8 were transfected 
into 293T cells using lipofectamine. After 24 hours cells were harvested and cell 
lysate was subject to immunoprecipitation (IP) using anti-FLAG M2 agarose 
(Sigma). Purified proteins were fractionated by SDS-PAGE alongside input 
samples equivalent to 1/10th volume of lysate used for the IP. Immunoblotting 
was performed against the FLAG-epitope (anti-FLAG) and CBX7 (HCHA1).  
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Figure 6.4 CBX7 enrichment across INK4a-ARF-INK4b following ChIP of CBX7 
using Ab21873 or HCHA1 antibodies 
Hs68 cells were fixed and chromatin was subject to sonication and chromatin 
immunoprecipitation (ChIP). ChIP was performed using Protein A agarose 
(Thermoscientific) and either 5µg Ab21873 (abcam) or between 2.5 and 20µg 
HCHA1 anti-CBX7 antibody, as indicated. Purified DNA was isolated from 
bound protein and amplified by qPCR using primer sets at positions within the 
INK4a-ARF-INK4b locus. Graphs show the percentage enrichment of CBX7 
relative to input DNA at the indicated primer sets.   
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Figure 6.5 ChIP-seq analysis of CBX7 in HDFs before and after DNA damage 
Profiles of DNA sequence tag densities at A) INK4a-ARF-INK4b B) GATA6 C) 
DLX1 and D) an AsiSI cut site, following ChIP-seq using anti-CBX7 (HCHA1). 
Profiles from AsiSI-ER-HA-Hs68 cells – 4OHT (light blue) and + 4OHT (dark 
blue) are shown, alongside data from uninfected Hs68 cells (green) (performed 
by Emma Anderton). Parallel analysis of input DNA is shown in grey. The 
genome organisation of each locus in A-C), as represented in the UCSC 
genome browser, is shown below. The AsiSI cut site in D) is indicated above 
the CBX7 binding profile in AsiSI-ER-HA-Hs68 + 4OHT cells and denoted 
‘Match_1086’. 
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Chapter 7. Discussion 
The aim of this thesis was to characterise the interaction of CK2 with PRC1 and to 
investigate the functional relevance of this association. We have found that CK2 
can interact with all five CBX proteins and in the case of CBX7, this was shown to 
depend on residues within the conserved Pc box near the C-terminus. Mutations at 
these residues abrogated binding of mCbx7 to endogenous CK2. However these 
mutants were also unable to bind endogenous RING2. Consequently, these 
mutations could not be used to tease out the functional relevance of the CK2 
interaction. We have shown that endogenous CBX7 is phosphorylated and that 
mCbx7 is phosphorylated by CK2 in vitro. However, we have been unable to 
identify the CK2 target residue of mCbx7 by mass spectrometry. Our data suggest 
that CK2 is not required for PRC1 repression of INK4a and evidence relating CBX7 
phosphorylation to function remains equivocal. To investigate the hypothesis that 
CK2 could influence PRC1 protein function in the DDR, we established a system to 
induce sequence-specific DSBs in HDFs that express a tamoxifen-regulated 
version of the AsiS1 restriction enzyme. Staining for γ-H2AX and 53BP1 confirms 
that the system operates as expected. However, detection of PRC1 proteins by 
either immunofluorescence or genome-wide ChIP-seq suggests that they are not 
recruited to AsiS1 sites in this system and extensive DNA damage does not 
mobilise PRC1 complexes from known binding sites. 
 
The following sections discuss the merits and weakness of the experimental data in 
relation to recently published findings and identify ways in which the investigation 
could be pursued in the future. 
 
7.1 The interaction of CK2 with PRC1 
As a starting point for further studies on the role of CK2 in the PRC1 complex, the 
interaction of CK2 with PRC1 components was confirmed by co-
immunoprecipitation of the endogenous CK2 subunits with overexpressed CBX2, 4, 
6, 7, and 8, and importantly, with endogenous RING2 (Figure 3.1). To our 
knowledge, this is the first report of an interaction between endogenous CK2 and 
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an endogenous PcG protein. The data provided confidence that the association 
could be physiologically relevant rather than an artificial consequence of over-
expression. They are also consistent with a previous report that CK2α co-
immunoprecipitates with overexpressed Ring1b (Sanchez et al., 2007) and more 
recent work showing that GST-tagged CK2α and β interact with overexpressed 
CBX4 and RING2 (Vandamme et al., 2011). 
 
The other important criterion for physiological relevance is whether the auxiliary 
protein is present in complexes of an appropriate size.  According to the gel 
filtration data, endogenous CK2 in 293T cells was present in high molecular weight 
fractions (Figure 3.2A), peaking at a size of approximately 550 kDa. This result is 
consistent with previous findings in mouse F9 cells (Guerra and Issinger, 1998), 
and suggests that CK2 is commonly associated with other proteins. The size range 
of CK2 complexes is consistent with that of endogenous PRC1 proteins although 
there is substantial variability in the sizes reported for different PCG proteins and in 
different studies (ranging from 400 kDa to over 2 mDa)(Gao et al., 2012, Sanchez 
et al., 2007, Vandamme et al., 2011, Tavares et al., 2012, Maertens et al., 2010). 
There are also discrepancies between the elution profiles of endogenous and 
ectopically expressed proteins (Figure 3.2B and (Vandamme et al., 2011)) 
suggesting that overexpressed PcG proteins may form additional interactions 
compared to their endogenous counterparts. Nevertheless, fractionation of 
immunoprecipitated CBX7-FLAG complexes showed that endogenous CK2 and 
RING2 co-purify with CBX7 in a complex greater than 669 kDa in size, consistent 
with that of a typical PRC1 complex (Figure 3.2B). A proper assessment of this 
issue would require co-immunoprecipitation of endogenous CK2 and PRC1 
components either before or after gel filtration but the levels of the PcG proteins 
and the poor sensitivity of the detection methods precluded this approach.  
 
Co-precipitation data do not indicate which component of the PRC1 complex is 
directly associated with CK2 but the peptide array data described here suggests 
that the principle contact is via the CBX protein. Recombinant CK2α bound strongly 
to a series of overlapping peptides that encompass the Pc box in the C-terminal 
domain of CBX7 (Figure 3.4). Neither the regulatory β subunits of CK2, nor any 
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other cellular proteins, were required for the interaction. It is also of note that ATP 
was absent from this system suggesting that the ability of CK2 to interact with 
these peptides is independent of CK2 kinase activity. Equivalent array data 
suggested that CK2α also binds to C-terminal peptides in CBX6 and CBX8, but not 
to RING2, HPH2 and BMI1 (Figure 3.3 and Figure 3.5). One caveat is that the 
signals detected on the latter peptide arrays were rather variable and less definitive. 
This could possibly reflect batch-to-batch variation in the recombinant CK2α 
obtained from a commercial supplier and, in retrospect, it might have been better to 
have produced our own recombinant CK2 in sufficient quantities to avoid this 
variable.  
 
The findings are nevertheless consistent with recently published data 
demonstrating a direct interaction between CK2 and the C-terminus of CBX4 
(specifically, the 290 amino acid isoform, which results from alternative splicing) 
(Vandamme et al., 2011). In this study, recombinant GST-CK2α and GST-
CK2β, produced in bacteria, were shown to bind TAP-tagged CBX4, RING2 and 
BMI1 in 293T cell nuclear extract. However, when the binding was performed with 
in vitro-translated versions of CBX4, RING2 and BMI1, only CBX4 co-purified with 
CK2 and specifically, only with the β subunit. Binding assays performed with 
variants of CBX4 that either lacked the chromodomain (CBX4(68-290)) or the Pc 
domain (CBX4(1-269)), demonstrated that the Pc box of CBX4 (272-286) is 
important for its direct interaction with the regulatory β subunit of CK2.  
 
In view of the peptide array data described here (Figure 3.4), it is curious that 
Vandamme and colleagues, did not detect binding between CBX4 and CK2α, as 
well as CK2β. It is conceivable that the GST-tag on the recombinant CK2α 
interfered with its ability to interact with CBX4. Another possibility is that CK2α and 
CK2β have different affinities for the Pc box of CBX4 and CBX7. However, this 
seems unlikely given the high conservation of the Pc domains of these proteins 
(Figure 3.7). It would be interesting to determine whether recombinant CK2β is able 
to bind the Pc box of CBX proteins in the context of a peptide array.  
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Although there is some evidence that the Pc box facilitates the self-association of 
Pc proteins (Reijnen et al., 1995), the best-characterised function of this domain is 
mediating the interaction of Pc proteins with RING2. The Pc box domains of CBX2, 
4, 6, 7, and 8 all bind to the C-terminus of RING2 (C-RING2) with strong affinity. 
Interestingly the Kd values for these interactions vary from 9.2 nM (the most stable) 
for CBX7-C-RING2 to 180 nM for CBX6- and CBX8-C-RING2. The interaction 
stabilises the conformation of C-RING2 and induces structural constraints in the Pc 
box, which is largely disordered in the absence of C-RING2 (Wang et al., 2008). 
Intrinsically disordered protein regions can expand the repertoire of binding 
partners by allowing for the creation of distinct interaction surfaces for different 
binding partners (Fink, 2005). This inherent flexibility of the Pc box could therefore 
mediate CBX-binding to other proteins, such as CK2, in the absence of RING2. 
Alternatively, the conformation of the Pc box, induced by its interaction with RING2, 
could be required for CBX to interact with other proteins. 
 
The crystal structure of the C-terminus of CBX7 bound to the C-terminal domain 
RING2 has been solved at a resolution of 1.7Å (PDB ID 3GS2, (Wang et al., 2010)). 
C-CBX7 has an antiparallel β-sheet structure that forms an extended, 
intermolecular β-sheet with the β-sheet region of C-RING2. Of note, Phe234 and 
surrounding residues in C-CBX7, including Val232, pack against a hydrophobic 
pocket in C-RING2 (Wang et al., 2010). It is not clear from the crystal structure, 
whether CK2 might be able to interact with CBX proteins that are complexed with 
RING2, or whether these interactions are likely to be mutually exclusive. As the 
peptide arrays and published data (Vandamme et al., 2011) imply that CK2 does 
not directly contact RING2, our ability to co-precipitate endogenous CK2 with 
RING2, suggests that the binding of CK2 and RING2 to CBX7 is not mutually 
exclusive. However, this hypothesis remains to be tested and it is conceivable that 
the interaction between CK2 and RING2 could be mediated by another protein.  
 
The mutation array of the CBX7 Pc box region showed that four residues were 
critically important for the in vitro interaction with CK2α: Ile230, Val232, Thr233 and 
Phe234. As mentioned above, Phe234 and Val232 are known to mediate the 
interaction between CBX7 and RING2, Phe234 critically so. In contrast, Ile230 and 
Thr233 appeared to point away from the CBX7-RING2 interface and it was hoped 
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that alteration of these residues might yield a CBX7 mutant that would be 
specifically unable to bind CK2. Indeed, when the equivalent residues in mouse 
Cbx7 were changed to aspartic acid, the GST-mCbx7 fusion protein with all three 
residues mutated did not bind CK2. However, this CBX mutant was also unable to 
bind both RING2 and BMI1 (Figure 3.9). Interestingly, the binding of HPH2 did not 
appear to be disrupted by these mutations. This suggests that HPH2 interacts with 
CBX7 in a BMI1-RING2 independent manner and that the relevant residues in the 
Pc box of CBX7 are not important for the interaction with HPH2.  
 
As BMI1 and RING2 are known to form a heterodimer (Buchwald et al., 2006, Li et 
al., 2006), the loss of BMI1 binding to the mCbx7 mutant was probably a 
consequence of the loss of RING2 binding. This illustrates an important limitation of 
the approach: as the binding assays were performed in the context of cell lysate, it 
is difficult to tell whether the failure of the mCbx7 mutant to interact with CK2 and 
RING2 reflects disruption of a direct contact with these proteins or of an interaction 
with a secondary protein that promotes the association of mCbx7 with CK2 and 
RING2. To investigate this further, it would be necessary to perform GST pull-down 
experiments with GST-tagged mCbx7 mutants and recombinant CK2 or 
recombinant RING2. Alternatively, these interactions could be tested amongst in 
vitro-translated versions of these proteins. Although this would be interesting, it 
would not shed light on whether it is theoretically possible to generate further 
variants of CBX7 that are specifically impaired for interacting with CK2 but not 
RING2.  
 
The peptide array data indicated that, in addition to the CBX proteins, CK2 might 
directly bind RYBP (Figure 3.5). Although we have not demonstrated that CK2 
binds full-length RYBP, this result is consistent with recent work by Gao and 
colleagues showing that CK2 co-purifies with TAP-tagged RYBP and YAF2 from 
293T cells (Gao et al., 2012). Importantly, the data here suggest that the interaction 
between CK2 and RYBP involves a domain in RYBP that has a degree of 
homology with the Pc box of CBX proteins (Figure 3.5). Moreover, this domain is 
predicted to interact with RING2 via similar structural folds as CBX7 (Wang et al., 
2010). This is interesting as it implies that the interaction domain of both CBX7 and 
RYBP with RING2 also mediates the interaction with CK2 in both complexes. 
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Whereas recruitment of the canonical PRC1 complex is in part dependent on PRC2 
and H3K27me3, recruitment of the RYBP complex is not (Tavares et al., 2012). As 
both complexes contain Psc and Sce subunits, they can both function as E3 
ubiquitin ligases. However, the balance of evidence suggests that H2A 
ubiquitination is largely carried out by the RYBP complex. The precise role of each 
complex has yet to be established but the association of CK2 in both complex 
types suggests its role is important for an aspect of PRC1 biology that is common 
to both.  
 
7.2 Phosphorylation of CBX7 by CK2 
The evidence that CK2 interacts directly with CBX7, and the presence of potential 
CK2 target sites in the CBX7 sequence, led us to investigate whether CBX7 is 
phosphorylated by CK2. The in vitro kinase assay, conducted using recombinant 
mCbx7 and commercial CK2 holoenzyme, showed clear incorporation of 32P into 
mCbx7 (Figure 4.2). Importantly, the extent of labelling was comparable to that of a 
known CK2 target, Cdc37 (Figure 4.3) (Miyata and Nishida, 2005). It was therefore 
disappointing that MS analyses did not detect any phosphorylated residues in two 
separate experiments. Unfortunately, the samples were submitted at a time when 
the LRI Protein Analysis and Proteomics service was relocating from Lincoln’s Inn 
Fields to Clare Hall laboratories, and subsequently undergoing a change in 
management. This caused a considerable delay in establishing an essentially 
negative result and, in retrospect, it might have been advisable to outsource the 
analysis.  
 
A potential explanation for the inability of MS to identify phosphorylated residues in 
mCbx7 would be that the phosphorylation is substoichiometric. Prior enrichment of 
the phosphorylated forms, for example on PMAC resin (Chapter 4.2), might have 
alleviated the problem. However, if substoichiometric phosphorylation occurs at 
multiple sites in mCbx7, the MS analysis would remain challenging.  
 
An equally plausible explanation would be that CBX7 is not a true substrate for 
CK2 in vivo and that the in vitro labelling of recombinant mCbx7 is non-specific. 
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This would be consistent with unpublished data from the Bernstein laboratory that 
was conveyed to us during the course of our investigations (Emily Bernstein, 
personal communication). They had performed affinity purification of TAP-tagged 
mCbx7, using a construct provided by us and used previously (Nicholls, 2006), and 
identified phosphorylated mCbx7 on Thr119 by MS analysis. This residue is not 
within a CK2 consensus, and no other phosphorylation events were detected. 
Moreover, in the experiments described in Chapter 4.2, inhibition of CK2 did not 
alter the status of CBX7 as a phosphorylated protein, as judged by retention on 
PMAC resin (Figure 4.6), implying that either CK2 does not phosphorylate CBX7 in 
vivo or, if it does, it is not the only kinase to do so.  
 
In collaboration with the Bernstein laboratory, we investigated whether the 
phosphorylation status of Thr119 had any bearing on measurable properties of 
mCbx7. We were able to show that phosphomimicking and phosphoablating 
mutations of Thr119 do not affect the ability of mCbx7 to bind the INK4a-ARF-
INK4b locus, to repress expression of p16INK4a, or to extend the lifespan of HDFs 
(Figure 4.8-Figure 4.11). Although It was conceivable that phosphorylation of this 
residue could have gene-specific effects on PRC1-mediated repression, gene 
expression profiling revealed very few differences between the effects of the wild-
type, T119A or T119E variants of Cbx7, (Emily Bernstein, personal communication). 
Together, these data suggest that Thr119 phosphorylation does not affect PRC1-
repression of target genes. 
 
The equivocal nature of the in vitro phosphorylation data precluded attempts to 
take a similar approach with candidate CK2 phosphorylation sites. However, as 
discussed above, one of the critical residues for the interaction between CBX7 and 
CK2 (Thr233 in the human protein, Thr140 in the mouse) is also a potential CK2 
target site. Interestingly, substituting this residue with aspartic acid caused a 
modest reduction in 32P-labelling by CK2 in vitro (Figure 4.3). This could suggest 
that Thr140 is indeed a CK2 target.  However, given the acidic nature of the 
consensus sequence, it was somewhat surprising that aspartic acid substitutions 
caused the most severe disruption of the CK2-CBX7 interaction as judged by 
peptide arrays and GST pull-down approaches. Paradoxically, the mCbx7 variant 
with three aspartic acid substitutions in the Pc box domain (V137D, V139D and 
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T140D) appeared to be a more effective substrate in the in vitro kinase assay 
despite being impaired for binding to CK2 (Figure 4.3). A plausible explanation for 
the increased phosphorylation of this variant is that the mutations create a novel 
CK2 consensus site centred on Ser136. However, the data imply that the aspartic 
acid substitutions affect the stable binding of CK2 to mCbx7 but not its ability to 
phosphorylate mCbx7.  
 
There are examples whereby the phosphorylation of a substrate by CK2 thereafter 
repels its interaction with CK2 (Filhol et al., 1992). However, this cannot explain the 
effects of aspartic acid substitutions on CK2 binding to the CBX7 peptide array as 
the binding assay was performed in the absence of ATP. Taken together, the data 
indicate that Val137, Val139 and Thr140 of mCbx7, and the equivalent residues in 
human CBX7, are important for the interaction with CK2 but this interaction is not 
required for the phosphorylation of mCbx7 in vitro. The data do not exclude the 
possibility that an interaction between CK2 and CBX7 is important for the 
phosphorylation of a CK2 target in vivo 
 
Although the focus in this thesis was on CBX7, all mammalian PRC1 proteins 
contain multiple CK2 consensus sequences (Table 1.2). It might therefore be 
informative to apply an unbiased approach to identifying CK2 targets within PRC1. 
For example, TAP-purified PRC1 complexes could be used in a kinase assay with 
recombinant CK2 and, though the analyses might prove challenging, 
phosphorylated peptides could be identified by MS. In particular it will be important 
to investigate Sce proteins as CK2 substrates. MS has identified several 
phosphorylation sites in Mel18, one of which lies within a CK2 consensus. 
Furthermore, the phosphorylation of Mel18 has been suggested to affect H2A 
recognition, and consequential ubiquitination, by a Ring1b-Mel18 complex assayed 
in vitro (Elderkin et al., 2007).  
 
7.3 Influence of CK2 on PRC1-repression of target genes 
It has been challenging to ascertain whether CK2 activity influences the ability of 
PRC1 to function as a transcriptional repressor. The fact that CK2 is essential for 
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cell viability, and the shear number of CK2 substrates, means that it is difficult to 
identify whether a perceived change is direct or indirect. We employed two 
approaches to manipulate CK2 activity. The first was to use shRNAs to reduce the 
levels of individual CK2 subunits. Although the shRNAs were very effective there 
was always some residual CK2 protein in the cells and only one subunit was 
targeted in a given population of HDFs. Attempts to knock down all three CK2 
subunits in the same cells were unsuccessful due to the loss of cell viability and it 
was clear that the combination of shRNAs had less substantial effects on each 
subunit as compared to the individual knockdowns. 
 
In the event, the knockdown of single CK2 subunits did not significantly affect the 
expression of INK4a or cell proliferation (Figure 5.2 and data not shown) This 
contrasts with previous experience in the lab following shRNA-mediated 
knockdown of other PRC1 auxiliary proteins in HDFs. For example, knockdown of 
the ubiquitin-specific proteases, USP7 and USP11, and the RNA helicase, MOV10, 
was found to relieve PcG repression of INK4a and cause p16INK4a-dependent 
senescence (El Messaoudi-Aubert et al., 2010, Maertens et al., 2010). USP7 and 
11 are thought to promote repression of INK4a by their ability to regulate the 
turnover of BMI1 and MEL18 (Maertens et al., 2010).  
 
The findings are also at odds with recent reports suggesting that siRNA-mediated 
knockdown of CK2 catalytic subunits in human mesenchymal stem cells and 
human fibroblasts can increase in the proportion of senescence-associated β-
galactosidase (SA-β-gal) positive cells (Wang and Jang, 2009, Kim et al., 2009, 
Ryu et al., 2006). However, only one of these studies considered additional 
markers of cell-cycle arrest or senescence following CK2 knockdown. In this study 
Wang and colleagues showed that p16INK4a protein levels were unchanged three 
days after siRNA knockdown of CK2α’ or CK2α  in human mesenchymal stem cells. 
After six days, p16INK4a protein levels increased slightly following the knockdown of 
CK2α‘ but not CK2α (Wang and Jang, 2009). However, as this study relied on 
single siRNAs against each subunit there could have been off-target effects. 
Moreover, the fact that cells remain viable following knockdown of CK2 subunits, 
both in our own and the published studies, suggests that the cells have enough 
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residual CK2 activity to maintain phosphorylation of critical CK2 targets. To avoid 
the uncertainties associated with shRNA-based approaches, the alternative 
strategy was to treat cells with a chemical inhibitor of CK2, TBB. Although CK2 
activity levels following TBB treatment were not measured directly, the cleavage of 
PARP indicated that CK2 was effectively inhibited. However, PARP-cleavage 
reflects engagement of an apoptotic program and highlights the substantial 
limitation of this approach. Studies in Jurkat human leukaemia cells have shown 
that inhibition of CK2 causes decreased phosphorylation of HS1, Max and Bid, a 
modification that protects these proteins from caspase-cleavage (Desagher et al., 
2001, Krippner-Heidenreich et al., 2001, Ruzzene et al., 2002). Loss of cell viability 
under such conditions limits the conclusions that can be drawn but it was 
nonetheless surprising that the expression of most of the PRC1-target genes 
investigated did not change following TBB treatment of HDFs (Figure 5.4). These 
data suggest that inhibition of CK2 for 24 hours does not alter the ability of PRC1 to 
repress target loci. However, it is important to note that the documented changes in 
p16INK4a expression following knockdown of PRC1 components take place over a 
much longer time scale. 
 
Although attempts to manipulate CK2 levels were problematic, it was clear that the 
endogenous levels of CK2 were reduced in senescent HDFs, albeit with differences 
between the subunits; CK2α and β subunits decreased substantially but α’ levels 
remained constant (Figure 5.1). The decrease in CK2 levels at senescence has 
also been described in two studies from Young-Seuk Bae’s laboratory. Together 
these studies suggested that both the mRNA and protein levels of CK2α and α’ 
declined at senescence in IMR90 human fibroblasts, whereas expression of CK2β 
remained stable. They also demonstrated that CK2α and CK2β protein levels were 
reduced in aged rat testis but only CK2β  decreased in aged rat liver; levels of 
CK2α’ were not reported (Kim et al., 2009, Ryu et al., 2006). Taken together, the 
data suggest that the changes affecting individual CK2 subunits might be context 
dependent. Whether the changes contribute to, or are consequence of, 
senescence remains unclear.  
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7.4 PcG proteins in the DDR 
Given the uncertainties regarding the role of CK2 in transcriptional regulation by 
PRC1 and the emerging evidence that both CK2 and PRC1 are implicated in the 
DDR, we were keen to establish a system in which we could assess the link 
between CK2 and PRC1 in the context of DNA damage. Having considered several 
possibilities, we adopted an inducible DNA damage system based on a fusion 
between the AsiS1 restriction enzyme and the tamoxifen-regulated ligand-binding 
domain of the estrogen receptor (ER). We validated this system in HDFs, and in 
the U2OS cell line in which it was originally reported, by demonstrating that the 
addition of 4OHT resulted in nuclear translocation of AsiSI and the induction of 
DSBs (as assessed by γH2AX foci) (Figure 6.1). Although we could show co-
localisation of 53BP1 with γH2AX, and co-localisation of different PRC1 proteins, 
we were only able to show, at best, a weak co-localisation of PRC1 proteins with 
γH2AX.  
 
The degree of protein co-localisation was determined using Pearson’s correlation 
coefficient (PCC), which is generally considered the best statistical tool for 
assessing the co-localisation of proteins from microscopy data. However, PCC has 
limitations when applied to the issues relevant to this thesis. For example, if a 
subpopulation of BMI1 became co-localised with γH2AX following DNA damage, 
while the majority remained associated with chromatin at sites of gene repression, 
then the PCC will present an average of these separate states but may not 
adequately reflect either. Moreover, if the presence of repressive PRC1 complexes 
impaired DNA damage and/or γH2AX recruitment, then BMI1 and γH2AX would be 
predicted to have a negative PCC at PcG target loci; further decreasing the 
average PCC. Such a scenario may well exist if AsiSI does not cut at PcG target 
genes either because of steric hindrance or CpG methylation (Roberts et al., 2010, 
Vire et al., 2006, Mohammad et al., 2009). 
 
Although several studies describe the detection of PRC1 proteins at sites of DNA 
damage by immunofluorescence, we are not aware of any relating to the induction 
of DSBs generated by an endonuclease. It is conceivable, therefore, that this type 
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of DNA damage does not elicit PRC1 recruitment, or does so to an extent that is 
not detectable by immunofluorescence. However, Ginjala and colleagues were able 
to demonstrate enrichment of BMI1 and CBX2 at a zinc-finger nuclease-site using 
ChIP in HeLa cells (Ginjala et al., 2011). In a separate, albeit less convincing study, 
YFP-tagged CBX4 was detected by ChIP at an I-SceI cut site in MCF7 cells (Ismail 
et al., 2012).  Curiously, the relatively modest enrichment (two-fold greater than 
IgG) was observed at a distance of 3kb and 4.5kb, but not adjacent to the cut site 
(Ismail et al., 2012).  
 
The reason for adopting the inducible AsiSI system was to gain a more genome-
wide impression of PRC1 recruitment at DSBs and we chose normal human 
fibroblasts as a cell system to avoid the genomic abnormalities associated with 
cancer cell lines. From on-going work in the laboratory, we also had a 
comprehensive picture of PRC1 binding profiles in the Hs68 strain of HDFs based 
on ChIP-seq analyses with antibodies against five different PRC1 components 
(unpublished results of Emma Anderton and Helen Pemberton). In the event, the 
ChIP-seq profiles for CBX7 before and after 4OHT treatment of AsiSI-ER-HA-Hs68 
cells were essentially indistinguishable from one another and from the profiles 
observed in parental Hs68 cells. Importantly, with the exception of one site, CBX7 
enrichment was not detected within 10kb of any AsiSI target sequences. As the 
immunofluorescence data suggested that a substantial proportion of the AsiSI sites 
must be cut in each cell following 4OHT treatment, we do not think that the lack of 
CBX7 enrichment at AsiSI sites reflects cleavage at different sites in different cells 
within the population. 
 
It is possible that PRC1 recruitment to DSBs is much less stable than the chromatin 
interactions detected by our standard ChIP protocol. Interestingly, the recruitment 
kinetics of PRC1 proteins to DSBs seem to vary, depending on the context and the 
protein in question. For example, BMI1, CBX4 and RING2 are recruited to sites of 
microirradiation within 11 seconds; comparable to early DNA damage response 
proteins such as RNF8, NBS1 and MRE11 (Ismail et al., 2010). Recruitment of 
MEL18 to sites of DNA damage is also rapid (less than 5 minutes), but short-lived 
(less than 20 minutes) (Chou et al., 2010, Ginjala et al., 2011). In contrast, Ring1b, 
CBX4 and BMI1 remain detectable at DNA breaks for sustained periods (30 
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minutes, 4 hours and 24 hours respectively) following microirradiation (Ginjala et al., 
2011, Chou et al., 2010, Ismail et al., 2010). Both our immunofluorescence 
observations and ChIP experiments were performed 4 hours after 4OHT treatment, 
when maximum γH2AX staining was observed by immunofluorescence. In contrast 
to microirradiation, we would expect the nuclease-generated DSBs to persist.  
 
Another possibility that could explain the absence of CBX7 enrichment at AsiSI 
sites is that only a subset of PRC1 proteins are involved in the DDR. The 
recruitment of CBX7 to sites of microirradiation has only been shown by one study, 
which used ectopically expressed GFP-tagged CBX7 in HeLa cells (Chou et al., 
2010). Although the focus on CBX7 provided continuity with other aspects of the 
work, it might be appropriate to extend the ChIP-seq analysis to additional PRC1 
proteins such as RING2. RING2 has been heavily implicated in the DDR and we 
have the capacity to perform ChIP-seq for RING2 in HDFs.  
 
One of the other reasons for establishing the AsiSI-inducible DNA damage system 
was to determine whether PRC1 recruitment at multiple DSBs would affect 
expression of PRC1-target genes. It has been suggested (Chou et al., 2010) that 
under conditions of persistent DNA damage, resulting for example from telomere 
erosion or oncogene-induced DNA replication stress, PRC1 recruitment to sites of 
DNA damage could mobilise PcG proteins from normal PRC1 targets, such as 
INK4a, leading to transcriptional derepression. With the same caveats as above, 
the CBX7 ChIP-seq data suggest that this hypothesis is not true. Another 
interesting way to investigate this hypothesis would be to perform ChIP-seq of 
PRC1 proteins in HDFs following artificial telomere uncapping by depletion of 
components that protect chromosome ends (d'Adda di Fagagna et al., 2003, Takai 
et al., 2003), or in HDFs that have undergone replicative senescence. 
 
To our knowledge, there is no evidence that PRC1 proteins can be recruited to 
DSBs in HDFs. While a few of the studies exploring PcG proteins in the DDR have 
been conducted in MEFs and stem cells, the vast majority have used cancer cell 
lines, such as U2OS. It would therefore be interesting to determine whether 
recruitment of PRC1 to AsiSI sites could be demonstrated by ChIP in AsiSI-ER-HA-
U2OS cells, instead of the HDF system. However, as the PRC1 targets in U2OS 
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cells are unknown, it is difficult to assess the quality of the ChIP samples prior to 
submission for DNA sequencing. For example, in a preliminary experiment, in 
which CBX7 ChIP was performed in AsiSI-ER-HA-U2OS cells before and after 
4OHT treatment, it was not possible to detect CBX7 enrichment at INK4a-ARF-
INK4b (data not shown). Additional PRC1 target genes will therefore need to be 
evaluated in U2OS cells before ChIP-seq analysis can be contemplated.  
 
The INK4a locus is known to be hypermethylated in U2OS cells, which may explain 
the absence of CBX7 at this locus. It is also possible that the congregation of PRC1 
proteins in PcG bodies in these cells distorts the binding profiles detected by ChIP. 
Indeed, in human tumour cells PcG proteins are predominantly found in a few, 
prominent foci, that associate with pericentromeric heterochromatin (Alkema et al., 
1997, Saurin et al., 1998, Cmarko et al., 2003, Hernandez-Munoz et al., 2005), 
whereas, in human fibroblasts, these proteins are typically found in around 100 
nuclear speckles that are evenly distributed throughout the nucleus (Voncken et al., 
1999, Buchenau et al., 1998, Saurin et al., 1998). The immunofluorescence data in 
Chapter 6 are consistent with these studies. It is conceivable that the differences in 
PcG protein localisation between HDFs and human tumour cells may reflect 
changes in PRC1 function, PRC1 genome-wide binding or PRC1 protein 
interactions in tumour cells. This could have important implications for our 
understanding of PRC1 complex composition, which based largely on proteomic 
analysis of these proteins in cell lines. Of particular relevance to this thesis is that 
the interaction of CK2 with PRC1 proteins has only been demonstrated by us in 
293T cells (El Messaoudi-Aubert et al., 2010, Nicholls, 2006) and by others in 293T 
cells (Dietrich et al., 2007, Gao et al., 2012), murine erythroleukemia (MEL) cells 
(Sanchez et al., 2007) and HeLa cells (Vandamme et al., 2011). It is therefore 
possible that CK2 is only relevant to PRC1 biology in abnormal contexts, such as 
tumorigenesis. It would be interesting to investigate this further by exploring 
whether an interaction of CK2 with PRC1 takes place in HDFs.  
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Figure 8.1 Calibration of Superose 6 column 
A Superose 6 column (GE healthcare) to be used for gel filtration was calibrated 
using low molecular weight and high molecular weight standard proteins. 
Elution volumes were taken at the maximum absorbance of each respective 
protein and these are noted in the figure. A) A graph showing the absorbance of 
column flow-through following the application of mix A to the column (Aprotinin 
(1.5mg/ml), Carbonic Anhydrase (1.5mg/ml), Aldolase (2mg/ml) and 
Thyrogobulin (2.5mg/ml)). B) A graph showing the absorbance of column flow-
through following the application of mix B to the column (Ribonuclease A 
(1.5mg/ml) Ovalbumin (2mg/ml) and Ferritin (0.15mg/ml)). C) A graph showing 
the absorbance of column flow-through following the application of Blue Dextran 
2000 (0.5mg/ml) to the column. The elution volume of Blue Dextran is equal to 
the column void volume. 
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Figure 8.2 Bacterial expression of GST-mCbx7 
Single colonies (clones A-C) of BL21 E. coli transformed with GST-mCbx7-
pGEX-6P1 plasmid were grown to log phase, induced with IPTG for 2, 3 and 4 
hours and then lysed. Protein lysates were fractionated by SDS-PAGE and 
proteins were subject to Coomassie staining overnight. Arrows indicate GST-
mCbx7 protein expression following IPTG induction. Asterisk indicates the clone 
chosen for large-scale purification. 
76  kDa
52  kDa
38  kDa
31  kDa
24  kDa
17  kDa
76  kDa
52  kDa
38  kDa
31  kDa
24  kDa
17  kDa
76  kDa
52  kDa
38  kDa
31  kDa
24  kDa
17  kDa
+  IPTG
2hr        3hr        4hr-­
Clone  B
Clone  C
+  IPTG
2hr        3hr        4hr-­
+  IPTG
2hr        3hr        4hr-­
Clone  A*
Appendix 
 
 178 
 
Clone  A*
    -­              +                      -­              +                    -­              +                    -­                +
76  kDa
52  kDa
38  kDa
31  kDa
24  kDa
Clone  B
IPTG
Clone  A* Clone  B
V137A V137D
76  kDa
52  kDa
38  kDa
31  kDa
24  kDa
Clone  A
    -­              +                        -­              +                      -­              +                      -­                +
Clone  B*
IPTG
Clone  A Clone  B*
V139A V139D
Clone  A
  -­              +                        -­              +                      -­              +                      -­                +
Clone  B*
76  kDa
52  kDa
38  kDa
31  kDa
24  kDa
IPTG
Clone  A* Clone  B
T140A T140D
A
Appendix 
 
 179 
 
Figure 8.3 Bacterial expression of GST-mCbx7 point mutants 
Single colonies (clones A-B or A-C) of BL21 E. coli transformed with the 
indicated GST-mCbx7-pGEX-6P1 mutant plasmid were grown to log phase, 
induced with IPTG for 3 hours and then lysed. Protein lysates were fractionated 
by SDS-PAGE and proteins were subject to Coomassie staining overnight. 
Arrows indicate GST-mCbx7 mutant protein expression following IPTG 
induction. Asterisks indicate the clones chosen for large-scale purification. 
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Figure 8.4 Purification of mCbx7 
BL21 E. coli transformed with GST-mCbx7-pGEX-6P1 plasmid (Clone A, see 
Figure 8.2) were grown to log phase, induced with IPTG for 2 hours and then 
lysed. GST-mCbx7 was purified from lysate and PreScission protease (GE 
Healthcare) was used to cleave the GST-tag. A) Purified mCbx7 was 
fractionated by SDS-PAGE and proteins were subject to Coomassie staining 
overnight. Arrows indicate GST-mCbx7 protein expression following IPTG 
induction and the size of mCbx7 following GST-tag cleavage. B) Purified 
mCbx7 was fractionated by SDS-PAGE and immunoblotted with an antibody 
that recognises mCbx7. 
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